Alexandria Medical Evidence Library
Library/Cancer/Non-Hodgkin Lymphoma

Cancer evidence library

Non-Hodgkin Lymphoma

PubMed-indexed evidence across major non-Hodgkin lymphoma subtypes and treatment strategies.

PubMed only Research ranked Conflicts shown Data downloadable

Living evidence synopsis

What the current PubMed collection shows.

Alexandria currently organizes 1,653 non-retracted PubMed-indexed records for Non-Hodgkin Lymphoma. The structured collection includes 18 guideline or consensus records, 108 evidence syntheses/systematic reviews/meta-analyses, and 104 randomized or phase III studies. 608 records were identified by the configured last-24-month search. Conflict-of-interest statements are available in the PubMed record for 998 of 1,653 included records.

Engine 0.3.2 Snapshot v33 Updated 2026-11-02 Download source data · CSV
PubMed records1,653Non-retracted records included
Last 24 months608Records found by the recent-research search
High-priority evidence212Syntheses, reviews, randomized and phase III studies
Effect estimates526Machine-readable values extracted from abstracts
COI statements60.4%Coverage within PubMed records
Funding records411PMIDs with grant/funding metadata
Evidence data

Research landscape

Charts are generated from Alexandria’s structured PubMed records, not copied from journal figures.

Publication activity

Records by publication year

Latest 12 represented years
2
2016
2
2017
4
2018
2
2019
2
2020
26
2021
86
2022
114
2023
155
2024
235
2025
981
2026
1
2027
Evidence composition

Study designs

Other or unclassified798
Case reports226
Preclinical/laboratory171
Phase II trials94
Randomized trials80
Meta-analyses66
Cohort studies52
Systematic reviews42
Phase I trials42
Phase III trials24
Transparency

Conflict-of-interest reporting

Not reported in PubMed record655
Reported no conflicts516
COI statement present279
Declared financial/industry relationship203

Absence of a conflict-of-interest statement in PubMed does not establish that no conflict existed.

Abstract result signals

Extracted result direction

Not extractable from abstract1495
Supportive signal54
Neutral/null signal49
Harm signal48
Mixed signal7
Reported outcomes

Numerical results extracted from PubMed abstracts

Each value remains attached to its original PMID. Alexandria does not pool these results or imply that unlike populations and endpoints are directly comparable.

Non-pooled ratio measures

Hazard, risk, and odds ratios reported in abstracts

Reference = 1.0
0.250.51.02.04.0
not_reported Odds Ratio · PMID 40953732 · 2026
1.92 95% CI 0.54–6.84
not_reported Odds Ratio · PMID 40953732 · 2026
1.76 95% CI 0.71–4.36
not_reported Odds Ratio · PMID 40953732 · 2026
1.93 95% CI 0.81–4.57
not_reported Odds Ratio · PMID 40953732 · 2026
4.00
overall survival Hazard Ratio · PMID 41145670 · 2026
4.51
overall survival Hazard Ratio · PMID 41145670 · 2026
3.34
overall survival Hazard Ratio · PMID 41145670 · 2026
6.38
not_reported Hazard Ratio · PMID 41260259 · 2026
0.72 95% CI 0.47–1.12
not_reported Odds Ratio · PMID 41544567 · 2026
0.42
not_reported Hazard Ratio · PMID 41580147 · 2026
0.36
not_reported Odds Ratio · PMID 41661178 · 2026
6.01 95% CI 2.46–18.20
not_reported Odds Ratio · PMID 41661178 · 2026
1.67 95% CI 1.21–2.57
not_reported Odds Ratio · PMID 41661178 · 2026
1.15 95% CI 1.04–1.27
survival Hazard Ratio · PMID 41876379 · 2026
0.20 95% CI 0.11–0.36
View extracted numerical results 60
PublicationOutcomeMeasureReported valueSource
Impact of Granulocyte Colony Stimulating Factor Use Following CD-19 Chimeric Antigen Receptor T-Cell Therapy.Transplantation and cellular therapy · 2026 not_reported Odds Ratio 1.92 95% CI 0.54–6.84 P = 0.317 PMID 40953732
Impact of Granulocyte Colony Stimulating Factor Use Following CD-19 Chimeric Antigen Receptor T-Cell Therapy.Transplantation and cellular therapy · 2026 not_reported Odds Ratio 1.76 95% CI 0.71–4.36 P = 0.223 PMID 40953732
Impact of Granulocyte Colony Stimulating Factor Use Following CD-19 Chimeric Antigen Receptor T-Cell Therapy.Transplantation and cellular therapy · 2026 not_reported Odds Ratio 1.93 95% CI 0.81–4.57 P=0.136 PMID 40953732
Impact of Granulocyte Colony Stimulating Factor Use Following CD-19 Chimeric Antigen Receptor T-Cell Therapy.Transplantation and cellular therapy · 2026 not_reported Odds Ratio 4.0 PMID 40953732
ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study.Leukemia · 2026 overall survival Hazard Ratio 4.51 p = 0.039 PMID 41145670
ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study.Leukemia · 2026 overall survival Hazard Ratio 3.34 p = 0.039 PMID 41145670
ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study.Leukemia · 2026 overall survival Hazard Ratio 6.38 p = 0.039 PMID 41145670
Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 not_reported Hazard Ratio 0.72 95% CI 0.47–1.12 PMID 41260259
Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 adverse events Percentage Comparison 54.7percent vs 62.7percent P = 0.046 PMID 41260259
Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 adverse events Percentage Comparison 9.5percent vs 14.2percent P = 0.046 PMID 41260259
Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 not_reported Percentage Comparison 43.0percent vs 92.0percent P = 1 PMID 41385760
Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 not_reported Percentage Comparison 42.0percent vs 95.0percent P < .001 PMID 41428995
Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 response Percentage Comparison 45.0percent vs 96.0percent P < .001 PMID 41428995
Establishing practical predictors of collection efficiency for optimized chimeric antigen receptor T-cell apheresis.Cytotherapy · 2026 not_reported Odds Ratio 0.416 p = 0.0339 PMID 41544567
Secondary outcomes of the TROG 99.03 randomized trial of systemic therapy after involved-field radiotherapy in early-stage follicular lymphoma, including toxicity, relapse and second malignancy data.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 not_reported Hazard Ratio 0.36 p = 0.01 PMID 41580147
Risk Factors for Invasive Infection in Febrile Oncology Patients Related to Cancer Type.Pediatric emergency care · 2026 not_reported Odds Ratio 6.006 95% CI 2.459–18.2 PMID 41661178
Risk Factors for Invasive Infection in Febrile Oncology Patients Related to Cancer Type.Pediatric emergency care · 2026 not_reported Odds Ratio 1.668 95% CI 1.205–2.571 PMID 41661178
Risk Factors for Invasive Infection in Febrile Oncology Patients Related to Cancer Type.Pediatric emergency care · 2026 not_reported Odds Ratio 1.145 95% CI 1.036–1.267 PMID 41661178
Clinical characteristics, treatment options, and prognosis of subcutaneous panniculitis-like T-cell lymphoma from the SEER database.Hematology (Amsterdam, Netherlands) · 2026 survival Hazard Ratio 0.197 95% CI 0.106–0.364 p = 0.000 PMID 41876379
Clinical characteristics, treatment options, and prognosis of subcutaneous panniculitis-like T-cell lymphoma from the SEER database.Hematology (Amsterdam, Netherlands) · 2026 survival Hazard Ratio 0.21 95% CI 0.049–0.902 p = 0.000 PMID 41876379
Clinical characteristics, treatment options, and prognosis of subcutaneous panniculitis-like T-cell lymphoma from the SEER database.Hematology (Amsterdam, Netherlands) · 2026 survival Hazard Ratio 3.213 95% CI 1.357–7.607 p = 0.000 PMID 41876379
Clinical characteristics, treatment options, and prognosis of subcutaneous panniculitis-like T-cell lymphoma from the SEER database.Hematology (Amsterdam, Netherlands) · 2026 survival Hazard Ratio 5.039 95% CI 2.327–10.911 p = 0.000 PMID 41876379
Clinical characteristics, treatment options, and prognosis of subcutaneous panniculitis-like T-cell lymphoma from the SEER database.Hematology (Amsterdam, Netherlands) · 2026 not_reported Hazard Ratio 0.216 95% CI 0.048–0.983 p = 0.048 PMID 41876379
Clinical characteristics, treatment options, and prognosis of subcutaneous panniculitis-like T-cell lymphoma from the SEER database.Hematology (Amsterdam, Netherlands) · 2026 not_reported Hazard Ratio 1.276 95% CI 0.644–2.529 p = 0.485 PMID 41876379
Clinical characteristics, treatment options, and prognosis of subcutaneous panniculitis-like T-cell lymphoma from the SEER database.Hematology (Amsterdam, Netherlands) · 2026 not_reported Hazard Ratio 1.283 95% CI 0.463–3.558 p = 0.485 PMID 41876379
Survival and prognostic features of early-stage diffuse large B-cell lymphoma in older adults.Hematology (Amsterdam, Netherlands) · 2026 not_reported Percentage Comparison 95.5percent vs 60.5percent p = 0.006 PMID 41922932
Outcomes With First-Line PD1 Inhibitors in Extranodal NK/T-Cell Lymphoma: A Comparative Analysis From a 755-Patient Multicenter Cohort.American journal of hematology · 2026 overall survival Hazard Ratio 0.62 p = 0.007 PMID 42036303
Outcomes With First-Line PD1 Inhibitors in Extranodal NK/T-Cell Lymphoma: A Comparative Analysis From a 755-Patient Multicenter Cohort.American journal of hematology · 2026 overall survival Hazard Ratio 0.55 p = 0.007 PMID 42036303
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.The Lancet. Haematology · 2026 not_reported Odds Ratio 20.0 PMID 42285113
CAR-T Cell Therapy Versus Salvage Chemotherapy in Relapsed/Refractory DLBCL: A Systematic Review and Meta-Analysis Integrating Radiologic, Laboratory, and Histopathologic Correlates.La Clinica terapeutica · 2026 not_reported Hazard Ratio 0.55 95% CI 0.42–0.71 p < 0.001 PMID 42340791
CAR-T Cell Therapy Versus Salvage Chemotherapy in Relapsed/Refractory DLBCL: A Systematic Review and Meta-Analysis Integrating Radiologic, Laboratory, and Histopathologic Correlates.La Clinica terapeutica · 2026 not_reported Hazard Ratio 0.68 95% CI 0.54–0.86 p < 0.001 PMID 42340791
CAR-T Cell Therapy Versus Salvage Chemotherapy in Relapsed/Refractory DLBCL: A Systematic Review and Meta-Analysis Integrating Radiologic, Laboratory, and Histopathologic Correlates.La Clinica terapeutica · 2026 not_reported Risk Ratio 2.28 95% CI 1.82–2.86 p < 0.001 PMID 42340791
Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes.British journal of haematology · 2026 not_reported Hazard Ratio 2.68 95% CI 1.09–6.58 PMID 41806244
Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes.British journal of haematology · 2026 not_reported Odds Ratio 2.57 95% CI 1.08–5.99 PMID 41806244
Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes.British journal of haematology · 2026 not_reported Hazard Ratio 1.7 95% CI 1.02–2.85 PMID 41806244
High Soluble Tumor Necrosis Factor Receptor 2 in Serum Is Associated With Inferior Overall Survival Across Major Lymphoma Subtypes.American journal of hematology · 2026 not_reported Hazard Ratio 12.6 p < 0.0001 PMID 41891328
High Soluble Tumor Necrosis Factor Receptor 2 in Serum Is Associated With Inferior Overall Survival Across Major Lymphoma Subtypes.American journal of hematology · 2026 not_reported Hazard Ratio 2.6 p < 0.0001 PMID 41891328
High Soluble Tumor Necrosis Factor Receptor 2 in Serum Is Associated With Inferior Overall Survival Across Major Lymphoma Subtypes.American journal of hematology · 2026 not_reported Hazard Ratio 2.5 p < 0.0001 PMID 41891328
High Soluble Tumor Necrosis Factor Receptor 2 in Serum Is Associated With Inferior Overall Survival Across Major Lymphoma Subtypes.American journal of hematology · 2026 not_reported Hazard Ratio 4.2 p < 0.0001 PMID 41891328
High Soluble Tumor Necrosis Factor Receptor 2 in Serum Is Associated With Inferior Overall Survival Across Major Lymphoma Subtypes.American journal of hematology · 2026 not_reported Hazard Ratio 2.4 p < 0.0001 PMID 41891328
Research transparency

Funding and conflicts of interest

Conflict and funding fields reproduce what is available in PubMed records. Missing disclosure data does not establish that no conflict or funding existed.

COI statement coverage60.4%655 records have no COI statement exposed in PubMed.
Funding metadata coverage24.9%Coverage indicates whether grant/funding metadata was present, not independence or study quality.
Most frequently reported funding agencies
NCI NIH HHS255
National Natural Science Foundation of China85
NHLBI NIH HHS50
National Natural Science Foundation of China (National Science Foundation of China)21
Instituto de Salud Carlos III17
National Science and Technology Council17
NIH HHS16
NCATS NIH HHS14
View records with declared financial or industry relationships 12

Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma.

Conflict-of-interest disclosure: J.F. has provided consultancy and received funding from Epizyme. K.K. is an employee and shareholder of Roche. D.W.S. and L.M.R. have IP rights to the Lymph2Cx assay. D.W.S. has provided consultancy to AbbVie, AstraZeneca, Celgene, Janssen, and Incyte, and has received research funding from Janssen, NanoString Technology, and Roche/Genentech.

PMID 35947123 · 2023

Real-World Treatment Patterns, Healthcare Resource Use, and Costs in Patients with Follicular Lymphoma, Waldenström Macroglobulinemia, and Marginal Zone Lymphoma: A Claims-Based Study in the USA.

Declarations. Conflict of Interest: Shravanthi Gandra is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and owns stock/stock options in Merck & Co., Inc., Rahway, NJ, USA. At the time this study was conducted, Mahek Garg was an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and owned stock/stock options in Merck & Co., Inc., Rahway, NJ, USA. Ambika Satija, Benjamin Meade, Yan Song, and James Signorovitch are employees of Analysis Group, Inc., a consulting company that provided paid consulting services to Merck & Co., Inc., which funded the development and conduct of this study and manuscript. Ethics Approval: Data were deidentified and comply with the patient requirements of the HIPAA of 1996. No review by an institutional review board was required per Title 45 of CFR, Part 46.101(b)(4) ( https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/#46.101 ). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. Consent to Participate: Not applicable. Data were deidentified and comply with the patient requirements of the HIPAA of 1996, therefore, consent to participate was not required. Consent for Publication: Not applicable. Data were deidentified and comply with the patient requirements of the HIPAA of 1996, therefore, consent for publication was not required. Data Availability Statement: The data that support the findings of this study are available from Optum. Restrictions apply to the availability of these data, which were used under license for this study. Permission to access these data must be requested from Optum ( https://www.optum.com/ ). Code Availability: Not applicable. Author Contributions: Mahek Garg and Shravanthi Gandra contributed to study conception and design, data analysis, and interpretation. Ambika Satija, Yan Song, and James Signorovitch contributed to study conception and design, collection and assembly of data, data analysis, and interpretation. Benjamin Meade contributed to collection and assembly of data, data analysis, and interpretation. All authors read and approved the final version and agree to be accountable for the work.

PMID 42763362 · 2026

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

POLATUZUMAB VEDOTIN PLUS RITUXIMAB, GEMCITABINE, AND OXALIPLATIN IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM THE PHASE III, RANDOMIZED POLARGO TRIAL: The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Matthew Matasar Stock and Other Ownership Interests: Merck Honoraria: Genentech, Roche, Bayer, Pharmacyclics, Seagen, Takeda, Immunovaccine, GlaxoSmithKline, Janssen, Epizyme, ADC Therapeutics, Bristol Myers Squibb/Celgene/Juno Consulting or Advisory Role: Genentech, Bayer, Merck, Juno Therapeutics, Roche, Teva, Rocket Medical, Seagen, Daiichi Sankyo, Takeda, Epizyme, Treeline Biosciences, Arvinas Research Funding: Genentech, Roche, GlaxoSmithKline, Bayer, Pharmacyclics, Janssen, Rocket Medical, Seagen, Immunovaccine, IGM Biosciences Expert Testimony: Bayer Travel, Accommodations, Expenses: Genentech, Roche, Seagen, Bayer Theodoros P. Vassilakopoulos Honoraria: Takeda (Inst), Roche (Inst), Genesis Pharma (Inst), Gilead Sciences (Inst), AstraZeneca (Inst), AbbVie (Inst), Janssen (Inst), Sandoz (Inst), Sobi (Inst), Swixx BioPharma (Inst), Lilly (Inst), BMS (Inst), AOP Orphan Pharmaceuticals (Inst) Consulting or Advisory Role: Takeda (Inst), Roche (Inst), Genesis Pharma (Inst), Gilead Sciences (Inst), Merck (Inst), Janssen (Inst), TEVA (Inst), Sandoz (Inst), AbbVie (Inst), AstraZeneca (Inst), Winmedica (Inst), Sobi (Inst), Swixx BioPharma (Inst), Lilly (Inst) Research Funding: Roche (Inst), Roche (Inst), AbbVie (Inst), BMSi (Inst), Merck (Inst) Travel, Accommodations, Expenses: Takeda, Roche, Genesis Pharma, Merck, Pfizer, Winmedica Juan-Manuel Sancho Honoraria: Roche, Gilead Sciences, Janssen, Incyte, Lilly, BMS, AbbVie, BeiGene Consulting or Advisory Role: Roche, Gilead Sciences, Janssen, BeiGene, Incyte, Lilly, BMS, SOBI Speakers' Bureau: Gilead Sciences, AbbVie, BeiGene Travel, Accommodations, Expenses: Roche, AbbVie, Gilead Sciences, BeiGene Andreas Viardot Honoraria: Roche, Kite/Gilead, BMS GmbH & Co. KG, Novartis, AbbVie Consulting or Advisory Role: Kite/Gilead, Roche, BMS GmbH & Co. KG, AbbVie Travel, Accommodations, Expenses: Roche, Kite, a Gilead company, AbbVie, Janssen, Sobi Andrew McMillan Honoraria: Roche/Genentech, Amgen, Protherics, Takeda Consulting or Advisory Role: Amgen Speakers' Bureau: Roche/Genentech Research Funding: Pfizer, Roche/Genentech (Inst) Travel, Accommodations, Expenses: Takeda Uncompensated Relationships: Kite/Gilead, Novartis Juliana Pereira Consulting or Advisory Role: AstraZeneca Jin Seok Kim Research Funding: Antengene Lugui Qiu Consulting or Advisory Role: Lilly, GlaxoSmithKline, BeiGene, Sanofi, Pfizer, Johnson & Johnson Speakers' Bureau: BeiGene, Johnson & Johnson, Roche, Sanofi, Pfizer Connie Lee Batlevi Employment: Genentech Stock and Other Ownership Interests: Roche/Genentech Open Payments Link: https://openpaymentsdata.cms.gov/physician/2778694 Rania Ibrahim Employment: Genentech/Roche, Amgen Stock and Other Ownership Interests: Amgen Juana Hernandez Employment: Roche Stock and Other Ownership Interests: Roche Honoraria: Roche Travel, Accommodations, Expenses: Roche Bruce McCall Employment: Genentech Stock and Other Ownership Interests: Roche/Genentech Travel, Accommodations, Expenses: Genentech Yanwen Jiang Employment: Genentech Stock and Other Ownership Interests: Genentech/Roche Travel, Accommodations, Expenses: Genentech/Roche (Inst) Mark Yan Employment: Roche Canada Stock and Other Ownership Interests: Roche Will Harris Employment: Genentech, Exelixis Stock and Other Ownership Interests: Roche Lisa Musick Employment: Roche/Genentech Stock and Other Ownership Interests: Roche/Genentech Corinne Haioun Honoraria: Roche, Janssen-Cilag, Gilead Sciences, Miltenyi Biotech, Amgen, Takeda, Celgene Travel, Accommodations, Expenses: Roche, Johnson & Johnson/Janssen No other potential conflicts of interest were reported.

PMID 42407012 · 2026

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Conflict-of-interest disclosure: J.S.A. received grants or contracts from Bristol Myers Squibb, Cellectis, Merck, Mustang Bio, Regeneron, and Seagen; consulting fees from AbbVie, ADC Therapeutics, AstraZeneca, BeOne Medicines, Bristol Myers Squibb, Celgene, Cellectar, Caribou Biosciences, Century Therapeutics, Celgene, Epizyme, Foresight Diagnostics, Genentech Inc, Gilead, Interius, Lilly, F. Hoffmann-La Roche Ltd, Seagen, and Takeda; and payment or honoraria for lectures, presentations, speakers bureaus, and manuscript writing or educational events from AbbVie, AstraZeneca, Bristol Myers Squibb, Incyte, Janssen, MorphoSys, Novartis, and Regeneron. W.T. has received grants or contracts and support for attending meetings and/or travel from F. Hoffmann-La Roche Ltd; consulting fees from, and participated on a data safety monitoring board or advisory board for, F. Hoffmann-La Roche Ltd, Takeda, AbbVie, Sobi, and Gilead; payment or honoraria for lectures, presentations, speakers bureaus, and manuscript writing or educational events from F. Hoffmann-La Roche Ltd, Takeda, Gilead Sciences, and AbbVie; and is grateful for and acknowledges funding and support from the UCLH Biomedical Research Centre. C.P.F. has received grants or contracts from BeOne Medicines, F. Hoffmann-La Roche Ltd, Genmab/AbbVie; consulting fees from AbbVie, AstraZeneca, Atara Biotherapeutics, Bristol Myers Squibb, Genmab, Gilead/Kite, Incyte, Janssen, Lilly, MorphoSys, Ono, F. Hoffmann-La Roche Ltd, SERB Pharmaceuticals, and Sobi; payment or honoraria for lectures, presentations, speakers bureaus, and manuscript writing or educational events from AbbVie, AstraZeneca, Atara Biotherapeutics, Bristol Myers Squibb, Genmab, Gilead/Kite, Incyte, Janssen, Lilly, MorphoSys, Ono, F. Hoffmann-La Roche Ltd, SERB Pharmaceuticals, Sobi, Takeda; and participated on a data safety monitoring board or advisory board for AbbVie, AstraZeneca, Atara Biotherapeutics, Bristol Myers Squibb, Genmab, Gilead/Kite, Incyte, Janssen, Lilly, MorphoSys, Ono, F. Hoffmann-La Roche Ltd, SERB Pharmaceuticals, and Sobi. M. Ku received grants or contracts and consulting fees from, and participated on a data safety monitoring board or advisory board for, F. Hoffmann-La Roche Ltd; a grant from BeOne Medicines; and consulting fee from AbbVie and Gilead. M.H. received grants from Janssen and F. Hoffmann-La Roche Ltd; consulting fees from AbbVie, F. Hoffmann-La Roche Ltd, Gilead Sciences, Otsuka, and Takeda; payment or honoraria for lectures, presentations, speakers bureaus, and manuscript writing or educational events from AbbVie, F. Hoffman-La Roche Ltd, Gilead Sciences, Otsuka, Pfizer, and Takeda; participated on a data safety monitoring board or advisory board for AbbVie, F. Hoffmann-La Roche Ltd, Gilead, Otsuka, and Takeda. D.H.Y. received grants or contracts from AbbVie, BeOne Medicines, Boryung, Celltrion, Janssen, Kyowa Kirin, Samyang, and Sanofi; consulting fees from AbClon, BeOne Medicines, Bristol Myers Squibb, F. Hoffmann-La Roche Ltd, GC Cell, GI Cell, Janssen, Novartis, Pharos Bio, and Verismo; payment or honoraria for lectures, presentations, speakers bureaus, and manuscript writing or educational events from Amgen, Antengene, Bristol Myers Squibb, Boryung, GSK, Kyowa Kirin, Novartis, F. Hoffmann-La Roche Ltd, Janssen, and Takeda; and participated on a data safety monitoring board or advisory board for AbClon, BeOne Medicines, Bristol Myers Squibb, F. Hoffmann-La Roche Ltd, GC Cell, GI Cell, Janssen, Novartis, Pharos Bio, and Verismo. H.A. received grants or contracts from Bristol Myers Squibb, Epizyme, Genentech Inc, MorphoSys, Novartis, and Pfizer; consulting fees from AbbVie, Acrotech, ADC therapeutics, Amgen, AstraZeneca, Bristol Myers Squibb, Genentech Inc, MorphoSys, and Novartis; payment or honoraria for lectures, presentations, speakers bureaus, and manuscript writing or educational events from Genentech Inc; and participated on a data safety monitoring board or advisory board for Amgen, Genentech Inc, MorphoSys, Novartis, AbbVie Acrotech, ADC therapeutics, AstraZeneca, and Bristol Myers Squibb. C.H. received grants or contacts from Takeda; payment or honoraria for lectures, presentations, speakers bureaus, and manuscript writing or educational events from AbbVie, F. Hoffmann-La Roche Ltd, Gilead Sciences, and Janssen-Cilag; and support for attending meetings and/or travel from Janssen-Cilag, AbbVie, and F. Hoffmann-La Roche Ltd. J.M.Z. received consulting fees from, and participated on a data safety monitoring board or advisory board for, AbbVie Amgen, AstraZeneca, Bristol Myers Squibb, F. Hoffmann-La Roche Ltd, Gilead Sciences, Novartis, Pfizer, Pierre Fabre, and Takeda; payment or honoraria for lectures, presentations, speakers bureaus, and manuscript writing or educational events from AbbVie, F. Hoffmann-La Roche Ltd, and Takeda; and support for attending meeting and/or travel from AbbVie and F. Hoffmann-La Roche Ltd. C.Y.C. received grants or contracts from AbbVie, Bristol Myers Squibb, F. Hoffmann-La Roche Ltd, Lilly, and Merck Sharp and Dohme; consulting fees from AbbVie, AstraZeneca, BeOne Medicines, Bristol Myers Squibb, Dizal, F. Hoffmann-La Roche Ltd, Genmab, Gilead Sciences, Janssen, Lilly, and Menarini; payment or honoraria for lectures, presentations, speakers bureaus, and manuscript writing or educational events from AbbVie, AstraZeneca, BeOne Medicines, Bristol Myers Squibb, Dizal, F. Hoffmann-La Roche Ltd, Genmab, Gilead Sciences, Janssen, Lilly, and Menarini; and participated on a data safety monitoring board or advisory board for AbbVie, AstraZeneca, BeOne Medicines, Bristol Myers Squibb Dizal, F. Hoffmann-La Roche Ltd, Genmab, Gilead Sciences, Janssen, Lilly, and Menarini. H.G. received consulting fees from Bristol Myers Squibb, F. Hoffmann-La Roche Ltd, and Takeda; and payment or honoraria for lectures, presentations, speakers bureaus, and manuscript writing or educational events from AbbVie, Bristol Myers Squibb, Gilead Sciences, F. Hoffmann-La Roche Ltd, and Takeda. E.M. is an employee of, has received grants or contracts from, has received support for attending meetings and/or travel from, and has stock or stock options in, F. Hoffmann-La Roche Ltd. M. Kesavan is an employee of, and has stock or stock options in, Genentech Inc/F. Hoffmann-La Roche Ltd. M. Kallemeijn has received grants or contracts from Roche Diagnostics International Ltd and F. Hoffmann-La Roche Ltd. R.T. is an employee of, has provided all support for this study for, has received support for attending meetings and/or travel from, and has stock or stock options in, Genentech, Inc/F. Hoffmann-La Roche Ltd. V.C. is an employee of, and has stock or stock options in, Genentech Inc/F. Hoffmann-La Roche Ltd. A. Belousov is an employee of, and has stock or stock options in, Genentech Inc/F. Hoffmann-La Roche Ltd. J.R. is an employee of F. Hoffmann-La Roche Ltd; and has stock or stock options in Nkarta Therapeutics, Spyre Therapeutics, Boundless Bio, and F. Hoffmann-La Roche Ltd. A. Bottos is an employee of, and has stock or stock options in, Genentech Inc/F. Hoffmann-La Roche Ltd. L.L. is an employee of, has received grants or contracts from, has received royalties or licenses from, has patents planned, issued or pending with, and has stock or stock options in, F. Hoffmann-La Roche Ltd. G.P.G. received grants or contracts from BeOne Medicines and Merck; consulting fees from AstraZeneca, Bristol Myers Squibb, Clinigen, F. Hoffmann-La Roche Ltd, Gilead Sciences, Merck, Novartis, and Prelude Therapeutics; payment or honoraria for lectures, presentations, speakers bureaus, and manuscript writing or educational events from AbbVie, Gilead Sciences, and F. Hoffmann-La Roche Ltd; and participated on a data safety monitoring board or advisory board for Merck, Gilead Sciences, Novartis, Bristol Myers Squibb, Clinigen, F. Hoffmann-La Roche Ltd, AstraZeneca, and Prelude Therapeutics. The remaining authors declare no competing financial interests.

PMID 42269085 · 2026

Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol.

NGM: Speaker's fees from Kite, MN: honoraria from Kite and BMS; RS: Kite Gilead—Speaker's bureau, travel grant, honoraria; CR: speaker fees, honoraria and advisory board payments from Kite/Gilead, Johnson & Johnson, Autolus, Abbvie and BMS/Cellistic; EK: Speaker's fees: Beigine, Astra Zeneca, AbbVie; Consultancy: Kite, AbbVie; Travel Grants: Roche, Kite, DY consulting honoraria from Amgen, Clinigen, Gilead Sciences, Pfizer, Autolu, and travel honoraria from Amgen, Kite Gilead, Servier, AK advisory boards and honoraria from Kite/Gilead, Novartis, AbbVie, Roche, BMS. The rest of the authors have no COI.

PMID 42397071 · 2026

Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL.

Conflict-of-interest disclosure: S.A. declares consultancy fees from ADC Therapeutics, Bristol Myers Squibb, Genmab, and Kite/Gilead and research funding from Bristol Myers Squibb, Caribou Biosciences, Chimagen, Genmab, Janssen, Kite/Gilead, Merck, Nektar Therapeutics, and Xencor. A.M.G.-S. declares consultancy fees from AbbVie, AstraZeneca, BeOne Medicines, Bristol Myers Squibb, Genmab, GlaxoSmithKline, Janssen, Kite/Gilead, Lilly, Merck Sharp & Dohme (MSD), Regeneron, Roche, and Sobi; honoraria from AbbVie, AstraZeneca, BeOne Medicines, Bristol Myers Squibb, Ideogen, Incyte Corporation, Janssen, Kite/Gilead, Kyowa Kirin, Lilly, Regeneron, Roche, Sobi, and Takeda; research funding to his institution from Kite/Gilead; and travel/accommodation expense support from AbbVie, Ideogen, Janssen, Kite/Gilead, and Roche. J.L.R.O. declares consultancy fees from Johnson & Johnson and Kite/Gilead; speakers bureau fees from Amgen, Bristol Myers Squibb, Johnson & Johnson, Kite/Gilead, and Sanofi; and travel/accommodation expense support from Bristol Myers Squibb, Johnson & Johnson, and Kite/Gilead. G.C. declares consultancy fees from AbbVie, Bristol Myers Squibb, BeiGene, Mabqi, and Roche; honoraria from AbbVie, Bristol Myers Squibb, Gilead, Janssen, Novartis, Roche, and Takeda; and travel/accommodation expense support from AbbVie, Gilead, Janssen, and Roche. K.I. declares consultancy fees from AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Chugai Pharma, Eisai, Genmab, GlaxoSmithKline, Kyowa Kirin, Mitsubishi Tanabe Pharma, MSD, Nippon Shinyaku, Ono Pharmaceutical, Otsuka, Takeda, and Zenyaku Kogyo; honoraria from AbbVie, AstraZeneca, BeiGene, BeOne Medicines, Bristol Myers Squibb, Chugai Pharma, Eisai, Genmab, Gilead, Janssen, Kyowa Kirin, Lilly, Meiji Seika Pharma, MSD, Nippon Shinyaku, Novartis, Ono Pharmaceutical, Otsuka, Pfizer, Recordati, SymBio Pharmaceuticals, and Takeda; and research funding from Chugai Pharma and Eisai. H. Ghesquieres declares consultancy fees from Bristol Myers Squibb, Roche, and Takeda and honoraria from AbbVie, Bristol Myers Squibb, Gilead, Roche, and Takeda. H. Goto declares honoraria from AbbVie, Bristol Myers Squibb, Chugai, Genmab, Kite/Gilead, Kyowa Kirin, and Novartis and research funding from Bristol Myers Squibb, Kyowa Kirin, Sanofi, and SymBio Pharmaceuticals. M.L.P. declares consulting fees from BeOne Medicines, Bristol Myers Squibb, Seres Therapeutics, and Synthekine; stock in Seres Therapeutics; honoraria from Garuda Therapeutics, Seres Therapeutics, and Thymofox; research funding (to her institution) from Seres Therapeutics; and intellectual property rights (to her institution) from Juno Therapeutics, a Bristol Myers Squibb company. J.S.A. declares consulting fees from AbbVie, ADC Therapeutics, Alimera Sciences, AstraZeneca, BeiGene, Bluebird Bio, Bristol Myers Squibb, C4 Therapeutics, Caribou Biosciences, Celgene (a Bristol Myers Squibb company), Cellectar Biosciences, Century Therapeutics, EMD Serono, Epizyme, Foresight Diagnostics, Genmab, Incyte Corporation, Interius BioTherapeutics, Janssen, Johnson & Johnson, Karyopharm Therapeutics, Kite/Gilead, Kymera Therapeutics, Lilly, Miltenyi Biotec, MorphoSys, Mustang Bio, Novartis, Ono Pharmaceutical, Roche/Genentech, Seagen, and Takeda and research funding from Alimera Sciences, Celgene (a Bristol Myers Squibb company), Cellectis, Genentech, Merck, Mustang Bio, Regeneron, Seagen, and Takeda. P.B. declares consulting fees from Amgen, BeiGene, Bristol Myers Squibb, Gilead, Incyte, Miltenyi Biotec, MSD, Novartis, Roche, and Takeda Oncology; honoraria from AbbVie, Bristol Myers Squibb, Celgene (a Bristol Myers Squibb company), Gilead, Miltenyi Biotec, MSD, Novartis, Roche, and Takeda Oncology; and research funding from Amgen, Incyte, MSD, and Takeda Oncology. U.J. declares consulting fees from Gilead and honoraria from Bristol Myers Squibb, Gilead, Janssen, and Novartis. M.K. declares consulting fees from AbbVie, Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, BeiGene, Celgene (a Bristol Myers Squibb company), Genentech/Roche, and Novartis. M.D. declares consulting fees from AbbVie, AstraZeneca, AvenCell Therapeutics, BeOne Medicines, Bristol Myers Squibb, Genmab, Incyte, Janssen, Kite/Gilead, Lilly, Novartis, Roche, and Sobi; honoraria from AbbVie, AstraZeneca, BeOne Medicines, Bristol Myers Squibb, Janssen, Kite/Gilead, Lilly, Roche, and Sobi; and research funding (to his institution) from AbbVie, Janssen, Kite/Gilead, Lilly, and Roche. M. Subklewe declares consulting fees and/or participation on a data and safety monitoring board or advisory board for AbbVie, Aculeus Therapeutics, Advesya, Amgen, Autolus Therapeutics, AvenCell Therapeutics, Bristol Myers Squibb, Caribou Biosciences, Crossbow Therapeutics, Debiopharm, Genmab, Kite/Gilead, Ichnos Sciences, Interius BioTherapeutics, Janssen, Kyverna Therapeutics, Miltenyi Biomedicine, Molecular Partners, Nektar Therapeutics, Novartis, Orbital Therapeutics, Otsuka, Roche, Square Pharmaceuticals, and Takeda; honoraria from Amgen, AstraZeneca, Bristol Myers Squibb, Kite/Gilead, Miltenyi Biomedicine, Novartis, Roche, and Takeda; travel support from AbbVie, Amgen, Kite/Gilead, Molecular Partners, Pierre Fabre, and Roche; and research support or educational grants (to their institution) from Amgen, AvenCell Therapeutics, Celgene (a Bristol Myers Squibb company), Kite/Gilead, Janssen, Miltenyi Biomedicine, Molecular Partners, Novartis, Roche, Seagen, and Takeda. S.D. declares participation on advisory boards for Adaptive Biotechnologies, Bristol Myers Squibb, and Kite and research funding from Kite and Kyverna Therapeutics. L.J.N. declares honoraria from AstraZeneca, Bristol Myers Squibb, Genentech/Roche, Genmab, Johnson & Johnson/Janssen, Novartis, and Regeneron. M.B., M. Strocchia, M.R., L.B., J.P., and S.C. declare employment and stock ownership in Bristol Myers Squibb. F.M. declares consulting fees from AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Gilead, Janssen, Miltenyi Biotec, Roche, and Takeda; honoraria from AstraZeneca; and research funding from Bristol Myers Squibb, Kite/Gilead, and Roche. A.P.R. declares no competing financial interests.

PMID 42462111 · 2026

Challenges in Diagnosing High-grade B-cell Lymphoma, NOS: Poor Interobserver Agreement on Its Morphologic Definition-An LLMPP Study.

Conflicts of Interest and Source of Funding: D.W.S. reports consultancy for Abbvie, AstraZeneca, GenMab, Roche and Veracyte, research funding from Roche/Genentech. A.R., E.C., T.C.G., E.S.J., D.D.W., W.C.C., K.F., J.D., L.M.R., D.W.S., G.O., and J.R.C. are inventors on patents describing the use of gene expression profiling for COO subtyping aggressive B-cell lymphomas. D.W.S. is an inventor on a patent describing the identification of dark zone signature positive DLBCL/HGBCL. L.M.R. reports honoraria from Roche Tissue Diagnostics. For the remaining authors, none were declared.

PMID 42138053 · 2026

Covariate selection and adjustment for efficacy and safety endpoints in indirect comparative effectiveness analyses of CAR-T-cell therapies for large B-cell lymphoma: a systematic review.

Competing interests disclosure. J Mahlich, S Riou and S Rungaldier were employees of Miltenyi Biomedicine GmbH during conduct of study. J Jost and S Walzer received funding from Miltenyi Biomedicine. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.

PMID 42359923 · 2026

Dupilumab therapy in atopic dermatitis when cutaneous lymphoma is suspected: Consensus recommendations from the EORTC Cutaneous Lymphoma Tumour Group.

Disclosure statement Disclosure of potential conflict of interest: J. Calvão has received honoraria and/or travel support from Kyowa Kirin, LEO, and Adcetris. C. Jonak has received consulting and/or lecture fees and/or travel support from Almirall, Kyowa Kirin, Recordati Rare Diseases, Stemline Therapeutics, and Takeda. J. P. Nicolay has received travel and congress participation funding by TEVA and Novartis; and consulting from TEVA, Almirall, Biogen, Novartis, Kyowa Kirin, Innate Pharma, Takeda, Actelion, Therakos, Pierre Fabre, UCB Pharma, and Recordati. M. Battistella has received honoraria and/or travel support from Kyowa Kirin, Innate Pharma, Takeda, Recordati, BMS, MSD, Regeneron, and Sanofi. W. Kempf has received honoraria and/or travel support from Stemline and Recordati. P. L. Ortiz-Romero has received honoraria from Kyowa Kirin, Takeda, Helsinn, Recordati Rare Diseases, and Mallinckrodt. P. Brunner has received personal fees from Almirall, Sanofi, Janssen, LEO Pharma, AbbVie, Pfizer, Boehringer Ingelheim, GSK, Regeneron, Eli Lilly, Celgene, Novartis, UCB, Merck, RAPT Therapeutics, Galderma, Immunocore, TD Securities, Apogee and Bristol Myers Squibb; P. Brunner has received research support from Pfizer (grant paid to his institution) and is an investigator for Pfizer and Abbvie. M. Gonçalo has received honoraria and/or served on advisory boards for AbbVie, Almirall, Astra-Zeneca, Janssen, LEO Pharma, Pfizer, Sanofi, Novartis, Biocryst, and Takeda; and reports service as secretary-general of European Academy of Dermatology and Venereology (EADV). E. Guenova is a member of the EADV and the European Organization for Research and Treatment of Cancer; and holds stock in Scailyte AG. The rest of the authors declare that they have no relevant conflicts of interest.

PMID 41967816 · 2026

Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study.

Conflict-of-interest disclosure: A.L.F. is an inventor of technology for which Mayo Clinic holds unlicensed patents; has intellectual property licensed to Zeno Pharmaceuticals; and has received research funding from Seattle Genetics. D.W.S. reports consultancy for AbbVie, AstraZeneca, Genmab, Roche, and Veracyte; reports research funding from Roche/Genentech; and is an inventor on patents describing the use of gene expression to subtype aggressive lymphoma, one of which is licensed to NanoString Technologies. E.C. has received honoraria from Janssen, EUSA Pharma, Roche, and ThermoFisher for speaking at educational activities; has received research funding from AstraZeneca; and is an inventor on 2 patents licensed to NanoString Technologies and 1 patent licensed to Diagnostica Longwood. K.J.S. reports honoraria from/consulting with Seattle Genetics and AbbVie; reports consultancy with Roche; reports research funding from Bristol Myers Squibb; serves on a data and safety monitoring committee for Regeneron; and reports steering committee membership with Corvus. A.S. receives research grants from Eisai Co, Ltd. K.K. receives research grants from Takeda Pharmaceuticals and Eisai Co Ltd; and receives honoraria from Takeda Pharmaceuticals, Eisai Co Ltd, Kyowa Kirin Co Ltd, and Meiji Seika Pharmatech. L.d.L. reports institutional honoraria from AbbVie, Blueprint Medicine, Gilead, Menarini, and Novartis; and travel support from Roche. The remaining authors declare no competing financial interests.

PMID 41329859 · 2026

Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.

Conflict-of-interest disclosure: R.M reports serving on the advisory board for Genmab, Bristol Myers Squibb (BMS), AbbVie, Ipsen, and Kite; consulting for DG Medicine; receiving honoraria from Genmab and AbbVie; receiving institutional research funding from Merck, BMS, Genmab, and Genentech/Roche. S.C.R. reports consulting for AbbVie, ADC Therapeutics, BMS, Genmab, Incyte, Ipsen, Karyopharm, Kite, and Pfizer; serving on the data and safety monitoring board of Karyopharm; and receiving research funding from Constellation, Genentech/Roche, Ipsen, and Karyopharm. P.A. is a consultant for Merck, BMS/Celgene, Pfizer, Affimed, Adaptive, Infinity, ADC Therapeutics, MorphoSys, Daiichi Sankyo, Miltenyi, Tessa, Genmab, C4 Therapeutics, Enterome, Regeneron, Epizyme, AstraZeneca, Genentech/Roche, Xencor, Foresight Diagnostics, ATB Therapeutics, and Mabqi; reports research funding from Kite, Merck, BMS/Celgene, Affimed, Adaptive, Tensha, Otsuka, Sigma Tau, Genentech/Roche, IGM Biosciences, and AstraZeneca; and reports honoraria from Merck and BMS. J.P.L. has received research support from National Institutes of Health/National Cancer Institute, Leukemia and Lymphoma Society, Genentech Foundation, Lymphoma Research Foundation, Follicular Lymphoma Foundation, Epizyme, and Janssen; consulting fees from AstraZeneca, BeiGene, Caribou Biosciences, Foresight, Genentech, Kyowa Kirin, Novartis, Ono, Pfizer, Regeneron, Sail Bio, and Treeline Biosciences. L.N. has received honoraria for consulting from AbbVie, AstraZeneca, BMS, Genentech, Genmab, Gilead/Kite, Incyte, Ipsen, Janssen, Novartis, Regeneron, and Takeda; research support from BMS, Daiichi Sankyo, Genentech, Genmab, Gilead/Kite, Janssen, Merck, Novartis, and Takeda. S.M.S. has received consulting fees (time limited and/or one time) for Genmab, Regeneron, and Foresight Diagnostics; and her spouse is employed by Caris Life Sciences. A.D.Z. has served as a consultant (including expert testimony) for, and has received honoraria from, Genentech, Ipsen, AbbVie, Allogene, Curio Science, DAVA Oncology, BeOne, Ono Pharma, Kite, AstraZeneca, Genmab, and Eli Lilly; Has received research funding from Genentech/Roche, Arvinas, BeOne, GSK, and Pharmacyclics (Rollover Study); serves as a data monitoring committee member for BMS/Celgene and Juno. C.C. has received honoraria from Incyte, AbbVie, Genentech/Roche, and Genmab; has served as a consultant for Incyte, AbbVie, Genentech/Roche, and Genmab; and has received research funding from Genmab, Gilead , and Genentech. J.C. has received research funding (to Mayo Clinic) from Genentech, Genmab, and BMS; and serves on the science advisory board for Protagonist. M. Green has received research funding from Sanofi, Kite/Gilead, AbbVie, and Allogene; consulting fees from AbbVie and Allogene; serves on the advisory board for BMS, Arvinas, and Johnson & Johnson; has received honoraria from BMS, Daiichi Sankyo, and DAVA Oncology; and has stock ownership in Melbridge Therapeutics and Shenandoah Therapeutics. B.K. reports consulting for AbbVie, BMS, GSK, Roche, BeiGene, Eli Lilly, ADC Therapeutics, AstraZeneca, Genentech, Pfizer, Merck, and Incyte; and receiving research funding from AstraZeneca, BeiGene, and Roche. R.K. has received research funding (to institution) from AbbVie, AstraZeneca, BMS, and Roche. M.J.M. has received research funding from Roche/Genentech and BMS; and honoraria from MD Education. B.N. has received grant/research support from BMS; and honoraria from BeiGene, Diatech Pharmaceutical, and Mabqi. A.J.R. is an employee of Leica Microsystems. E.L. has received consulting fees from Pfizer and ADC Therapeutics. G.S. is a member of advisory boards, consulting committees, or data monitoring committees for AbbVie, BeiGene, BMS, Canopy, Daiichi Sankyo, Ellipses, Genentech/Roche, Genmab, Janssen, Incyte, Ipsen Kite/Gilead, Eli Lilly, Merck, Novartis, and SERB Pharmaceuticals; and has received research support from AbbVie, Genentech, Genmab Janssen, and Ipsen, which was managed by his institution. L.S. has received consulting fees or honoraria from AbbVie, AstraZeneca, BeiGene, Cargo, Chugai, BMS, Eli Lilly, Genmab, Kite/Gilead, Incyte, Janssen, Merck, Seagen, and Roche/Genentech; and research funding from Roche/Genentech. L.P. has received research grant from AstraZeneca. A.S.L. has received consulting fees from Genmab, Kite, and Pierre Fabre. The remaining authors declare no competing financial interests.

PMID 41337699 · 2026

Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G Committee.

GD: Honoraria: Takeda, Amgen. Travel support: Takeda. Research support: Takeda, Ideogen. ADM: Honoraria: Takeda, Kyowa Kirin, Helsinn, Recordati Rare Diseases, Almirall, Novartis. Travel support: Kyowa Kirin, Recordati Rare Diseases, Novartis. Research support: Kyowa Kirin. PD: None reported. AB: Honoraria: Takeda, Amgen, Janssen, Roche, Maat Pharma Research Support: Takeda, Roche, Novartis, Janssen. PB: None reported. FS: None reported. RFD: None reported. CPF: Consultancy: AbbVie, Arvinas, Atarabio, BMS, GenMab, Gilead/Kite, Incyte, Lilly, Morphosys, Ono, Roche, SERB, SOBI, Takeda. Research funding: BeiGene, AbbVie/GenMab, Incyte. EG: honoraria and/or grant support from Mallinckrodt, Helsinn, Takeda Pharmaceuticals, Recordati Rare Diseases, Novartis, Sanofi, Stemline Therapeutics and Kyowa Kirin. OH: Research fund, BMS, Bluueprint, Abbvie, Roche. CK: Research support BMS, Travel support Takeda. AT: Honoraria: Genesis Pharma, SOBI, Johnson&Johnson, AbbVie. OT: Honoraria: Takeda, BeiGene. Travel support: Takeda, AbbVie, Astra‐Zeneca, BeiGene. Research Support: Takeda. WJ: Honoraria: Takeda, AbbVie. IEK: supported by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)—493624047 (Clinician Scientist CareerS Muenster), Honoraria: Kite/Gilead, Travel grants: BeiGene. SNQ: Honoraria: Jazz Pharma, Novartis, AbbVie, Gilead; Travel support: AbbVie, Gilead, Sanofi, Neovii. YS: None reported. GW: Honoraria: Takeda, Gilead Scienes, Novartis, Clinigen; Travel support: Medac, Janssen. AS: Honoraria: Takeda, BMS/Celgene, MSD, Janssen, Amgen, Novartis, Gilead Kite, Sanofi, Roche, GenMab, AbbVie, Jazz Pharmaceuticals, Therakos, Menarini; Consultancy: Takeda, BMS/Celgene, Novartis, Janssen, Gilead, Sanofi, GenMab, AbbVie; Speaker's Bureau: Takeda; Research Support: Takeda; non‐profit organizations: Presidency of the EBMT. EP: Takeda, Recordati, Helsinn, Kyowa Kirin, Novartis, UCB, Leo, Abbvie, Jansen. PLOR: Honoraria: Takeda, Kyowa Kirin, Helsinn, Recordati Rare Diseases. Travel support: UCB, Kyowa Kirin, Recordati Rare Diseases, Novartis. ALR: None reported. ISO: None reported. JS: Honoraria & Consultancy Helsinn, Recordati, Takeda, Therakos, Kyowa Kirin. IYA: Honoraria: Novartis, BMS, Kite/Gilead, Janssen and Pfizer. FO: Honoraria: Takeda, MEDAC Pharma, Kyowa Kirin; Travel support: Takeda, Jazz Pharma, Kyowa Kirin; NS: Travel support: Beigene, Roche, Stocks: BMS.

PMID 41031482 · 2026
01

Current Standard-of-Care Sources

Alexandria uses this label only for PubMed-indexed guidelines or consensus documents. These are source publications, not individualized recommendations.

02

Highest-Priority Research

clinical guideline

[China lymphoma diagnosis and treatment guideline (2026 edition)].

Zhonghua zhong liu za zhi [Chinese journal of oncology] · 2026

Lymphoma is one of the most common malignancies in China. Lymphoma exhibited complex pathological subtypes with significant heterogeneity, the treatment strategies varied. In recent years, with a deeper understanding of the mechanisms of oncogenesis and disease progression of lymphoma, significant development has been made in diagnosis and treatment, leading to the improvement of patients' clinical outcomes. In order to update the progress in the diagnosis and treatment of lymphoma. The Medical Oncology Branch of China International Exchange and Promotive Association for Medical and Health Care, the China Anti-cancer Association Lymphoma Committee, and the Chinese Association for Clinical On…

PMID 41876194
clinical guideline

Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee.

Bone marrow transplantation · 2026

Cellular therapies, namely autologous hematopoietic cell transplantation (autoHCT), allogeneic HCT (alloHCT) and more recently, chimeric antigen receptor T-cell therapies (CART), play a major role in state-of-the-art treatment of mantle cell lymphoma (MCL). With numerous therapeutic innovations currently entering the MCL treatment landscape, guidance for indication, sequencing and application of cellular therapies is of key importance. To address this practical need, the European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonisation and Guidelines Committee convened an international expert meeting in Berlin on Sept 29/30, 2025. EBMT provided funding and logistical suppor…

PMID 42420469
clinical guideline

European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders.

The British journal of dermatology · 2025

In recent classifications several cutaneous lymphomas were reclassified as lymphoproliferative disorder (LPDs). These include primary cutaneous CD4+ small/medium T-cell LPD (PCSM-TCLPD), primary cutaneous acral CD8+ T-cell LPD (acral CD8+ TCLPD) and primary cutaneous marginal zone lymphoma/LPD (PCMZL/LPD). The latter is still classified as primary cutaneous marginal zone lymphoma (PCMZL) in the 5th edition of the World Health Organization classification. A survey was previously carried out among 30 cutaneous lymphoma centres on the effects of this new terminology on clinical management. The results revealed considerable heterogeneity and emphasized the need to develop uniform recommendations…

PMID 40795052
clinical guideline

The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline.

British journal of haematology · 2026

Primary mediastinal B-cell lymphoma (PMBCL) is a distinct clinicopathological entity within the spectrum of aggressive B-cell lymphomas, characterised by unique clinical, immunophenotypic and molecular features. Since publication of the 2019 British Society for Haematology (BSH) Good Practice Paper, there have been important advances in imaging, radiotherapy approaches and systemic therapies, including chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint inhibition. Key updates include the use of PET-adapted approaches to guide radiotherapy decisions following first-line chemoimmunotherapy, with omission of consolidative radiotherapy in patients achieving complete metabolic r…

PMID 42634099
clinical guideline

Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G Committee.

Journal of the European Academy of Dermatology and Venereology : JEADV · 2026

This manuscript provides expert recommendations on the role of allogeneic haematopoietic cell transplantation (allo-HCT) for cutaneous T-cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sezary syndrome (SS). Critical aspects such as patient selection, timing, and bridging therapy are addressed, as well as donor source, conditioning regimens and post-transplant management. These consensus guidelines are based on a thorough literature review and discussions among leading dermatologists and haematologists. These recommendations aim to harmonize clinical practice towards improving patient outcomes in these rare but aggressive lymphomas. It is of critical importance to consider allo-…

PMID 41031482
clinical guideline

Large B-cell lymphoma: The LYSA pragmatic guidelines.

European journal of cancer (Oxford, England : 1990) · 2026

The management of large B-cell lymphomas (LBCL) has undergone major changes over the last 5 years. These changes reflect the availability of new therapies (immunotherapies, cell therapies, targeted molecules), but also a better compartmentalization of the entities and their specific clinical characteristics. Numerous first-, second- and third-line therapeutic strategies are available, and each practitioner is committed to selecting the treatment that offers the best balance between efficacy and toxicity. Advances in the understanding of LBCL biology, coupled with improvements in diagnostic and monitoring tools and therapeutic approaches, have significantly enhanced patient outcomes in recent…

PMID 41352004
clinical guideline

B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN · 2026

Mantle cell lymphoma (MCL) is a heterogenous subtype of B-cell non-Hodgkin lymphoma (NHL). The treatment landscape of newly diagnosed MCL has evolved in recent years with the incorporation of covalent BTK inhibitors, sensitive assays for the assessment of measurable residual disease (MRD), and predefined maintenance or continuous therapy. Covalent BTK inhibitor-based regimens are also appropriate options for patients with previously untreated classic MCL with TP53 mutations. Pirtobrutinib (a highly selective noncovalent BTK inhibitor) and CAR T-cell therapy (brexucabtagene autoleucel or lisocabtagene maraleucel) have emerged as effective treatment options for refractory or progressive diseas…

PMID 42753811
meta analysisn=140841

Is tattooing associated with an increased risk of cancer? A systematic review and meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026

BACKGROUND: Tattoo inks may contain carcinogenic compounds, and pigment migration to lymphatic tissues raises concerns regarding potential cancer risk. Epidemiological evidence remains inconclusive. OBJECTIVES: To assess the association between tattoo exposure and the incidence of skin cancer and hematological malignancies. METHODS: PubMed, Embase, and the Cochrane Library were searched from inception to January 2026 for cohort and case-control studies comparing cancer incidence in tattooed versus non-tattooed adults. Random-effects meta-analyses using restricted maximum-likelihood estimators were performed to pool odds ratios (ORs) with 95% confidence intervals (CIs). Heterogeneity was quan…

PMID 42250187
meta analysisn=550385

Long-term cardiovascular risk in survivors of hematologic malignancies: a meta-analysis.

BMC cancer · 2026

BACKGROUND: The survival rate for hematologic malignancies is steadily improving. With the encouraging trend and the aging of these survivors, there is an ever-increasing responsibility for identifying adverse cardiovascular outcomes associated with carcinogenesis and/or anti-cancer therapies across the span of their lives. However, prospective studies have yielded inconsistent results. METHODS: We performed a meta-analysis to summarize the evidence regarding the association between leukemia, Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL) in relation to later risk of cardiovascular disease (CVD). Relevant literatures were identified from PubMed and Web of Science databases through May…

PMID 42332608
clinical guideline

Narrowband UVB Phototherapy in Dermatology: GEF-CILAD 2026 Update.

Actas dermo-sifiliograficas · 2026

This document updates the scientific evidence and clinical practice regarding narrowband UVB phototherapy (NB-UVB) in dermatology. The review addresses indications, therapeutic regimens, safety aspects, combinations with systemic and biologic agents, and adaptation to special populations. NB-UVB remains a first-line therapy for psoriasis, vitiligo, atopic dermatitis, early mycosis fungoides, and photodermatoses due to its efficacy, safety, and cost-effectiveness. Emerging evidence supports its integration with next-generation systemic therapies. This update provides recommendations for its application in the era of targeted therapies, with an emphasis on efficiency and patient-centered care.

PMID 42323047
clinical guideline

Executive Summary of the American Radium Society Appropriate Use Criteria for Extranodal Natural Killer/T-cell Lymphoma.

International journal of radiation oncology, biology, physics · 2026

Extranodal natural killer/T-cell lymphoma is a rare and aggressive extranodal non-Hodgkin lymphoma. These evidence-based recommendations for natural killer/T-cell lymphoma by the American Radium Society were developed by a multidisciplinary panel of medical and radiation oncologists to propose treatment approaches. This guideline was based on a literature review with a consensus methodology to rate the appropriateness of treatment recommendations for each natural killer/T-cell lymphoma clinical presentation. Six variants highlight the recommended treatment strategies.

PMID 41785936
clinical guideline

Japanese Dermatological Association Guidelines: Outlines of Japanese Guidelines for the Management of Primary Cutaneous Lymphomas 2025.

The Journal of dermatology · 2025

Since the publication of the Japanese guidelines for the management of cutaneous lymphomas in 2020, the WHO classification of hematolymphoid neoplasms has been updated, and a number of novel systemic drugs for cutaneous T-cell lymphoma have been approved in Japan. In 2025, we revised the Japanese guidelines for the management of cutaneous lymphomas in consideration of recent advances in our understanding of the pathophysiology and classification of cutaneous lymphomas, together with the update in treatment strategies reflecting the advent of novel drugs. This revision was also conducted under the Japanese Dermatological Association's commission, incorporating expert reviews and public commen…

PMID 41204060
03

Latest Research — Last 24 Months

04

Treatment Options Studied in the PubMed Collection

These are interventions detected in PubMed metadata and abstracts. Inclusion does not establish approval, effectiveness, suitability, or standard-of-care status.

preliminary evidence

Rituximab

95 linked PMIDs69306 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
overall survival, progression-free survival, reported clinical outcomes, adverse events, response rate, complete response, cytokine release syndrome, quality of life
Populations represented
diffuse large B-cell lymphoma; general population; diffuse large B-cell lymphoma; first-line; follicular lymphoma; diffuse large B-cell lymphoma; CD20; follicular lymphoma; first-line; CD20
Mechanism
They differ not only in the therapy evaluated in the experimental arm, but in the choice of control arm, primary end point, and patient selection strategy, with some targeting specific biologic subtypes, some focusing on specific high-risk patient populations, and others enrolling older or frail patients Oral Azacitadine (AZA) is a hypomethylating agent that inhibits DNA methyltransferase and has provided evidence of chemotherapy sensitization in DLBCL
PMID 42362499PMID 42743819PMID 42801438PMID 37014666PMID 42645398PMID 40344323PMID 40829156PMID 42910135
preliminary evidence

Receptors, Chimeric Antigen

73 linked PMIDs7726 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, cytokine release syndrome, response rate, overall survival, progression-free survival, complete response, mortality, quality of life
Populations represented
general population; CD19; diffuse large B-cell lymphoma; CD20; CD19; diffuse large B-cell lymphoma; CD19; follicular lymphoma; CD19
Mechanism
Pharmacological inhibition of iNOS enhances CAR T cell treatment efficacy in vivo Targeting iNOS in immunoregulatory macrophages, potentially by modulating CAR T-produced IFN-γ, could improve LBCL outcomes
PMID 42782760PMID 42890243PMID 42623673PMID 42242005PMID 39393068PMID 35167008PMID 35922564PMID 41288531
limited evidence

Biomarkers, Tumor

53 linked PMIDs5567 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, overall survival
Populations represented
general population; diffuse large B-cell lymphoma; follicular lymphoma; mantle cell lymphoma; diffuse large B-cell lymphoma; MYC; BCL2; BCL6; diffuse large B-cell lymphoma; first-line
Mechanism
Immune checkpoints are key regulators of tumor-immune interactions and important targets in cancer therapy These findings demonstrate that ferroptosis regulates DLBCL progression and identify potential biomarkers/therapeutic targets requiring validation to develop new therapies
PMID 34226673PMID 42595015PMID 38497417PMID 40026197PMID 41746860PMID 38750139PMID 40511879PMID 41548166
moderate-confidence evidence

Doxorubicin

43 linked PMIDs13122 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
overall survival, progression-free survival, reported clinical outcomes, complete response, response rate, recurrence, adverse events
Populations represented
diffuse large B-cell lymphoma; diffuse large B-cell lymphoma; first-line; general population; diffuse large B-cell lymphoma; CD20; first-line; diffuse large B-cell lymphoma; first-line; older adults
Mechanism
Erianin, a natural compound derived from the Chinese herb Dendrobium , has been shown to exhibit anticancer effects in certain types of cancer; however, its role and mechanism of action in DLBCL have not yet been reported Mechanistically, erianin induced inhibition of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway in DLBCL cells, which led to increased reactive oxygen species (ROS) formation, inflammasome activation, and caspase-1/Gasdermin D (GSDMD)-dependent pyroptosis
PMID 42801438PMID 37014666PMID 42645398PMID 42910135PMID 40859046PMID 37812294PMID 41411222PMID 41420335
preliminary evidence

Antigens, CD19

43 linked PMIDs2031 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, cytokine release syndrome, response rate, overall survival, progression-free survival, complete response, adverse events, mortality
Populations represented
CD19; CD20; CD19; follicular lymphoma; CD19; second-line; third-line; CD19; diffuse large B-cell lymphoma; CD19; general population
Mechanism
At present, there are two targeting CD19 CAR-T cells for the treatment of B-cell lymphoma, which gradually changed the diagnosis and treatment practice of lymphoma in China Thus, defining complementary targets to CD19 is critical to avoid target-dependent limitations
PMID 38266761PMID 41483380PMID 41443729PMID 40504989PMID 38102213PMID 38615142PMID 39240498PMID 42849448
preliminary evidence

Vincristine

41 linked PMIDs12769 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
overall survival, progression-free survival, reported clinical outcomes, complete response, response rate, recurrence, adverse events
Populations represented
diffuse large B-cell lymphoma; general population; diffuse large B-cell lymphoma; first-line; diffuse large B-cell lymphoma; CD20; first-line; diffuse large B-cell lymphoma; first-line; older adults
Mechanism
They differ not only in the therapy evaluated in the experimental arm, but in the choice of control arm, primary end point, and patient selection strategy, with some targeting specific biologic subtypes, some focusing on specific high-risk patient populations, and others enrolling older or frail patients Moreover, the combination of mitotic kinase inhibitors and the microtubules-targeting agent vincristine (VCR) exhibit synergistic anti-tumor effects in B-cell lymphoma mouse models
PMID 42801438PMID 37014666PMID 42645398PMID 42910135PMID 40859046PMID 37812294PMID 41411222PMID 41420335
moderate-confidence evidence

Cyclophosphamide

39 linked PMIDs13299 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
overall survival, progression-free survival, reported clinical outcomes, complete response, response rate, recurrence, adverse events
Populations represented
diffuse large B-cell lymphoma; diffuse large B-cell lymphoma; first-line; general population; first-line; diffuse large B-cell lymphoma; first-line; older adults
Mechanism
They differ not only in the therapy evaluated in the experimental arm, but in the choice of control arm, primary end point, and patient selection strategy, with some targeting specific biologic subtypes, some focusing on specific high-risk patient populations, and others enrolling older or frail patients Mechanistically, the WNT signaling regulator casein kinase 1ɛ (CSNK1E) was upregulated in these stemlike drug-persistent cells, in part through the activation of the A proliferation-inducing ligand (APRIL)-TNFRSF13B axis
PMID 42801438PMID 37014666PMID 42645398PMID 42910135PMID 40859046PMID 37812294PMID 40844644PMID 41411222
preliminary evidence

Prednisone

34 linked PMIDs12609 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
overall survival, progression-free survival, reported clinical outcomes, complete response, response rate, recurrence, adverse events
Populations represented
diffuse large B-cell lymphoma; diffuse large B-cell lymphoma; first-line; general population; first-line; diffuse large B-cell lymphoma; first-line; older adults
Mechanism
They differ not only in the therapy evaluated in the experimental arm, but in the choice of control arm, primary end point, and patient selection strategy, with some targeting specific biologic subtypes, some focusing on specific high-risk patient populations, and others enrolling older or frail patients Mechanistically, the WNT signaling regulator casein kinase 1ɛ (CSNK1E) was upregulated in these stemlike drug-persistent cells, in part through the activation of the A proliferation-inducing ligand (APRIL)-TNFRSF13B axis
PMID 42801438PMID 42645398PMID 42910135PMID 40859046PMID 37812294PMID 41411222PMID 41420335PMID 35536508
preliminary evidence

CAR T-cell therapy

32 linked PMIDs3676 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
cytokine release syndrome, reported clinical outcomes, progression-free survival, overall survival, response rate, complete response, adverse events, mortality
Populations represented
CD19; general population; diffuse large B-cell lymphoma; CD19; follicular lymphoma; CD19; diffuse large B-cell lymphoma; CD20; CD19
Mechanism
Prizloncabtagene autoleucel (prizlon-cel), a novel bispecific chimeric antigen receptor T cell, targets and eliminates CD19/CD20-positive tumor cells We review the basis for targeting eIF4A1, the clinical experience with drugs directed at the eIF4F axis, and the disease settings that should be prioritized next
PMID 42332219PMID 42885507PMID 39938007PMID 38996463PMID 42242517PMID 42890243PMID 42623673PMID 36869888
limited evidence

Antineoplastic Agents

26 linked PMIDs891 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, overall survival, complete response, adverse events, recurrence, mortality
Populations represented
general population; diffuse large B-cell lymphoma; MYC; CD20; children
Mechanism
We leveraged this extensive data set to define the molecular underpinnings of CTCL progression in individual patients at single-cell resolution with the goal of identifying clinically useful biomarkers and therapeutic targets We identified a gain-of-function mutation in STAT3 (D661Y) and demonstrated, using cleavage under targets and release using nuclease (CUT&RUN) and RNA sequencing, that it enhances binding to and transcription of genes in Rho GTPase pathways
PMID 21748202PMID 41662591PMID 34894347PMID 41410728PMID 40237047PMID 40257544PMID 40913453PMID 37149665
preliminary evidence

Antibodies, Bispecific

25 linked PMIDs11778 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, overall survival, response rate, complete response, cytokine release syndrome, progression-free survival, adverse events, mortality
Populations represented
general population; diffuse large B-cell lymphoma; CD20; CD20; follicular lymphoma; CD20; CD19
Mechanism
Macrophages are critical effectors of antibody therapies for lymphoma, but the best targets to engage their function remain unknown Across both mouse and human systems, we identify multiple unappreciated targets of opsonization as well as putative immune checkpoints
PMID 42313425PMID 41871044PMID 39708278PMID 41746860PMID 42385177PMID 39984633PMID 39792928PMID 40434509
preliminary evidence

R-CHOP

24 linked PMIDs12754 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
reported clinical outcomes, overall survival, progression-free survival
Populations represented
diffuse large B-cell lymphoma; diffuse large B-cell lymphoma; first-line; diffuse large B-cell lymphoma; MYC; diffuse large B-cell lymphoma; CD20; general population
Mechanism
Further experiments demonstrated that AP-48 exerted its anti-DLBCL effects through the PI3K/AKT/mTOR pathway, and that the PI3K agonist YS49 partially alleviated the inhibition of cell proliferation and apoptosis induced by AP-48 Mechanistically, the WNT signaling regulator casein kinase 1ɛ (CSNK1E) was upregulated in these stemlike drug-persistent cells, in part through the activation of the A proliferation-inducing ligand (APRIL)-TNFRSF13B axis
PMID 42877641PMID 35947123PMID 42644796PMID 42871637PMID 42613996PMID 36242752PMID 39073639PMID 37014666
preliminary evidence

bispecific antibody

17 linked PMIDs9913 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
overall survival, response rate, complete response, cytokine release syndrome, reported clinical outcomes, progression-free survival, adverse events, objective response rate
Populations represented
diffuse large B-cell lymphoma; CD20; general population; follicular lymphoma; first-line; CD20; CD20; CD19; follicular lymphoma
Mechanism
Bispecific antibodies (BsAbs) offer a novel multi-antigen targeting strategy In multiple myeloma (MM), BCMA- and GPRC5D-targeting BsAbs achieved MRD negativity and deep responses including very good partial response (VGPR) and stringent complete response (sCR)
PMID 39792928PMID 40434509PMID 42955341PMID 39786390PMID 42313425PMID 39708278PMID 42385177PMID 39984633
preliminary evidence

R-CHOP protocol

15 linked PMIDs10481 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
overall survival, progression-free survival, reported clinical outcomes
Populations represented
diffuse large B-cell lymphoma; diffuse large B-cell lymphoma; first-line; diffuse large B-cell lymphoma; first-line; older adults
Mechanism
Mechanistically, the WNT signaling regulator casein kinase 1ɛ (CSNK1E) was upregulated in these stemlike drug-persistent cells, in part through the activation of the A proliferation-inducing ligand (APRIL)-TNFRSF13B axis
PMID 42645398PMID 40859046PMID 41411222PMID 41420335PMID 41171506PMID 42839187PMID 41941177PMID 41758931
preliminary evidence

Antibodies, Monoclonal, Humanized

14 linked PMIDs1116 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
response rate, adverse events, reported clinical outcomes, overall survival, progression-free survival, objective response rate, complete response
Populations represented
general population; diffuse large B-cell lymphoma; CD19
Mechanism
BACKGROUND: Tetraspanin CD37, highly expressed in mature B-cells, represents an opportunity for therapeutic targeting in B-cell malignancies GEN3009 (DuoHexaBody-CD37), a humanized biparatopic IgG1 antibody with an E430G hexamerization-enhancing mutation targeting two non-overlapping CD37 epitopes, was shown to induce potent tumor cell killing through enhanced complement-dependent cytotoxicity (CDC) and other fragment crystallizable-mediated effector functions, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), in vitro and in vivo
PMID 40073374PMID 34893942PMID 37255002PMID 39294486PMID 36398795PMID 42413982PMID 41967816PMID 42805618
preliminary evidence

Antineoplastic Agents, Immunological

12 linked PMIDs5203 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
progression-free survival, adverse events, overall survival, complete response, reported clinical outcomes, response rate
Populations represented
general population; diffuse large B-cell lymphoma; CD19; diffuse large B-cell lymphoma; CD20; CD20; CD19
Mechanism
BACKGROUND: Tetraspanin CD37, highly expressed in mature B-cells, represents an opportunity for therapeutic targeting in B-cell malignancies GEN3009 (DuoHexaBody-CD37), a humanized biparatopic IgG1 antibody with an E430G hexamerization-enhancing mutation targeting two non-overlapping CD37 epitopes, was shown to induce potent tumor cell killing through enhanced complement-dependent cytotoxicity (CDC) and other fragment crystallizable-mediated effector functions, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), in vitro and in vivo
PMID 41025752PMID 39294486PMID 42263668PMID 42413982PMID 42620849PMID 39234866PMID 41212511PMID 42955341
limited evidence

Antigens, CD20

12 linked PMIDs1664 reported cumulative sample signal
Research status
insufficiently reported
Outcomes represented
overall survival, response rate, reported clinical outcomes, progression-free survival, cytokine release syndrome, complete response, adverse events, recurrence
Populations represented
CD20; CD19; CD20; diffuse large B-cell lymphoma; CD20
Mechanism
Prizloncabtagene autoleucel (prizlon-cel), a novel bispecific chimeric antigen receptor T cell, targets and eliminates CD19/CD20-positive tumor cells To overcome single-antigen escape, we evaluated a trispecific CAR targeting CD19, CD20, and CD22 with an OX40 costimulatory domain
PMID 41804087PMID 41986386PMID 39813680PMID 39351902PMID 42446920PMID 42890889PMID 13130315PMID 42764913
05

Conflicting Research

higher-confidence evidence

Rituximab · multiple reported outcomes

45 studies

Status: apparently conflicting; different clinical questions. Population: diffuse large B-cell lymphoma. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
mixed: 1unknown: 38null: 3benefit: 3
PMID 42362499PMID 42912792PMID 42062177PMID 42743819PMID 40997297PMID 42801438PMID 27196701PMID 42572648PMID 37403255PMID 37014666
higher-confidence evidence

Rituximab · multiple reported outcomes

33 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 29null: 1harm: 1benefit: 2
PMID 41785936PMID 42213311PMID 40397196PMID 41989666PMID 41335575PMID 33938097PMID 42298056PMID 23562041PMID 37463687PMID 42283231
higher-confidence evidence

Doxorubicin · multiple reported outcomes

24 studies

Status: apparently conflicting; different clinical questions. Population: diffuse large B-cell lymphoma. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
mixed: 1unknown: 20benefit: 2null: 1
PMID 42912792PMID 42062177PMID 40997297PMID 42801438PMID 27196701PMID 37403255PMID 37014666PMID 41402979PMID 42645398PMID 42910135
higher-confidence evidence

Cyclophosphamide · multiple reported outcomes

23 studies

Status: apparently conflicting; different clinical questions. Population: diffuse large B-cell lymphoma. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 19mixed: 1benefit: 2null: 1
PMID 42912792PMID 42062177PMID 40997297PMID 42801438PMID 27196701PMID 37403255PMID 37014666PMID 41402979PMID 42645398PMID 42910135
higher-confidence evidence

Vincristine · multiple reported outcomes

21 studies

Status: apparently conflicting; different clinical questions. Population: diffuse large B-cell lymphoma. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
mixed: 1unknown: 17benefit: 2null: 1
PMID 42912792PMID 42062177PMID 40997297PMID 42801438PMID 27196701PMID 37403255PMID 37014666PMID 33394214PMID 42645398PMID 42910135
higher-confidence evidence

R-CHOP · multiple reported outcomes

21 studies

Status: apparently conflicting; different clinical questions. Population: diffuse large B-cell lymphoma. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
mixed: 1unknown: 19benefit: 1
PMID 40997297PMID 37403255PMID 37014666PMID 42645398PMID 42458006PMID 40518458PMID 40859046PMID 37812294PMID 42962272PMID 41668558
higher-confidence evidence

Prednisone · multiple reported outcomes

20 studies

Status: apparently conflicting; different clinical questions. Population: diffuse large B-cell lymphoma. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
mixed: 1unknown: 16benefit: 2null: 1
PMID 42912792PMID 42062177PMID 40997297PMID 42801438PMID 27196701PMID 37403255PMID 42645398PMID 42910135PMID 42458006PMID 41171506
higher-confidence evidence

Cyclophosphamide · multiple reported outcomes

20 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 14null: 3benefit: 1harm: 1mixed: 1
PMID 41785936PMID 41656180PMID 40397196PMID 40829107PMID 33938097PMID 40939190PMID 42901914PMID 21748202PMID 40419413PMID 39316716
higher-confidence evidence

Doxorubicin · multiple reported outcomes

18 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 13null: 2benefit: 1harm: 1mixed: 1
PMID 41785936PMID 41656180PMID 40397196PMID 40829107PMID 33938097PMID 40939190PMID 42901914PMID 21748202PMID 40419413PMID 39316716
higher-confidence evidence

Vincristine · multiple reported outcomes

18 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 13null: 2benefit: 1harm: 1mixed: 1
PMID 41785936PMID 41656180PMID 40397196PMID 40829107PMID 33938097PMID 40939190PMID 42901914PMID 21748202PMID 40419413PMID 39316716
higher-confidence evidence

Prednisone · multiple reported outcomes

16 studies

Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 12null: 1benefit: 1harm: 1mixed: 1
PMID 41785936PMID 41656180PMID 40397196PMID 40829107PMID 33938097PMID 40939190PMID 42901914PMID 21748202PMID 40419413PMID 39316716
higher-confidence evidence

Rituximab · multiple reported outcomes

16 studies

Status: apparently conflicting; different clinical questions. Population: follicular lymphoma. Comparator: multiple or inconsistently reported comparators.

  • The records use different or inconsistently reported comparators.
  • The records report different endpoints or outcome definitions.
  • The evidence combines different study designs.
  • Some abstracts do not state whether the primary endpoint was met.
unknown: 13benefit: 2null: 1
PMID 42349017PMID 39374535PMID 38096461PMID 41990300PMID 42820870PMID 33452448PMID 35583725PMID 41980013PMID 35857194PMID 42527721
06

Failed or Negative Trials

07

Emerging and Experimental Research

08

Evidence Gaps

Detailed risk-of-bias assessment remains limited

PubMed abstracts often do not include enough methodological detail for a complete study-level risk-of-bias assessment.

R

Complete Ranked PubMed Index

The retrieval-priority score orders records using publication type, recency, sample-size signals, and replication signals. It is not a recommendation or a formal risk-of-bias grade.

Current Standard Of Care116 records
Rank112.0
Clinical guideline or consensus statement

[China lymphoma diagnosis and treatment guideline (2026 edition)].

Zhonghua zhong liu za zhi [Chinese journal of oncology] · 2026 · PMID 41876194

Lymphoma is one of the most common malignancies in China. Lymphoma exhibited complex pathological subtypes with significant heterogeneity, the treatment strategies varied. In recent years, with a deeper understanding of the mechanisms of oncogenesis and disease progression of lymphoma, significant development has been made in diagnosis and treatment, leading to the improvement of patients' clinical outcomes. In order to update the progress in the diagnosis and treatment of lymphoma. The Medical Oncology Branch of C…

Rank112.0
Clinical guideline or consensus statement

European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders.

The British journal of dermatology · 2025 · PMID 40795052

In recent classifications several cutaneous lymphomas were reclassified as lymphoproliferative disorder (LPDs). These include primary cutaneous CD4+ small/medium T-cell LPD (PCSM-TCLPD), primary cutaneous acral CD8+ T-cell LPD (acral CD8+ TCLPD) and primary cutaneous marginal zone lymphoma/LPD (PCMZL/LPD). The latter is still classified as primary cutaneous marginal zone lymphoma (PCMZL) in the 5th edition of the World Health Organization classification. A survey was previously carried out among 30 cutaneous lympho…

Rank112.0
Clinical guideline or consensus statement

Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee.

Bone marrow transplantation · 2026 · PMID 42420469

Cellular therapies, namely autologous hematopoietic cell transplantation (autoHCT), allogeneic HCT (alloHCT) and more recently, chimeric antigen receptor T-cell therapies (CART), play a major role in state-of-the-art treatment of mantle cell lymphoma (MCL). With numerous therapeutic innovations currently entering the MCL treatment landscape, guidance for indication, sequencing and application of cellular therapies is of key importance. To address this practical need, the European Society for Blood and Marrow Transp…

Rank110.0
Clinical guideline or consensus statement

Narrowband UVB Phototherapy in Dermatology: GEF-CILAD 2026 Update.

Actas dermo-sifiliograficas · 2026 · PMID 42323047

This document updates the scientific evidence and clinical practice regarding narrowband UVB phototherapy (NB-UVB) in dermatology. The review addresses indications, therapeutic regimens, safety aspects, combinations with systemic and biologic agents, and adaptation to special populations. NB-UVB remains a first-line therapy for psoriasis, vitiligo, atopic dermatitis, early mycosis fungoides, and photodermatoses due to its efficacy, safety, and cost-effectiveness. Emerging evidence supports its integration with next…

Rank110.0
Clinical guideline or consensus statement

Japanese Dermatological Association Guidelines: Outlines of Japanese Guidelines for the Management of Primary Cutaneous Lymphomas 2025.

The Journal of dermatology · 2025 · PMID 41204060

Since the publication of the Japanese guidelines for the management of cutaneous lymphomas in 2020, the WHO classification of hematolymphoid neoplasms has been updated, and a number of novel systemic drugs for cutaneous T-cell lymphoma have been approved in Japan. In 2025, we revised the Japanese guidelines for the management of cutaneous lymphomas in consideration of recent advances in our understanding of the pathophysiology and classification of cutaneous lymphomas, together with the update in treatment strategi…

Rank110.0
Clinical guideline or consensus statement

Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G Committee.

Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · PMID 41031482

This manuscript provides expert recommendations on the role of allogeneic haematopoietic cell transplantation (allo-HCT) for cutaneous T-cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sezary syndrome (SS). Critical aspects such as patient selection, timing, and bridging therapy are addressed, as well as donor source, conditioning regimens and post-transplant management. These consensus guidelines are based on a thorough literature review and discussions among leading dermatologists and haematologists…

Rank110.0
Clinical guideline or consensus statementResult signal: benefit

SEOM-GOTEL clinical guidelines on diffuse large B-cell lymphoma (update 2025).

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025 · PMID 41129029

Diffuse large B-cell lymphoma (DLBCL) is the most frequent histological subtype of non-Hodgkin lymphoma and the paradigm for the management of aggressive lymphoma. An excisional or incisional lymph node biopsy evaluated by an experienced hematopathologist is recommended to establish the diagnosis. Twenty years following its introduction, the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) remains the standard first-line treatment. No modification of this scheme (increas…

Rank110.0
Clinical guideline or consensus statement

Executive Summary of the American Radium Society Appropriate Use Criteria for Extranodal Natural Killer/T-cell Lymphoma.

International journal of radiation oncology, biology, physics · 2026 · PMID 41785936

Extranodal natural killer/T-cell lymphoma is a rare and aggressive extranodal non-Hodgkin lymphoma. These evidence-based recommendations for natural killer/T-cell lymphoma by the American Radium Society were developed by a multidisciplinary panel of medical and radiation oncologists to propose treatment approaches. This guideline was based on a literature review with a consensus methodology to rate the appropriateness of treatment recommendations for each natural killer/T-cell lymphoma clinical presentation. Six va…

Rank110.0
Clinical guideline or consensus statement

The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline.

British journal of haematology · 2026 · PMID 42634099

Primary mediastinal B-cell lymphoma (PMBCL) is a distinct clinicopathological entity within the spectrum of aggressive B-cell lymphomas, characterised by unique clinical, immunophenotypic and molecular features. Since publication of the 2019 British Society for Haematology (BSH) Good Practice Paper, there have been important advances in imaging, radiotherapy approaches and systemic therapies, including chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint inhibition. Key updates include the use of PE…

Rank110.0
Clinical guideline or consensus statement

Modern approaches to radiotherapy in primary cutaneous lymphomas: insights and recommendations from the DEGRO dermato-oncology working group.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025 · PMID 40924120

The growing use of reduced-dose radiotherapy in patients with primary cutaneous lymphoma is a promising development. Nevertheless, the absence of controlled clinical trials to ascertain standardized doses for each specific type constitutes a significant impediment to the advancement of this field. This expert opinion strongly advocates for advancements in radiation oncology practice that address the unique complexities of primary cutaneous lymphoma. By refining our methodologies, we can optimize patient care and ou…

Rank110.0
Clinical guideline or consensus statement

Large B-cell lymphoma: The LYSA pragmatic guidelines.

European journal of cancer (Oxford, England : 1990) · 2026 · PMID 41352004

The management of large B-cell lymphomas (LBCL) has undergone major changes over the last 5 years. These changes reflect the availability of new therapies (immunotherapies, cell therapies, targeted molecules), but also a better compartmentalization of the entities and their specific clinical characteristics. Numerous first-, second- and third-line therapeutic strategies are available, and each practitioner is committed to selecting the treatment that offers the best balance between efficacy and toxicity. Advances i…

Rank110.0
Clinical guideline or consensus statement

Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G Committee.

Bone marrow transplantation · 2025 · PMID 41034407

This manuscript provides expert recommendations on the role of allogeneic hematopoietic cell transplantation (allo-HCT) for cutaneous T-cell lymphoma (CTCL), specifically Mycosis Fungoides (MF) and Sezary Syndrome (SS). Critical aspects such as patient selection, timing, and bridging therapy are addressed, as well as donor source, conditioning regimens and post-transplant management. These consensus guidelines are based on a thorough literature review and discussions among leading dermatologists and hematologists. …

Rank110.0
Clinical guideline or consensus statement

B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN · 2026 · PMID 42753811

Mantle cell lymphoma (MCL) is a heterogenous subtype of B-cell non-Hodgkin lymphoma (NHL). The treatment landscape of newly diagnosed MCL has evolved in recent years with the incorporation of covalent BTK inhibitors, sensitive assays for the assessment of measurable residual disease (MRD), and predefined maintenance or continuous therapy. Covalent BTK inhibitor-based regimens are also appropriate options for patients with previously untreated classic MCL with TP53 mutations. Pirtobrutinib (a highly selective noncov…

Rank107.0
Clinical guideline or consensus statement

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).

Annals of oncology : official journal of the European Society for Medical Oncology · 2022 · PMID 34923107

BACKGROUND: Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lymphoma. Products for other diseases such as multiple myeloma and follicular lymphoma are likely to be approved by the European Medicines Agency in the near future. DESIGN: The European Society for Blood and Marrow Transplantation (EBMT)-Joint Accreditation Committe…

Rank105.5
Systematic review or meta-analysis

Cutaneous T-cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus.

Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · PMID 41821352

INTRODUCTION: Dupilumab, a standard treatment for atopic dermatitis (AD), has been associated with cutaneous T-cell lymphomas (CTCL), particularly mycosis fungoides (MF) and Sézary syndrome (SS). Nevertheless, the available data remain heterogeneous. OBJECTIVES: To characterize the clinical features, timeline and outcomes of dupilumab-related CTCL emergence in order to develop consensus-based recommendations for dupilumab use in CTCL-related settings. METHODS: A systematic review was conducted involving 51 studies …

Rank102.6
Systematic review or meta-analysis

Current evidence on diagnosis and treatment of parotid gland lymphomas: a systematic review.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023 · PMID 37638999

BACKGROUND AND PURPOSE: Parotid gland lymphoma (PGL) is a rare and challenging diagnosis. Different lymphomas can develop in the parotid gland, with the most common being the mucosa-associated lymphoid tissue (MALT) lymphoma, which originates directly from the glandular parenchyma. Other histologic subtypes arise from both intraglandular and extraglandular parotid lymph nodes. A consensus on diagnosis and treatment of PGL is still lacking, and published data is scarce and heterogeneous. METHODS: We performed a syst…

Rank102.2
Systematic review or meta-analysis

Prognostic value of circulating tumor DNA in lymphoma: a meta-analysis.

Clinical and experimental medicine · 2022 · PMID 33990849

Circulating tumor DNA (ctDNA) can be used to evaluate the prognosis of lymphoma. However, there is no uniform consensus about the mechanistic role that ctDNA plays in the prognosis of lymphoma. This meta-analysis explores the prognostic value of ctDNA in lymphoma, especially in diffuse large B cell lymphoma (DLBCL). All relevant reports published as of May 14, 2020, were retrieved by searching electronic databases in Pubmed, Embase and Cochrane Library. The prognostic value of ctDNA was evaluated using meta-analysi…

Rank100.0
Systematic review or meta-analysis

Adiposity and cancer: systematic review and meta-analysis.

Nature metabolism · 2026 · PMID 42297908

Obesity is a major health challenge. Here we show that body mass index is positively associated with risk of 19 cancers and inversely associated with 3, based on a systematic review and meta-analysis of prospective studies of 25 cancer types. We searched PubMed, EMBASE and Scopus through to 23 April 2025, identifying 226 articles comprising 1.5 million incident cancers. We identified positive associations for leukaemia, non-Hodgkin lymphoma, bladder cancer and glioma, not previously identified by major consensus re…

Rank100.0
Systematic review or meta-analysis

Covariate selection and adjustment for efficacy and safety endpoints in indirect comparative effectiveness analyses of CAR-T-cell therapies for large B-cell lymphoma: a systematic review.

Journal of comparative effectiveness research · 2026 · PMID 42359923

Aim: Several CAR-T cell therapies have received regulatory approval from both the US FDA and the EMA for the treatment of large B-cell lymphoma. However, direct comparative trials between CAR-T cell therapies are lacking, mainly due to different clinical development timelines and availabilities as well as substantial resource requirements and difficulties in recruiting sufficiently large and homogeneous cohorts from a highly pre-treated patient population. Consequently, indirect treatment comparisons (ITCs) play a …

Rank100.0
Systematic review or meta-analysis

Role of upfront autologous transplant for peripheral T-cell lymphoma patients achieving a complete remission with first-line therapy: a systematic review and meta-analysis.

Bone marrow transplantation · 2024 · PMID 38443704

There is currently no consensus on the role of upfront autologous transplantation (ASCT) for patients with peripheral T-cell lymphomas (PTCL), especially in patients achieving first complete remission (CR1) following chemotherapy, and data in the literature is conflicting. A systematic review and meta-analysis was performed to address this question. We searched key databases from January 2000 to February 2022. Six prospective and eleven retrospective studies were included among 2959 unique records. Median follow up…

Rank100.0
Systematic review or meta-analysisResult signal: benefit

Systematic review and meta-analysis: CAR-T vs bispecific antibody as third or later-line therapy for follicular lymphoma.

Blood cancer journal · 2025 · PMID 41461632

There is currently no clear consensus on the standard of care for relapsed or refractory follicular lymphoma (FL) beyond third-line therapy, where both anti-CD19 CAR-T-cell therapy (CAR-T) and CD3×CD20 bispecific antibodies (BsAbs) have demonstrated efficacy. This study aimed to examine their efficacy and toxicity profiles. Relevant studies published between January 2010 and June 2025 were identified through major databases. Of 3960 records screened, 12 studies met the inclusion criteria-7 involving CAR-T and 5 inv…

Rank98.0
Systematic review or meta-analysis

Protocol for a mixed-methods modified Delphi study for the development of a core domain set to assess the health-related quality of life of patients with mycosis fungoides and Sézary syndrome in clinical trials.

BMJ open · 2026 · PMID 41651511

INTRODUCTION: Cutaneous T cell lymphoma (CTCL) is a group of non-Hodgkin lymphomas that primarily affects the skin and can mimic inflammatory dermatoses. Unlike many skin diseases, CTCL can lead to disabling symptoms, and advanced CTCL can even be fatal. Early studies investigating health-related quality of life (HRQOL) in patients with mycosis fungoides (MF) and Sézary syndrome (SS), common subtypes of CTCL, demonstrated significant impairment across numerous domains. The aim of this current study is to develop a …

Rank87.0
Randomized clinical studyResult signal: benefit

[Diagnosis and management of peripheral T-cell lymphoma].

[Rinsho ketsueki] The Japanese journal of clinical hematology · 2026 · PMID 42951637

Peripheral T-cell lymphoma (PTCL) comprises more than 30 distinct disease entities and represents a rare and heterogeneous group of lymphoid neoplasms. The 2022 WHO Classification of Haematolymphoid Tumours, 5th edition (WHO-HAEM5) and the International Consensus Classification (ICC) substantially refined the classification of nodal PTCL, most notably through the reorganization of TFH-phenotype nodal T-cell lymphomas into nodal T-follicular helper cell lymphoma (nTFHL) and the recognition of EBV-positive nodal T/NK…

Rank85.0
Randomized clinical study

Current status of hematopoietic cell transplantation in patients with peripheral T-cell lymphoma including adult T-cell leukemia-lymphoma.

International journal of hematology · 2026 · PMID 41283963

Peripheral T-cell lymphomas (PTCLs) are biologically diverse and clinically aggressive, and are difficult to control long-term with conventional immunochemotherapy. Hematopoietic cell transplantation (HCT) is a key treatment option. Autologous HCT (auto-HCT) as first-line consolidation has shown durable progression-free survival in phase 2 studies and in the auto-HCT arm of the randomized AATT trial (intent-to-treat PFS 30-49%), although its routine use after complete metabolic response remains controversial. A pha…

Rank85.0
Randomized clinical study

Canadian Hematology Consensus Group Recommendations for the Management of Relapsed and/or Refractory Follicular Lymphoma.

Current oncology (Toronto, Ont.) · 2026 · PMID 42645356

Relapsed and/or refractory follicular lymphoma (R/R FL) remains a therapeutic challenge due to its chronic relapsing course and increasingly complex treatment landscape. Novel therapies, including immunomodulatory combinations, bispecific antibodies (BsAbs), Bruton tyrosine kinase inhibitors, and chimeric antigen receptor (CAR) T-cell therapies, have expanded treatment options and increased the complexity of treatment selection and sequencing. The Canadian Hematology Consensus Group (CHCG) convened a national panel…

Diagnosis And Screening557 records
Rank110.0
Clinical guideline or consensus statement

The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline.

British journal of haematology · 2026 · PMID 42634099

Primary mediastinal B-cell lymphoma (PMBCL) is a distinct clinicopathological entity within the spectrum of aggressive B-cell lymphomas, characterised by unique clinical, immunophenotypic and molecular features. Since publication of the 2019 British Society for Haematology (BSH) Good Practice Paper, there have been important advances in imaging, radiotherapy approaches and systemic therapies, including chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint inhibition. Key updates include the use of PE…

Rank107.9
Systematic review or meta-analysis

Second Primary Malignancies in Patients With B-Cell Lymphomas Treated With Bruton's Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis.

European journal of haematology · 2026 · PMID 42289275

OBJECTIVE: To evaluate the overall second primary malignancy (SPM) burden in patients with B-cell lymphomas treated with Bruton's tyrosine kinase (BTK) inhibitors and compare SPM risk versus non-BTK inhibitor or placebo controls. METHODS: We searched major databases from inception to September 30, 2025. The primary outcome was SPM incidence. Consistent treatment backgrounds were defined as comparable baseline clinical and treatment characteristics, with BTK inhibitor exposure as the main between-arm difference. RES…

Rank106.9
Systematic review or meta-analysis

Burden of Epstein-Barr virus in gastric cancer, nasopharyngeal carcinoma, and Burkitt lymphoma in Africa: a systematic review and meta-analysis.

BMC infectious diseases · 2026 · PMID 42426668

BACKGROUND: Epstein-Barr virus (EBV) is implicated in nasopharyngeal carcinoma (NPC), gastric cancer (GC), and Burkitt lymphoma (BL), but its burden across Africa remains poorly characterized due to fragmented evidence. This systematic review and meta-analysis estimated the pooled prevalence of EBV in NPC, GC, and BL across Africa, stratified by cancer type, region, and detection method. METHODS: PubMed, Scopus, Web of Science, and African Journals Online were searched for studies published between January 2000 and…

Rank104.4
Systematic review or meta-analysis

Prostate lymphoma uncovered during urological encounters: Diagnostic challenges and clinical outcomes in a case series with systematic review of the literature.

Urologic oncology · 2026 · PMID 42686439

INTRODUCTION: Prostatic lymphoma is a rare malignancy that can clinically resemble benign prostatic hyperplasia (BPH) or adenocarcinoma, often delaying diagnosis. Primary prostatic lymphoma (PPL) comprises <0.1% of prostate tumors and non-Hodgkin lymphomas, whereas secondary involvement occurs more commonly in systemic disease. METHODS: A retrospective review was conducted at the University of Miami Health System (2015-2024). All prostate specimens demonstrating lymphoma or related hematologic malignancies were ide…

Rank103.1
Systematic review or meta-analysis

A systematic review regarding the prevalence of malignancy in patients with the hyper-IgE syndrome.

Clinical and experimental medicine · 2023 · PMID 37924455

The hyper-immunoglobulin E syndrome (HIES) is a primary immunodeficiency disease originally described as Job syndrome. The fundamental causative variant of the HIES is an autosomal dominant mutation in the signal transducer and activator of transcription 3 (STAT3) gene. It is characterized by recurrent staphylococcal cold skin abscess, sinopulmonary infection, eczema, head and face anomalies, frequent bone fractures, eosinophilia and extremely high serum IgE levels (IgE ≥ 2000 IU/mL). However, multiple other geneti…

Rank102.6
Systematic review or meta-analysis

Current evidence on diagnosis and treatment of parotid gland lymphomas: a systematic review.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023 · PMID 37638999

BACKGROUND AND PURPOSE: Parotid gland lymphoma (PGL) is a rare and challenging diagnosis. Different lymphomas can develop in the parotid gland, with the most common being the mucosa-associated lymphoid tissue (MALT) lymphoma, which originates directly from the glandular parenchyma. Other histologic subtypes arise from both intraglandular and extraglandular parotid lymph nodes. A consensus on diagnosis and treatment of PGL is still lacking, and published data is scarce and heterogeneous. METHODS: We performed a syst…

Rank101.3
Systematic review or meta-analysis

A public-data audit of transcriptomic prognostic transportability in R-CHOP-treated diffuse large B-cell lymphoma.

PloS one · 2026 · PMID 42912792

Gene-expression biomarkers for diffuse large B-cell lymphoma (DLBCL) are often transported across retrospective cohorts that differ in treatment, assay platform, and clinical annotation. Using REMARK as the reporting framework, we audited prognostic associations with fixed scoring rules. Four Gene Expression Omnibus cohorts were harmonized for survival analysis. Treatment context was assessed after outcome-blind transcriptional state discovery. A directly mapped five-gene historical benchmark was evaluated with con…

Rank100.6
Systematic review or meta-analysis

Subcutaneous panniculitis-like T-cell lymphoma associated with hemophagocytic lymphohistiocytosis: a systematic review of 63 patients reported in the literature.

Clinical and experimental medicine · 2023 · PMID 37840116

To review and summarize the clinical features, treatment strategies, and prognosis of subcutaneous panniculitis-like T-cell lymphoma complicated with hemophagocytic lymphohistiocytosis (SPTCL-HLH). We searched the Web of Science, Embase, Cochrane Library, and PubMed databases. The keywords were subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis or hemophagocytic syndrome. The patients were divided into a mutated group and a wild-type group based on the existence of HAVCR2 gene mut…

Rank100.0
Systematic review or meta-analysis

Comparison of anti-PD-1/PD-L1-based regimens in relapsed/refractory diffuse large B-cell lymphoma: a meta-analysis.

PeerJ · 2025 · PMID 41282995

AIM: To evaluate the therapeutic value and find out potential combination agents of programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) monoclonal antibody (mAb) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). METHODS: We conducted a meta-analysis to assess the efficacy and safety of PD-1/PD-L1 mAb in r/r DLBCL, potential qualified studies were searched in PubMed, Embase, Web of Science, and ClinicalTrials.gov. This meta-analysis had been registered on the PROSPERO platform (CRD42023340031…

Rank100.0
Systematic review or meta-analysisResult signal: harm

Pulmonary amyloidosis, gastric MALT lymphoma, and multiple sclerosis in a patient with Sjögren's disease: a case report and review of the literature.

Rheumatology international · 2026 · PMID 42640321

Sjögren's disease (SjD) is a systemic autoimmune disorder associated with lymphocytic gland infiltration and an increased risk of B-cell lymphomas, particularly mucosa-associated lymphoid tissue (MALT) lymphoma. Neurological involvement may mimic multiple sclerosis (MS), while true coexistence, especially with amyloidosis, is exceptionally rare. We performed a systematic review and present a representative clinical case. A registered systematic literature review (PROSPERO CRD4201332325) was conducted according to P…

Rank100.0
Systematic review or meta-analysis

Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma - A systematic review of literature.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS · 2026 · PMID 41380366

INTRODUCTION: Breast Implant Associated - Anaplastic Large Cell Lymphoma (BIA-ALCL) cases are steadily increasing worldwide. When considering only the patients with textured implant as the active population, prevalence appears higher than previously reported, and uncertainty regarding incidence rate (IR) trends. We aimed to provide comprehensive estimates by identifying epidemiologic studies reporting prevalence, risk, and IR. METHODS: A systematic review was conducted up to November 2024 across PubMed, Google Scho…

Rank100.0
Systematic review or meta-analysis

Rare colorectal manifestations of pediatric gastrointestinal lymphoma: a systematic review of clinical spectrum and surgical implications.

Pediatric surgery international · 2026 · PMID 42437396

PURPOSE: Pediatric colorectal malignancies are rare, with lymphomas- predominantly non- Hodgkin's lymphoma (NHL) representing the most common type, accounting to 0.5-2% of large bowel malignancies. Colorectal NHL can be primary or secondary. This study analyzes the rare manifestations of pediatric colorectal lymphoma and examines their diagnostic challenges and surgical implications. METHOD: A Pubmed search was done with search words "lymphoma of colon pediatric" with filter of last 5 years on 12 Feb 2026. The sear…

Rank100.0
Systematic review or meta-analysisResult signal: harm

Cancer risk across sex, region, and disease subtype in ANCA-associated vasculitis patients : A meta-analysis.

Zeitschrift fur Rheumatologie · 2025 · PMID 40890556

OBJECTIVE: To evaluate standardized incidence ratios (SIRs) of cancer in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). METHODS: A systematic review and meta-analysis of studies from Medline, Embase, and Cochrane databases (inception to May 2025) was performed. Pooled SIRs were analyzed overall and by region, sex, age, AAV subtype, and cancer type. RESULTS: Fourteen studies involving 5553 AAV patients and 883 cancers were included. Overall cancer risk was significantly elevate…

Rank99.3
Randomized controlled trial

Baseline Tumor Transcriptional Features and Event-Free Survival After Anti-CD19 CAR T-Cell Therapy with Axicabtagene Ciloleucel in Large B-Cell Lymphoma: An Exploratory Reanalysis of the Randomized ZUMA-7 Trial.

Medical sciences (Basel, Switzerland) · 2026 · PMID 42930590

Background/Objectives: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with axicabtagene ciloleucel (axi-cel) improves outcomes in relapsed/refractory large B-cell lymphoma (LBCL), but many patients relapse despite retained CD19 expression. We explored baseline tumor transcriptional features associated with event-free survival (EFS) after axi-cel. Methods: We reanalyzed baseline NanoString IO 360 profiles from the randomized ZUMA-7 trial (axi-cel, n = 134; standard of care [SOC], n = 122) using differentia…

Rank98.0
Systematic review or meta-analysisCorrection flagged

Cancer Trends in Inborn Errors of Immunity: A Systematic Review and Meta-Analysis.

Journal of clinical immunology · 2024 · PMID 39466473

BACKGROUND: Patients with inborn errors of immunity (IEI) are susceptible to developing cancer due to defects in the immune system. The prevalence of cancer is higher in IEI patients compared to the immunocompetent population and cancers are considered as an important and common cause of death in IEI patients. OBJECTIVES: To systematically review demographic, genetic and cancer-related data of IEI patients with a history of malignancy. Moreover, we performed a meta-analysis aiming to determine the frequency of canc…

Rank97.0
Systematic review or meta-analysis

SHP1 loss augments DLBCL cellular response to ibrutinib: a candidate predictive biomarker.

Oncogene · 2023 · PMID 36482202

SHP1, a tyrosine phosphatase, negatively regulates B-cell receptor (BCR) signaling. Ibrutinib selectively inhibits BTK and has been approved for the treatment of several types of B-cell lymphomas, but not yet in diffuse large B-cell lymphoma (DLBCL). A phase 3 clinical trial of ibrutinib-containing regimen has been completed to evaluate its activity in subtypes or subsets of DLBCL patients. Although the subtype of activated B-cell like (ABC) DLBCL is characterized by chronic active BCR signaling, only a fraction of…

Rank96.3
Randomized controlled trial

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.

Blood · 2025 · PMID 40499012

Patients with follicular lymphoma who experience disease progression within 24 months of diagnosis (POD24) have a lower survival. Positron emission tomography (PET) response and circulating tumor DNA (ctDNA) minimal residual disease (MRD) assessment at end of induction (EOI) may allow their early identification. A representative cohort of 141 patients from the RELEVANCE phase 3 trial with both available serum samples for ctDNA testing and PET images at randomization and at EOI (week 24) was investigated. Twelve per…

Rank95.2
Phase III clinical trialResult signal: mixed

A multicentre phase III clinical trial of dual-epigenetic therapy plus CHOP compared with CHOP in previously untreated patients with peripheral T-cell lymphoma.

Blood cancer journal · 2026 · PMID 42901914

This phase 3 multicenter trial evaluated the efficacy and safety of adding dual epigenetic agents azacitidine and chidamide to CHOP (AC-CHOP) versus CHOP alone in previously untreated peripheral T-cell lymphoma (PTCL). A total of 128 patients were enrolled from 9 centers in China and assigned according to participating centers (AC-CHOP, N = 84; CHOP, N = 44). Azacitidine 200 mg on days 1-2, 100 mg on day 3 and chidamide 20 mg twice weekly were administered in the AC-CHOP arm. The AC-CHOP arm showed numerically high…

Rank92.6
Randomized controlled trial

End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial.

European journal of nuclear medicine and molecular imaging · 2024 · PMID 38795120

PURPOSE: To evaluate the reliability of the Deauville score (DS) in therapy response assessment and to define the prognostic value of the metabolic response of end of induction (EOI) [18F]FDG PET (PET) in follicular lymphoma patients. METHODS: Adult patients with untreated grade 1-3a FL/ stage II-IV enrolled in the multicentre, prospective, phase III FOLL12 trial (NCT02063685) were randomized to receive standard immunochemotherapy followed by rituximab maintenance (standard arm) versus standard immunochemotherapy f…

Rank91.0
Randomized controlled trial

Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.

Leukemia · 2022 · PMID 35963941

Mantle cell lymphoma (MCL) is a rare, incurable lymphoma subtype characterized by heterogeneous outcomes. To better understand the clinical behavior and response to treatment, predictive biomarkers are needed. Using residual archived material from patients enrolled in the MCL3001 (RAY) study, we performed detailed analyses of gene expression and targeted genetic sequencing. This phase III clinical trial randomized patients with relapsed or refractory MCL to treatment with either ibrutinib or temsirolimus. We confir…

Rank87.4
Randomized clinical study

The clinical outcomes of ultra-low-dose radiotherapy for primary conjunctival mucosa-associated lymphoid tissue lymphoma.

International ophthalmology · 2025 · PMID 40576839

PURPOSE: To assess the treatment efficacy, long-term outcomes and ocular toxicity of ultra-low-dose radiotherapy (4 Gy) in managing conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma. METHODS: This study retrospectively analyzed 15 patients with conjunctival MALT lymphoma between 2020 and 2022, who received 4 Gy radiotherapy (RT) delivered in consecutive 2-Gy fractions. The long-term outcomes included response rate, response time, recurrences or progression, and RT-related toxic effects. RESULTS: fiftee…

Rank87.0
Randomized clinical studyResult signal: benefit

[Diagnosis and management of peripheral T-cell lymphoma].

[Rinsho ketsueki] The Japanese journal of clinical hematology · 2026 · PMID 42951637

Peripheral T-cell lymphoma (PTCL) comprises more than 30 distinct disease entities and represents a rare and heterogeneous group of lymphoid neoplasms. The 2022 WHO Classification of Haematolymphoid Tumours, 5th edition (WHO-HAEM5) and the International Consensus Classification (ICC) substantially refined the classification of nodal PTCL, most notably through the reorganization of TFH-phenotype nodal T-cell lymphomas into nodal T-follicular helper cell lymphoma (nTFHL) and the recognition of EBV-positive nodal T/NK…

Rank86.6
Randomized clinical study

Clinical Outcomes of Breast-Involved Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Real-World Study with Insights into CNS Prophylaxis.

Current oncology (Toronto, Ont.) · 2026 · PMID 42645398

This study evaluated clinical characteristics, treatment outcomes, and CNS relapse patterns in patients with breast-involved diffuse large B-cell lymphoma (DLBCL), a rare extranodal presentation with limited real-world data. We conducted a retrospective study on 33 consecutive patients with newly diagnosed breast-involved DLBCL treated from 2019 to 2024. All patients received R-CHOP. Baseline CNS screening-including neurological examination, fundoscopy, brain magnetic resonance imaging (MRI), and cerebrospinal flui…

Rank85.0
Randomized clinical study

Immune checkpoint therapy in pediatric and adolescent lymphomas.

Haematologica · 2026 · PMID 42237783

Immune checkpoint therapy (ICT) is designed to unleash the anti-tumor activity of T-lymphocytes. Cytotoxic T-lymphocyte- associated antigen 4 (CTLA-4) inhibition and programmed death 1 (PD-1) inhibition are the most commonly utilized ICT in clinical cancer therapy, and they enhance anti-tumor immunity by interrupting the inhibitory signals CTLA-4 and programmed death ligand 1 (PD-L1), respectively. In pediatric Hodgkin lymphoma, ICT has demonstrated remarkable efficacy in both high-risk and relapsed disease, with i…

Rank85.0
Randomized clinical study

Clinical trial: Chidamide plus CHOP improve the survival of newly diagnosed angioimmunoblastic T-cell lymphoma.

Frontiers in immunology · 2024 · PMID 39229263

BACKGROUND: Angioimmunoblastic T-cell lymphoma (AITL) is known for its unfavorable survival prognosis. Chidamide has shown efficacy in relapsed/refractory AITL, but its efficacy in newly diagnosed AITL is uncertain. OBJECTIVE: This retrospective research aimed to evaluate the effectiveness and safety of chidamide when used with doxorubicin, cyclophosphamide, prednisone, and vincristine (CHOP) in comparison to CHOP by itself for individuals newly diagnosed with AITL, and to examine the impact of transplantation. MET…

Evidence Syntheses104 records
Rank112.0
Clinical guideline or consensus statement

Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee.

Bone marrow transplantation · 2026 · PMID 42420469

Cellular therapies, namely autologous hematopoietic cell transplantation (autoHCT), allogeneic HCT (alloHCT) and more recently, chimeric antigen receptor T-cell therapies (CART), play a major role in state-of-the-art treatment of mantle cell lymphoma (MCL). With numerous therapeutic innovations currently entering the MCL treatment landscape, guidance for indication, sequencing and application of cellular therapies is of key importance. To address this practical need, the European Society for Blood and Marrow Transp…

Rank110.0
Clinical guideline or consensus statement

Narrowband UVB Phototherapy in Dermatology: GEF-CILAD 2026 Update.

Actas dermo-sifiliograficas · 2026 · PMID 42323047

This document updates the scientific evidence and clinical practice regarding narrowband UVB phototherapy (NB-UVB) in dermatology. The review addresses indications, therapeutic regimens, safety aspects, combinations with systemic and biologic agents, and adaptation to special populations. NB-UVB remains a first-line therapy for psoriasis, vitiligo, atopic dermatitis, early mycosis fungoides, and photodermatoses due to its efficacy, safety, and cost-effectiveness. Emerging evidence supports its integration with next…

Rank110.0
Clinical guideline or consensus statement

The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline.

British journal of haematology · 2026 · PMID 42634099

Primary mediastinal B-cell lymphoma (PMBCL) is a distinct clinicopathological entity within the spectrum of aggressive B-cell lymphomas, characterised by unique clinical, immunophenotypic and molecular features. Since publication of the 2019 British Society for Haematology (BSH) Good Practice Paper, there have been important advances in imaging, radiotherapy approaches and systemic therapies, including chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint inhibition. Key updates include the use of PE…

Rank110.0
Systematic review or meta-analysis

Long-term cardiovascular risk in survivors of hematologic malignancies: a meta-analysis.

BMC cancer · 2026 · PMID 42332608

BACKGROUND: The survival rate for hematologic malignancies is steadily improving. With the encouraging trend and the aging of these survivors, there is an ever-increasing responsibility for identifying adverse cardiovascular outcomes associated with carcinogenesis and/or anti-cancer therapies across the span of their lives. However, prospective studies have yielded inconsistent results. METHODS: We performed a meta-analysis to summarize the evidence regarding the association between leukemia, Hodgkin lymphoma (HL),…

Rank110.0
Clinical guideline or consensus statement

Executive Summary of the American Radium Society Appropriate Use Criteria for Extranodal Natural Killer/T-cell Lymphoma.

International journal of radiation oncology, biology, physics · 2026 · PMID 41785936

Extranodal natural killer/T-cell lymphoma is a rare and aggressive extranodal non-Hodgkin lymphoma. These evidence-based recommendations for natural killer/T-cell lymphoma by the American Radium Society were developed by a multidisciplinary panel of medical and radiation oncologists to propose treatment approaches. This guideline was based on a literature review with a consensus methodology to rate the appropriateness of treatment recommendations for each natural killer/T-cell lymphoma clinical presentation. Six va…

Rank110.0
Clinical guideline or consensus statement

B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN · 2026 · PMID 42753811

Mantle cell lymphoma (MCL) is a heterogenous subtype of B-cell non-Hodgkin lymphoma (NHL). The treatment landscape of newly diagnosed MCL has evolved in recent years with the incorporation of covalent BTK inhibitors, sensitive assays for the assessment of measurable residual disease (MRD), and predefined maintenance or continuous therapy. Covalent BTK inhibitor-based regimens are also appropriate options for patients with previously untreated classic MCL with TP53 mutations. Pirtobrutinib (a highly selective noncov…

Rank110.0
Systematic review or meta-analysis

Is tattooing associated with an increased risk of cancer? A systematic review and meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 42250187

BACKGROUND: Tattoo inks may contain carcinogenic compounds, and pigment migration to lymphatic tissues raises concerns regarding potential cancer risk. Epidemiological evidence remains inconclusive. OBJECTIVES: To assess the association between tattoo exposure and the incidence of skin cancer and hematological malignancies. METHODS: PubMed, Embase, and the Cochrane Library were searched from inception to January 2026 for cohort and case-control studies comparing cancer incidence in tattooed versus non-tattooed adul…

Rank109.8
Systematic review or meta-analysis

Prognostic value of geriatric nutritional risk index in patients with diffuse large B-cell lymphoma: a meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024 · PMID 37438653

BACKGROUND: Geriatric nutritional risk index (GNRI) on the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) remains unclear. The purpose of this meta-analysis was to discuss the value of the GNRI in evaluating long-term outcomes in DLBCL. METHODS: We systematically and roundly retrieved PubMed, Cochrane Library, Embase, Scopus and Web of Science electronic databases from inception of the databases to March 20, 2023. At the same time, we calculated the pool hazard ratios (HRs) with their 95% confiden…

Rank109.5
Systematic review or meta-analysis

Association between interleukin-10 (IL-10) genetic polymorphisms and non-hodgkin lymphoma: a systematic review and meta-analysis.

Leukemia & lymphoma · 2026 · PMID 42335190

Non-Hodgkin lymphoma (NHL) has been associated with IL-10 single-nucleotide polymorphisms (SNPs), although findings remain inconsistent. This meta-analysis aims to investigate the association between key IL-10 SNPs (rs1800871, rs1800872, rs1800890, and rs1800896) with NHL. A systematic search of multiple databases was conducted to get relevant articles. The study included 53,864 cases and 60,448 controls from 41 studies. Pooled ORs with 95% CIs were calculated for each SNP, along with a heterogeneity test and publi…

Rank109.1
Systematic review or meta-analysisResult signal: null

Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence.

Blood cancer journal · 2026 · PMID 42362499

Pola-R-CHP regimen is the new standard of care for untreated diffuse large B-cell lymphoma (DLBCL) patients, following the POLARIX trial. This study evaluates whether clinical trial (RCT) efficacy and safety are reproducible in real-world evidence (RWE) settings. This systematic review and meta-analysis compared outcomes between RCTs and RWE studies. Primary endpoints were complete response (CR) rate, progression-free survival (PFS), and overall survival (OS). Meta-regression explored heterogeneity using age, Inter…

Rank108.2
Systematic review or meta-analysis

Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review/Meta-Analysis.

Transplantation and cellular therapy · 2026 · PMID 41525947

In oncology, overall survival (OS) is the benchmark endpoint for assessing therapy effectiveness, but requires large patient cohorts and extended follow-up to attain meaningful data. The identification of reliable surrogate markers for OS may enable earlier treatment decisions and streamline clinical trial design, potentially reducing costs and accelerating access to new therapies. The objective of this study was to evaluate whether complete response (CR) could serve as an early surrogate for OS in patients with re…

Rank107.9
Systematic review or meta-analysisResult signal: null

Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma.

Molecular therapy : the journal of the American Society of Gene Therapy · 2025 · PMID 40170355

Bispecific antibodies (BsAb) are associated with distinct immune-related toxicities that impact morbidity and mortality. This systematic review and meta-analysis examined non-relapse mortality (NRM) with BsAb therapy in B-cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). A PubMed and Embase search up to October 2024 identified 29 studies (21 NHL, 8 MM) involving 2,535 patients. The overall NRM point estimate was 4.7% (95% confidence interval [CI] 3.4%-6.4%), with a median follow-up of 12.0 months. We noted…

Rank107.9
Systematic review or meta-analysis

Second Primary Malignancies in Patients With B-Cell Lymphomas Treated With Bruton's Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis.

European journal of haematology · 2026 · PMID 42289275

OBJECTIVE: To evaluate the overall second primary malignancy (SPM) burden in patients with B-cell lymphomas treated with Bruton's tyrosine kinase (BTK) inhibitors and compare SPM risk versus non-BTK inhibitor or placebo controls. METHODS: We searched major databases from inception to September 30, 2025. The primary outcome was SPM incidence. Consistent treatment backgrounds were defined as comparable baseline clinical and treatment characteristics, with BTK inhibitor exposure as the main between-arm difference. RES…

Rank107.6
Systematic review or meta-analysis

Association Between Progression-Free Survival and Overall Survival in Mantle Cell Lymphoma: A Trial-level Surrogate Endpoint Analysis.

Clinical lymphoma, myeloma & leukemia · 2026 · PMID 42177127

INTRODUCTION: Survival outcomes of patients with mantle cell lymphoma (MCL) have substantially improved. In the setting of extended overall survival (OS), progression-free survival (PFS) is typically used as a primary endpoint in MCL clinical trials rather than OS to limit trial duration and cost. However, no prior analysis has assessed whether PFS can reliably predict OS. The aim of this study is to perform a systematic evaluation of PFS as a surrogate endpoint for OS in phase III MCL clinical trials. MATERIALS AN…

Rank107.5
Systematic review or meta-analysis

Febrile neutropenia in adults with diffuse large B-cell lymphoma receiving first-line R-CHOP-based therapy: a systematic review and meta-analysis of observational and trial evidence.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42839187

INTRODUCTION: Febrile neutropenia (FN) is an important complication of first-line immunochemotherapy for diffuse large B-cell lymphoma (DLBCL). Thresholds for primary granulocyte colony-stimulating factor (G-CSF) prophylaxis are risk-based, but the FN burden in routine practice is uncertain, and whether trial-derived estimates describe it is unknown. METHODS: Systematic review and meta-analysis of proportions. MEDLINE, CENTRAL, ClinicalTrials.gov, Europe PMC, Epistemonikos, Lens.org, Google Scholar, and citation tr…

Rank107.2
Systematic review or meta-analysis

reFLASH: a proof-of-concept meta-analytic framework to validate surrogate endpoints in the absence of randomized clinical trial data.

Journal of clinical epidemiology · 2026 · PMID 42641770

BACKGROUND AND OBJECTIVES: Within a meta-analytic framework, validating surrogate endpoints traditionally requires individual patient data (IPD) from multiple randomized controlled trials (RCTs). This is rarely feasible in rare and indolent diseases. We propose a proof-of-concept strategy that creates synthetic comparative evidence from multiple single-arm trials to enable trial-level surrogacy assessment. METHODS: Using IPD from 12 follicular lymphoma RCTs (FLASH; 3996 patients), we decoupled each trial's randomiz…

Rank107.2
Systematic review or meta-analysisResult signal: benefit

Maintenance treatment and survival in patients with newly diagnosed diffuse large B cell lymphoma in the immunochemotherapy era: a systematic review and network meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 42213311

OBJECTIVE: To assess the comparative efficacy of various maintenance strategies for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL). METHODS: We conducted a comprehensive search of PubMed, Embase, Web of Science, the Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Trials for randomized clinical trials evaluating maintenance strategies in previously untreated DLBCL patients. The primary outcomes were progression-free survival (PFS) and overall survival (OS…

Rank107.0
Clinical guideline or consensus statement

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).

Annals of oncology : official journal of the European Society for Medical Oncology · 2022 · PMID 34923107

BACKGROUND: Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lymphoma. Products for other diseases such as multiple myeloma and follicular lymphoma are likely to be approved by the European Medicines Agency in the near future. DESIGN: The European Society for Blood and Marrow Transplantation (EBMT)-Joint Accreditation Committe…

Rank106.9
Systematic review or meta-analysis

Burden of Epstein-Barr virus in gastric cancer, nasopharyngeal carcinoma, and Burkitt lymphoma in Africa: a systematic review and meta-analysis.

BMC infectious diseases · 2026 · PMID 42426668

BACKGROUND: Epstein-Barr virus (EBV) is implicated in nasopharyngeal carcinoma (NPC), gastric cancer (GC), and Burkitt lymphoma (BL), but its burden across Africa remains poorly characterized due to fragmented evidence. This systematic review and meta-analysis estimated the pooled prevalence of EBV in NPC, GC, and BL across Africa, stratified by cancer type, region, and detection method. METHODS: PubMed, Scopus, Web of Science, and African Journals Online were searched for studies published between January 2000 and…

Rank106.9
Systematic review or meta-analysis

Genetic susceptibility of diffuse large B-cell lymphoma: a meta genome-wide association study in Asian population.

Leukemia · 2025 · PMID 39707004

Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy and the most common form of non-Hodgkin lymphoma (NHL) that occurs worldwide. To discover risk factors and pathogenesis of DLBCL, we performed the largest GWAS of DLBCL to date in samples of East Asian ancestry, consisting of 2,888 patients with DLBCL and 12,458 controls. The meta-analysis identified three novel loci, rs2233434 on 6p21.1 (OR = 1.26, P = 1.17 × 10-8), rs11066015 on 12q24.12 (OR = 1.24, P = 6.57 × 10-9) and rs6032662 on 20q13.12 (OR = …

Rank106.9
Systematic review or meta-analysis

Efficacy-safety trade-off and patient selection: a meta-analysis informing clinical choice between CAR-T and bispecific antibodies for R/R B-NHL.

Frontiers in immunology · 2026 · PMID 42495620

This meta-analysis compared chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAbs) for relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), focusing on efficacy and safety. We analyzed 59 phase I/II trials involving 2,914 patients. CAR-T achieved higher ORR (72% [95% CI 67-77%] vs. 50% [38-62%]) and CR (54% [49-59%] vs. 33% [23-46%]) than BsAbs. However, it was associated with higher rates of grade ≥3 CRS (8% [6-11%] vs. 4% [3-7%]), ICANS (12% [9-16%] vs. 6% [2-18%]), and neuroto…

Rank106.8
Systematic review or meta-analysis

Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.

JAMA oncology · 2026 · PMID 42313425

IMPORTANCE: T-cell-engaging bispecific antibodies (BsAbs) are increasingly used in B-cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). As these agents transition into earlier courses of therapy and broader clinical use, understanding their safety profile is critical. While second primary malignant neoplasms (SPMs) represent a key long-term safety signal, small sample sizes, single-arm trials, short follow-up, and heterogeneous reporting have limited reliable estimation of their frequency. OBJECTIVE: To est…

Rank106.8
Systematic review or meta-analysis

Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.

British journal of haematology · 2026 · PMID 42383996

Relapsed/refractory follicular lymphoma (R/R FL) remains a clinically challenging condition, with progressively declining benefit across consecutive lines of therapy. While anti-Cluster of Differentiation 20 (CD20) antibodies remain the therapeutic backbone, the optimal targeted or immune-based partner remains undefined. A systematic review and network meta-analysis (NMA) of 5 phase III and 1 phase II trials (2500 patients) evaluated seven anti-CD20-based combination strategies. Primary end-points were overall surv…

Rank106.7
Systematic review or meta-analysis

Role of rituximab in treatment of patients with primary central nervous system lymphoma: An updated systematic review and meta-analysis.

Acta neurologica Belgica · 2026 · PMID 41212511

BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a rare and aggressive form of extranodal non-Hodgkin lymphoma, most often a diffuse large B-cell lymphoma. Rituximab, an anti-CD20 monoclonal antibody is widely used in PCNSL treatment but its efficacy remains uncertain. Therefore, we conducted a systematic review and meta-analysis to assess the efficacy of rituximab in newly diagnosed adult PCNSL patients. METHODS: Medline/PubMed and Scopus were searched for studies comparing rituximab/rituximab-contai…

Rank106.7
Systematic review or meta-analysisResult signal: harm

Comparative efficacy and toxicity of Axicabtagene Ciloleucel versus Tisagenlecleucel in European patients with large B-cell lymphoma: a systematic review and meta-analysis.

PeerJ · 2026 · PMID 42428526

BACKGROUND AND OBJECTIVES: Large B-cell lymphoma (LBCL) is a common and aggressive non-Hodgkin lymphoma (NHL) characterized by abnormal proliferation of mature B lymphocytes, with a 10-year prevalence of up to 45 cases per 100,000 individuals in European populations and a continuing upward trend. Axicabtagene ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) are the two most established chimeric antigen receptor T-cell (CAR-T) therapy products for LBCL, yet a systematic comparison of their efficacy and safety in…

Landmark Evidence111 records
Rank110.0
Clinical guideline or consensus statement

The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline.

British journal of haematology · 2026 · PMID 42634099

Primary mediastinal B-cell lymphoma (PMBCL) is a distinct clinicopathological entity within the spectrum of aggressive B-cell lymphomas, characterised by unique clinical, immunophenotypic and molecular features. Since publication of the 2019 British Society for Haematology (BSH) Good Practice Paper, there have been important advances in imaging, radiotherapy approaches and systemic therapies, including chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint inhibition. Key updates include the use of PE…

Rank110.0
Systematic review or meta-analysis

Is tattooing associated with an increased risk of cancer? A systematic review and meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 42250187

BACKGROUND: Tattoo inks may contain carcinogenic compounds, and pigment migration to lymphatic tissues raises concerns regarding potential cancer risk. Epidemiological evidence remains inconclusive. OBJECTIVES: To assess the association between tattoo exposure and the incidence of skin cancer and hematological malignancies. METHODS: PubMed, Embase, and the Cochrane Library were searched from inception to January 2026 for cohort and case-control studies comparing cancer incidence in tattooed versus non-tattooed adul…

Rank109.8
Systematic review or meta-analysis

Prognostic value of geriatric nutritional risk index in patients with diffuse large B-cell lymphoma: a meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024 · PMID 37438653

BACKGROUND: Geriatric nutritional risk index (GNRI) on the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) remains unclear. The purpose of this meta-analysis was to discuss the value of the GNRI in evaluating long-term outcomes in DLBCL. METHODS: We systematically and roundly retrieved PubMed, Cochrane Library, Embase, Scopus and Web of Science electronic databases from inception of the databases to March 20, 2023. At the same time, we calculated the pool hazard ratios (HRs) with their 95% confiden…

Rank108.2
Systematic review or meta-analysis

Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review/Meta-Analysis.

Transplantation and cellular therapy · 2026 · PMID 41525947

In oncology, overall survival (OS) is the benchmark endpoint for assessing therapy effectiveness, but requires large patient cohorts and extended follow-up to attain meaningful data. The identification of reliable surrogate markers for OS may enable earlier treatment decisions and streamline clinical trial design, potentially reducing costs and accelerating access to new therapies. The objective of this study was to evaluate whether complete response (CR) could serve as an early surrogate for OS in patients with re…

Rank108.0
Clinical guideline or consensus statementCorrection flagged

Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation.

Transplantation and cellular therapy · 2024 · PMID 38972511

Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma (NHL), accounting for nearly one-third of all NHL. The therapeutic landscape for patients with FL has significantly expanded over the past decade, but the disease continues to be considered incurable. Hematopoietic cell transplantation (HCT) is potentially curative in some cases. Recently, the emergence of chimeric antigen receptor T-cell therapy (CAR-T) for patients with relapsed/refractory (R/R) FL has yielded impressive response rat…

Rank107.9
Systematic review or meta-analysisResult signal: null

Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma.

Molecular therapy : the journal of the American Society of Gene Therapy · 2025 · PMID 40170355

Bispecific antibodies (BsAb) are associated with distinct immune-related toxicities that impact morbidity and mortality. This systematic review and meta-analysis examined non-relapse mortality (NRM) with BsAb therapy in B-cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). A PubMed and Embase search up to October 2024 identified 29 studies (21 NHL, 8 MM) involving 2,535 patients. The overall NRM point estimate was 4.7% (95% confidence interval [CI] 3.4%-6.4%), with a median follow-up of 12.0 months. We noted…

Rank107.5
Systematic review or meta-analysis

Febrile neutropenia in adults with diffuse large B-cell lymphoma receiving first-line R-CHOP-based therapy: a systematic review and meta-analysis of observational and trial evidence.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42839187

INTRODUCTION: Febrile neutropenia (FN) is an important complication of first-line immunochemotherapy for diffuse large B-cell lymphoma (DLBCL). Thresholds for primary granulocyte colony-stimulating factor (G-CSF) prophylaxis are risk-based, but the FN burden in routine practice is uncertain, and whether trial-derived estimates describe it is unknown. METHODS: Systematic review and meta-analysis of proportions. MEDLINE, CENTRAL, ClinicalTrials.gov, Europe PMC, Epistemonikos, Lens.org, Google Scholar, and citation tr…

Rank107.2
Systematic review or meta-analysis

reFLASH: a proof-of-concept meta-analytic framework to validate surrogate endpoints in the absence of randomized clinical trial data.

Journal of clinical epidemiology · 2026 · PMID 42641770

BACKGROUND AND OBJECTIVES: Within a meta-analytic framework, validating surrogate endpoints traditionally requires individual patient data (IPD) from multiple randomized controlled trials (RCTs). This is rarely feasible in rare and indolent diseases. We propose a proof-of-concept strategy that creates synthetic comparative evidence from multiple single-arm trials to enable trial-level surrogacy assessment. METHODS: Using IPD from 12 follicular lymphoma RCTs (FLASH; 3996 patients), we decoupled each trial's randomiz…

Rank107.2
Systematic review or meta-analysisResult signal: benefit

Maintenance treatment and survival in patients with newly diagnosed diffuse large B cell lymphoma in the immunochemotherapy era: a systematic review and network meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 42213311

OBJECTIVE: To assess the comparative efficacy of various maintenance strategies for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL). METHODS: We conducted a comprehensive search of PubMed, Embase, Web of Science, the Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Trials for randomized clinical trials evaluating maintenance strategies in previously untreated DLBCL patients. The primary outcomes were progression-free survival (PFS) and overall survival (OS…

Rank107.0
Systematic review or meta-analysis

Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis.

Blood advances · 2025 · PMID 40590871

CD3xCD20 bispecific antibody (BsAb) therapy and CD19-directed chimeric antigen receptor T-cell therapy (CAR T) are novel immunotherapies that have shown impressive efficacy in B-cell lymphomas, but also come with significant morbidity and mortality, including infections. This meta-analysis compares rates of infections between commercially approved CAR T and BsAb therapy in patients with B-cell non-Hodgkin lymphoma (B-NHL). We conducted a systematic review for prospective trials assessing commercially approved CAR T…

Rank107.0
Clinical guideline or consensus statement

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).

Annals of oncology : official journal of the European Society for Medical Oncology · 2022 · PMID 34923107

BACKGROUND: Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lymphoma. Products for other diseases such as multiple myeloma and follicular lymphoma are likely to be approved by the European Medicines Agency in the near future. DESIGN: The European Society for Blood and Marrow Transplantation (EBMT)-Joint Accreditation Committe…

Rank106.9
Systematic review or meta-analysis

Burden of Epstein-Barr virus in gastric cancer, nasopharyngeal carcinoma, and Burkitt lymphoma in Africa: a systematic review and meta-analysis.

BMC infectious diseases · 2026 · PMID 42426668

BACKGROUND: Epstein-Barr virus (EBV) is implicated in nasopharyngeal carcinoma (NPC), gastric cancer (GC), and Burkitt lymphoma (BL), but its burden across Africa remains poorly characterized due to fragmented evidence. This systematic review and meta-analysis estimated the pooled prevalence of EBV in NPC, GC, and BL across Africa, stratified by cancer type, region, and detection method. METHODS: PubMed, Scopus, Web of Science, and African Journals Online were searched for studies published between January 2000 and…

Rank106.9
Systematic review or meta-analysis

Genetic susceptibility of diffuse large B-cell lymphoma: a meta genome-wide association study in Asian population.

Leukemia · 2025 · PMID 39707004

Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy and the most common form of non-Hodgkin lymphoma (NHL) that occurs worldwide. To discover risk factors and pathogenesis of DLBCL, we performed the largest GWAS of DLBCL to date in samples of East Asian ancestry, consisting of 2,888 patients with DLBCL and 12,458 controls. The meta-analysis identified three novel loci, rs2233434 on 6p21.1 (OR = 1.26, P = 1.17 × 10-8), rs11066015 on 12q24.12 (OR = 1.24, P = 6.57 × 10-9) and rs6032662 on 20q13.12 (OR = …

Rank106.8
Systematic review or meta-analysis

Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.

British journal of haematology · 2026 · PMID 42383996

Relapsed/refractory follicular lymphoma (R/R FL) remains a clinically challenging condition, with progressively declining benefit across consecutive lines of therapy. While anti-Cluster of Differentiation 20 (CD20) antibodies remain the therapeutic backbone, the optimal targeted or immune-based partner remains undefined. A systematic review and network meta-analysis (NMA) of 5 phase III and 1 phase II trials (2500 patients) evaluated seven anti-CD20-based combination strategies. Primary end-points were overall surv…

Rank106.4
Systematic review or meta-analysis

Application of CAR-T cell therapy in B-cell lymphoma: a meta-analysis of randomized controlled trials.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025 · PMID 39514165

BACKGROUND: This study aims to compare the efficacy and safety of chimeric antigen receptor T-cell (CAR-T) immunotherapy with standard treatment for B-cell lymphoma, providing evidence-based support for the more efficient use of CAR-T cell immunotherapy. METHODS: We conducted a comprehensive literature search of high-quality randomized controlled trials (RCTs) on CAR-T therapy for B-cell lymphoma in the following databases: Wanfang, Web of Science, CNKI, VIP database, and PubMed, up to February 2024. The outcome me…

Rank106.3
Systematic review or meta-analysis

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis.

Blood · 2024 · PMID 38696731

This meta-analysis evaluates the efficacy and safety of chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). We searched MEDLINE, Embase, and Cochrane databases until July 2023 for trials assessing CAR T-cell therapies and CD20×CD3 bispecific antibodies as third or subsequent lines in R/R DLBCL. Random-effects models estimated the complete response (CR) rate and secondary outcomes, with meta-regressions adjusting for relevant cov…

Rank106.3
Systematic review or meta-analysis

Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review.

Bone marrow transplantation · 2026 · PMID 42332219

Lymphodepletion (LD) is a critical prerequisite for successful chimeric antigen receptor T-cell (CAR-T) therapy. While fludarabine and cyclophosphamide (Flu/Cy) remain the standard LD regimen, bendamustine has emerged as a potential alternative due to its distinct immunomodulatory properties and more favorable toxicity profile. This systematic review evaluates the safety, efficacy, and feasibility of bendamustine-based LD in patients undergoing CAR-T therapy for hematologic malignancies. A comprehensive literature …

Rank106.0
Systematic review or meta-analysis

Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: a systematic review and meta-analysis.

Frontiers in immunology · 2024 · PMID 39308870

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy (CAR-T therapy) has demonstrated significant efficacy in the ZUMA-2 study. After regulatory approvals, several clinical trials and real-world studies on CAR-T therapy for relapsed or refractory mantle cell lymphoma (R/R MCL) were conducted. However, data on clinical safety and efficacy are inconsistent. In this study, we aimed to conduct a systematic analysis of the effectiveness and safety of CAR-T therapy across a wider and more representative cohort of p…

Rank105.9
Systematic review or meta-analysis

Reduced-Dose Total Skin Electron Beam Radiation Therapy in Mycosis Fungoides and Sézary Syndrome: Systematic Review and Meta-Analysis.

International journal of radiation oncology, biology, physics · 2026 · PMID 42128185

PURPOSE: Primary cutaneous T-cell lymphomas are a heterogeneous group of T-cell neoplastic entities associated with significant morbidity and high radiosensitivity. Although research on reduced-dose radiation treatment for mycosis fungoides and Sézary syndrome has significantly increased over the past 2 decades, randomized data are lacking. We aim to summarize the available evidence and analyze the safety and efficacy of reduced-dose total skin electron beam therapy (TSEBT). METHODS AND MATERIALS: A literature sear…

Rank105.5
Systematic review or meta-analysis

Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis.

Bone marrow transplantation · 2024 · PMID 37853164

Allogeneic hematopoietic stem cell transplant (allo-HSCT) has been noted to be a potential curative treatment in cases of advanced-stage mycosis fungoides (MF) or Sezary syndrome (SS). To assess outcomes of allo-HSCT for MF/SS we performed a systematic review and meta-analysis including 15 manuscripts and 557 patients, published from 2010-2023. Meta-analysis revealed 1-year and 3+year overall survival (OS) of 51% (95% CI 39-64%) and 40% (32-49%). Progression-free survival at 1 year and 3+years were 42% (31-53%) and…

Rank104.8
Systematic review or meta-analysis

NKG2D genetic variants and cancer susceptibility: Integrating case-control evidence with meta-analysis.

Immunogenetics · 2026 · PMID 41491293

Lymphomas are biologically heterogeneous malignancies with multifactorial etiologies involving genetic, environmental, and immune dysregulation. The functional variant rs1049174 SNP in the KLRK1 gene (encoding NKG2D) regulates NKG2D expression and modulates NK cells immune surveillance pathways, which may influence lymphoma susceptibility. We investigated this association through a two-stage case-control study and meta-analysis. First, we analyzed 246 diffuse large B-cell lymphoma (DLBCL) patients and 599 healthy c…

Rank104.5
Systematic review or meta-analysisCorrection flagged

Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation.

Bone marrow transplantation · 2025 · PMID 39375527

Autologous peripheral blood stem cell (PBSC) transplantation is a standard treatment of multiple myeloma (MM), Hodgkin lymphoma and various subtypes of non-Hodgkin lymphoma. Cryopreservation of hematopoietic stem cells is standard practice that allows time for delivery of conditioning regimen prior to cell infusion. The aim of this Worldwide Network for Blood & Marrow Transplantation (WBMT) work was to assess existing evidence on non-cryopreserved autologous transplants through a systematic review/meta-analysis, to…

Rank104.2
Systematic review or meta-analysis

The role of allogeneic hematopoietic stem cell transplantation in adults with mature T-cell lymphomas.

The Cochrane database of systematic reviews · 2026 · PMID 42905121

RATIONALE: Mature T-cell lymphomas (MTCL) are a rare, heterogeneous group of malignancies that arise from post-thymic T-lymphocytes, with a generally poor prognosis. For a long time, the standard therapy for most MTCL subtypes has been polychemotherapies. Hopes to prolong overall survival in MTCL have been associated with transplant procedures such as high-dose therapy with autologous stem cell transplantation (autoSCT) or allogeneic stem cell transplantation (alloSCT). OBJECTIVES: To assess the benefits and harms …

Rank103.5
Systematic review or meta-analysisResult signal: benefit

Primary esophageal non-Hodgkin's lymphoma: demographics, clinical characteristics, histopathologic types, and survival in 179 patients from the SEER program and systematic review of the literature.

Esophagus : official journal of the Japan Esophageal Society · 2021 · PMID 33880688

BACKGROUND: The most frequent site for the extranodal appearance of primary non-Hodgkin's lymphomas (NHL) is the gastrointestinal (G.I.) tract. However, primary esophageal lymphoma is extremely rare. The purpose of the present study was to describe and analyze the demographics, clinical characteristics, histopathologic types, and long-term survival of patients with primary esophageal NHL registered in the surveillance, epidemiology, and end results (SEER) database. METHODS: Retrospective cohort study. Individuals w…

Rank103.2
Systematic review or meta-analysis

Systemic Glucocorticoid Use and Risk of Site-Specific Cancers: A Methodologic Systematic Review of Observational Studies.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026 · PMID 41931525

Systemic glucocorticoids, widely prescribed for inflammatory and autoimmune diseases, have long been suspected of increasing cancer risk through immunosuppressive and metabolic effects. Randomized trials are often unethical and difficult to conduct, leaving observational studies the best option to determine whether the use of systemic glucocorticoids affects cancer development. However, these studies face significant methodologic issues that may compromise the validity of their findings. We systematically reviewed …

Most Effective Evidence Supported Treatments129 records
Rank112.0
Clinical guideline or consensus statement

Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee.

Bone marrow transplantation · 2026 · PMID 42420469

Cellular therapies, namely autologous hematopoietic cell transplantation (autoHCT), allogeneic HCT (alloHCT) and more recently, chimeric antigen receptor T-cell therapies (CART), play a major role in state-of-the-art treatment of mantle cell lymphoma (MCL). With numerous therapeutic innovations currently entering the MCL treatment landscape, guidance for indication, sequencing and application of cellular therapies is of key importance. To address this practical need, the European Society for Blood and Marrow Transp…

Rank110.0
Clinical guideline or consensus statement

Executive Summary of the American Radium Society Appropriate Use Criteria for Extranodal Natural Killer/T-cell Lymphoma.

International journal of radiation oncology, biology, physics · 2026 · PMID 41785936

Extranodal natural killer/T-cell lymphoma is a rare and aggressive extranodal non-Hodgkin lymphoma. These evidence-based recommendations for natural killer/T-cell lymphoma by the American Radium Society were developed by a multidisciplinary panel of medical and radiation oncologists to propose treatment approaches. This guideline was based on a literature review with a consensus methodology to rate the appropriateness of treatment recommendations for each natural killer/T-cell lymphoma clinical presentation. Six va…

Rank110.0
Clinical guideline or consensus statement

B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN · 2026 · PMID 42753811

Mantle cell lymphoma (MCL) is a heterogenous subtype of B-cell non-Hodgkin lymphoma (NHL). The treatment landscape of newly diagnosed MCL has evolved in recent years with the incorporation of covalent BTK inhibitors, sensitive assays for the assessment of measurable residual disease (MRD), and predefined maintenance or continuous therapy. Covalent BTK inhibitor-based regimens are also appropriate options for patients with previously untreated classic MCL with TP53 mutations. Pirtobrutinib (a highly selective noncov…

Rank110.0
Clinical guideline or consensus statement

The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline.

British journal of haematology · 2026 · PMID 42634099

Primary mediastinal B-cell lymphoma (PMBCL) is a distinct clinicopathological entity within the spectrum of aggressive B-cell lymphomas, characterised by unique clinical, immunophenotypic and molecular features. Since publication of the 2019 British Society for Haematology (BSH) Good Practice Paper, there have been important advances in imaging, radiotherapy approaches and systemic therapies, including chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint inhibition. Key updates include the use of PE…

Rank110.0
Clinical guideline or consensus statement

Narrowband UVB Phototherapy in Dermatology: GEF-CILAD 2026 Update.

Actas dermo-sifiliograficas · 2026 · PMID 42323047

This document updates the scientific evidence and clinical practice regarding narrowband UVB phototherapy (NB-UVB) in dermatology. The review addresses indications, therapeutic regimens, safety aspects, combinations with systemic and biologic agents, and adaptation to special populations. NB-UVB remains a first-line therapy for psoriasis, vitiligo, atopic dermatitis, early mycosis fungoides, and photodermatoses due to its efficacy, safety, and cost-effectiveness. Emerging evidence supports its integration with next…

Rank108.2
Systematic review or meta-analysis

Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review/Meta-Analysis.

Transplantation and cellular therapy · 2026 · PMID 41525947

In oncology, overall survival (OS) is the benchmark endpoint for assessing therapy effectiveness, but requires large patient cohorts and extended follow-up to attain meaningful data. The identification of reliable surrogate markers for OS may enable earlier treatment decisions and streamline clinical trial design, potentially reducing costs and accelerating access to new therapies. The objective of this study was to evaluate whether complete response (CR) could serve as an early surrogate for OS in patients with re…

Rank107.9
Systematic review or meta-analysisResult signal: null

Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma.

Molecular therapy : the journal of the American Society of Gene Therapy · 2025 · PMID 40170355

Bispecific antibodies (BsAb) are associated with distinct immune-related toxicities that impact morbidity and mortality. This systematic review and meta-analysis examined non-relapse mortality (NRM) with BsAb therapy in B-cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). A PubMed and Embase search up to October 2024 identified 29 studies (21 NHL, 8 MM) involving 2,535 patients. The overall NRM point estimate was 4.7% (95% confidence interval [CI] 3.4%-6.4%), with a median follow-up of 12.0 months. We noted…

Rank107.9
Systematic review or meta-analysis

Second Primary Malignancies in Patients With B-Cell Lymphomas Treated With Bruton's Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis.

European journal of haematology · 2026 · PMID 42289275

OBJECTIVE: To evaluate the overall second primary malignancy (SPM) burden in patients with B-cell lymphomas treated with Bruton's tyrosine kinase (BTK) inhibitors and compare SPM risk versus non-BTK inhibitor or placebo controls. METHODS: We searched major databases from inception to September 30, 2025. The primary outcome was SPM incidence. Consistent treatment backgrounds were defined as comparable baseline clinical and treatment characteristics, with BTK inhibitor exposure as the main between-arm difference. RES…

Rank107.5
Systematic review or meta-analysis

Febrile neutropenia in adults with diffuse large B-cell lymphoma receiving first-line R-CHOP-based therapy: a systematic review and meta-analysis of observational and trial evidence.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42839187

INTRODUCTION: Febrile neutropenia (FN) is an important complication of first-line immunochemotherapy for diffuse large B-cell lymphoma (DLBCL). Thresholds for primary granulocyte colony-stimulating factor (G-CSF) prophylaxis are risk-based, but the FN burden in routine practice is uncertain, and whether trial-derived estimates describe it is unknown. METHODS: Systematic review and meta-analysis of proportions. MEDLINE, CENTRAL, ClinicalTrials.gov, Europe PMC, Epistemonikos, Lens.org, Google Scholar, and citation tr…

Rank107.2
Systematic review or meta-analysisResult signal: benefit

Maintenance treatment and survival in patients with newly diagnosed diffuse large B cell lymphoma in the immunochemotherapy era: a systematic review and network meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 42213311

OBJECTIVE: To assess the comparative efficacy of various maintenance strategies for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL). METHODS: We conducted a comprehensive search of PubMed, Embase, Web of Science, the Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Trials for randomized clinical trials evaluating maintenance strategies in previously untreated DLBCL patients. The primary outcomes were progression-free survival (PFS) and overall survival (OS…

Rank107.2
Systematic review or meta-analysis

reFLASH: a proof-of-concept meta-analytic framework to validate surrogate endpoints in the absence of randomized clinical trial data.

Journal of clinical epidemiology · 2026 · PMID 42641770

BACKGROUND AND OBJECTIVES: Within a meta-analytic framework, validating surrogate endpoints traditionally requires individual patient data (IPD) from multiple randomized controlled trials (RCTs). This is rarely feasible in rare and indolent diseases. We propose a proof-of-concept strategy that creates synthetic comparative evidence from multiple single-arm trials to enable trial-level surrogacy assessment. METHODS: Using IPD from 12 follicular lymphoma RCTs (FLASH; 3996 patients), we decoupled each trial's randomiz…

Rank106.9
Systematic review or meta-analysis

Efficacy-safety trade-off and patient selection: a meta-analysis informing clinical choice between CAR-T and bispecific antibodies for R/R B-NHL.

Frontiers in immunology · 2026 · PMID 42495620

This meta-analysis compared chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAbs) for relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), focusing on efficacy and safety. We analyzed 59 phase I/II trials involving 2,914 patients. CAR-T achieved higher ORR (72% [95% CI 67-77%] vs. 50% [38-62%]) and CR (54% [49-59%] vs. 33% [23-46%]) than BsAbs. However, it was associated with higher rates of grade ≥3 CRS (8% [6-11%] vs. 4% [3-7%]), ICANS (12% [9-16%] vs. 6% [2-18%]), and neuroto…

Rank106.8
Systematic review or meta-analysis

Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.

British journal of haematology · 2026 · PMID 42383996

Relapsed/refractory follicular lymphoma (R/R FL) remains a clinically challenging condition, with progressively declining benefit across consecutive lines of therapy. While anti-Cluster of Differentiation 20 (CD20) antibodies remain the therapeutic backbone, the optimal targeted or immune-based partner remains undefined. A systematic review and network meta-analysis (NMA) of 5 phase III and 1 phase II trials (2500 patients) evaluated seven anti-CD20-based combination strategies. Primary end-points were overall surv…

Rank106.8
Systematic review or meta-analysis

Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.

JAMA oncology · 2026 · PMID 42313425

IMPORTANCE: T-cell-engaging bispecific antibodies (BsAbs) are increasingly used in B-cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). As these agents transition into earlier courses of therapy and broader clinical use, understanding their safety profile is critical. While second primary malignant neoplasms (SPMs) represent a key long-term safety signal, small sample sizes, single-arm trials, short follow-up, and heterogeneous reporting have limited reliable estimation of their frequency. OBJECTIVE: To est…

Rank106.7
Systematic review or meta-analysisResult signal: mixed

CAR-T Cell Therapy Versus Salvage Chemotherapy in Relapsed/Refractory DLBCL: A Systematic Review and Meta-Analysis Integrating Radiologic, Laboratory, and Histopathologic Correlates.

La Clinica terapeutica · 2026 · PMID 42340791

BACKGROUND: Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) remains a major therapeutic challenge, particularly among patients with high-risk molecular features or primary refractory disease. Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising treatment strategy; however, its comparative effectiveness versus salvage chemotherapy requires comprehensive evaluation. METHODS: This systematic review and meta-analysis were conducted in accordance with PRISMA 2020 and MOOSE guideli…

Rank106.7
Systematic review or meta-analysisResult signal: harm

Comparative efficacy and toxicity of Axicabtagene Ciloleucel versus Tisagenlecleucel in European patients with large B-cell lymphoma: a systematic review and meta-analysis.

PeerJ · 2026 · PMID 42428526

BACKGROUND AND OBJECTIVES: Large B-cell lymphoma (LBCL) is a common and aggressive non-Hodgkin lymphoma (NHL) characterized by abnormal proliferation of mature B lymphocytes, with a 10-year prevalence of up to 45 cases per 100,000 individuals in European populations and a continuing upward trend. Axicabtagene ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) are the two most established chimeric antigen receptor T-cell (CAR-T) therapy products for LBCL, yet a systematic comparison of their efficacy and safety in…

Rank106.4
Systematic review or meta-analysis

Application of CAR-T cell therapy in B-cell lymphoma: a meta-analysis of randomized controlled trials.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025 · PMID 39514165

BACKGROUND: This study aims to compare the efficacy and safety of chimeric antigen receptor T-cell (CAR-T) immunotherapy with standard treatment for B-cell lymphoma, providing evidence-based support for the more efficient use of CAR-T cell immunotherapy. METHODS: We conducted a comprehensive literature search of high-quality randomized controlled trials (RCTs) on CAR-T therapy for B-cell lymphoma in the following databases: Wanfang, Web of Science, CNKI, VIP database, and PubMed, up to February 2024. The outcome me…

Rank106.3
Systematic review or meta-analysis

Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review.

Bone marrow transplantation · 2026 · PMID 42332219

Lymphodepletion (LD) is a critical prerequisite for successful chimeric antigen receptor T-cell (CAR-T) therapy. While fludarabine and cyclophosphamide (Flu/Cy) remain the standard LD regimen, bendamustine has emerged as a potential alternative due to its distinct immunomodulatory properties and more favorable toxicity profile. This systematic review evaluates the safety, efficacy, and feasibility of bendamustine-based LD in patients undergoing CAR-T therapy for hematologic malignancies. A comprehensive literature …

Rank106.3
Systematic review or meta-analysis

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis.

Blood · 2024 · PMID 38696731

This meta-analysis evaluates the efficacy and safety of chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). We searched MEDLINE, Embase, and Cochrane databases until July 2023 for trials assessing CAR T-cell therapies and CD20×CD3 bispecific antibodies as third or subsequent lines in R/R DLBCL. Random-effects models estimated the complete response (CR) rate and secondary outcomes, with meta-regressions adjusting for relevant cov…

Rank106.0
Systematic review or meta-analysis

Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: a systematic review and meta-analysis.

Frontiers in immunology · 2024 · PMID 39308870

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy (CAR-T therapy) has demonstrated significant efficacy in the ZUMA-2 study. After regulatory approvals, several clinical trials and real-world studies on CAR-T therapy for relapsed or refractory mantle cell lymphoma (R/R MCL) were conducted. However, data on clinical safety and efficacy are inconsistent. In this study, we aimed to conduct a systematic analysis of the effectiveness and safety of CAR-T therapy across a wider and more representative cohort of p…

Rank105.9
Systematic review or meta-analysis

Reduced-Dose Total Skin Electron Beam Radiation Therapy in Mycosis Fungoides and Sézary Syndrome: Systematic Review and Meta-Analysis.

International journal of radiation oncology, biology, physics · 2026 · PMID 42128185

PURPOSE: Primary cutaneous T-cell lymphomas are a heterogeneous group of T-cell neoplastic entities associated with significant morbidity and high radiosensitivity. Although research on reduced-dose radiation treatment for mycosis fungoides and Sézary syndrome has significantly increased over the past 2 decades, randomized data are lacking. We aim to summarize the available evidence and analyze the safety and efficacy of reduced-dose total skin electron beam therapy (TSEBT). METHODS AND MATERIALS: A literature sear…

Rank105.6
Systematic review or meta-analysis

Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B-cell lymphoma, including the post-CAR T-cell therapy setting: A meta-analysis.

Cancer · 2026 · PMID 42487493

BACKGROUND: Loncastuximab tesirine, a CD19-directed antibody-drug conjugate, is a therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), including after chimeric antigen receptor T-cell therapy. This study summarized efficacy and safety across published cohorts. METHODS: The authors did a systematic review and meta-analysis of loncastuximab tesirine monotherapy in adults with relapsed or refractory DLBCL. They searched PubMed, Embase, and the Cochrane Library from inception to October 25, 2025, plus…

Rank105.5
Systematic review or meta-analysis

Cutaneous T-cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus.

Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · PMID 41821352

INTRODUCTION: Dupilumab, a standard treatment for atopic dermatitis (AD), has been associated with cutaneous T-cell lymphomas (CTCL), particularly mycosis fungoides (MF) and Sézary syndrome (SS). Nevertheless, the available data remain heterogeneous. OBJECTIVES: To characterize the clinical features, timeline and outcomes of dupilumab-related CTCL emergence in order to develop consensus-based recommendations for dupilumab use in CTCL-related settings. METHODS: A systematic review was conducted involving 51 studies …

Rank105.5
Systematic review or meta-analysis

Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis.

Bone marrow transplantation · 2024 · PMID 37853164

Allogeneic hematopoietic stem cell transplant (allo-HSCT) has been noted to be a potential curative treatment in cases of advanced-stage mycosis fungoides (MF) or Sezary syndrome (SS). To assess outcomes of allo-HSCT for MF/SS we performed a systematic review and meta-analysis including 15 manuscripts and 557 patients, published from 2010-2023. Meta-analysis revealed 1-year and 3+year overall survival (OS) of 51% (95% CI 39-64%) and 40% (32-49%). Progression-free survival at 1 year and 3+years were 42% (31-53%) and…

Rank105.1
Systematic review or meta-analysis

The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis.

Clinical lymphoma, myeloma & leukemia · 2026 · PMID 42409674

The prognostic value of interim 18F-fluorodeoxyglucose positron emission tomography/computed tomography (iPET/CT) in diffuse large B-cell lymphoma (DLBCL) remains a subject of debate due to inconsistencies in timing and interpretation. This updated systematic review and meta-analysis aimed to investigate the ability of iPET to predict progression-free survival (PFS). A systematic literature search was conducted across PubMed/MEDLINE, Cochrane, and Embase databases until December 31, 2025. Studies investigating the …

New Research Last 24 Months608 records
Rank110.0
Clinical guideline or consensus statement

The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline.

British journal of haematology · 2026 · PMID 42634099

Primary mediastinal B-cell lymphoma (PMBCL) is a distinct clinicopathological entity within the spectrum of aggressive B-cell lymphomas, characterised by unique clinical, immunophenotypic and molecular features. Since publication of the 2019 British Society for Haematology (BSH) Good Practice Paper, there have been important advances in imaging, radiotherapy approaches and systemic therapies, including chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint inhibition. Key updates include the use of PE…

Rank110.0
Systematic review or meta-analysis

Is tattooing associated with an increased risk of cancer? A systematic review and meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 42250187

BACKGROUND: Tattoo inks may contain carcinogenic compounds, and pigment migration to lymphatic tissues raises concerns regarding potential cancer risk. Epidemiological evidence remains inconclusive. OBJECTIVES: To assess the association between tattoo exposure and the incidence of skin cancer and hematological malignancies. METHODS: PubMed, Embase, and the Cochrane Library were searched from inception to January 2026 for cohort and case-control studies comparing cancer incidence in tattooed versus non-tattooed adul…

Rank107.5
Systematic review or meta-analysis

Febrile neutropenia in adults with diffuse large B-cell lymphoma receiving first-line R-CHOP-based therapy: a systematic review and meta-analysis of observational and trial evidence.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42839187

INTRODUCTION: Febrile neutropenia (FN) is an important complication of first-line immunochemotherapy for diffuse large B-cell lymphoma (DLBCL). Thresholds for primary granulocyte colony-stimulating factor (G-CSF) prophylaxis are risk-based, but the FN burden in routine practice is uncertain, and whether trial-derived estimates describe it is unknown. METHODS: Systematic review and meta-analysis of proportions. MEDLINE, CENTRAL, ClinicalTrials.gov, Europe PMC, Epistemonikos, Lens.org, Google Scholar, and citation tr…

Rank107.2
Systematic review or meta-analysisResult signal: benefit

Maintenance treatment and survival in patients with newly diagnosed diffuse large B cell lymphoma in the immunochemotherapy era: a systematic review and network meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 42213311

OBJECTIVE: To assess the comparative efficacy of various maintenance strategies for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL). METHODS: We conducted a comprehensive search of PubMed, Embase, Web of Science, the Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Trials for randomized clinical trials evaluating maintenance strategies in previously untreated DLBCL patients. The primary outcomes were progression-free survival (PFS) and overall survival (OS…

Rank107.2
Systematic review or meta-analysis

reFLASH: a proof-of-concept meta-analytic framework to validate surrogate endpoints in the absence of randomized clinical trial data.

Journal of clinical epidemiology · 2026 · PMID 42641770

BACKGROUND AND OBJECTIVES: Within a meta-analytic framework, validating surrogate endpoints traditionally requires individual patient data (IPD) from multiple randomized controlled trials (RCTs). This is rarely feasible in rare and indolent diseases. We propose a proof-of-concept strategy that creates synthetic comparative evidence from multiple single-arm trials to enable trial-level surrogacy assessment. METHODS: Using IPD from 12 follicular lymphoma RCTs (FLASH; 3996 patients), we decoupled each trial's randomiz…

Rank106.9
Systematic review or meta-analysis

Burden of Epstein-Barr virus in gastric cancer, nasopharyngeal carcinoma, and Burkitt lymphoma in Africa: a systematic review and meta-analysis.

BMC infectious diseases · 2026 · PMID 42426668

BACKGROUND: Epstein-Barr virus (EBV) is implicated in nasopharyngeal carcinoma (NPC), gastric cancer (GC), and Burkitt lymphoma (BL), but its burden across Africa remains poorly characterized due to fragmented evidence. This systematic review and meta-analysis estimated the pooled prevalence of EBV in NPC, GC, and BL across Africa, stratified by cancer type, region, and detection method. METHODS: PubMed, Scopus, Web of Science, and African Journals Online were searched for studies published between January 2000 and…

Rank106.3
Systematic review or meta-analysis

Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review.

Bone marrow transplantation · 2026 · PMID 42332219

Lymphodepletion (LD) is a critical prerequisite for successful chimeric antigen receptor T-cell (CAR-T) therapy. While fludarabine and cyclophosphamide (Flu/Cy) remain the standard LD regimen, bendamustine has emerged as a potential alternative due to its distinct immunomodulatory properties and more favorable toxicity profile. This systematic review evaluates the safety, efficacy, and feasibility of bendamustine-based LD in patients undergoing CAR-T therapy for hematologic malignancies. A comprehensive literature …

Rank105.9
Systematic review or meta-analysis

Reduced-Dose Total Skin Electron Beam Radiation Therapy in Mycosis Fungoides and Sézary Syndrome: Systematic Review and Meta-Analysis.

International journal of radiation oncology, biology, physics · 2026 · PMID 42128185

PURPOSE: Primary cutaneous T-cell lymphomas are a heterogeneous group of T-cell neoplastic entities associated with significant morbidity and high radiosensitivity. Although research on reduced-dose radiation treatment for mycosis fungoides and Sézary syndrome has significantly increased over the past 2 decades, randomized data are lacking. We aim to summarize the available evidence and analyze the safety and efficacy of reduced-dose total skin electron beam therapy (TSEBT). METHODS AND MATERIALS: A literature sear…

Rank105.1
Systematic review or meta-analysis

An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.

Journal of medical economics · 2026 · PMID 42452801

OBJECTIVE: No head-to-head trials have compared the efficacy of zanubrutinib versus ibrutinib in relapsed/refractory mantle-cell lymphoma (R/R MCL). METHODS: Following a systematic literature review, individual patient data from trials of zanubrutinib (n = 118) and aggregate data from a pooled analysis of ibrutinib trials (n = 370) were analyzed using an unanchored matching-adjusted indirect comparison (MAIC). RESULTS: After matching selected covariates, statistically significant differences were observed with zanu…

Rank104.8
Systematic review or meta-analysis

NKG2D genetic variants and cancer susceptibility: Integrating case-control evidence with meta-analysis.

Immunogenetics · 2026 · PMID 41491293

Lymphomas are biologically heterogeneous malignancies with multifactorial etiologies involving genetic, environmental, and immune dysregulation. The functional variant rs1049174 SNP in the KLRK1 gene (encoding NKG2D) regulates NKG2D expression and modulates NK cells immune surveillance pathways, which may influence lymphoma susceptibility. We investigated this association through a two-stage case-control study and meta-analysis. First, we analyzed 246 diffuse large B-cell lymphoma (DLBCL) patients and 599 healthy c…

Rank104.5
Systematic review or meta-analysisCorrection flagged

Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation.

Bone marrow transplantation · 2025 · PMID 39375527

Autologous peripheral blood stem cell (PBSC) transplantation is a standard treatment of multiple myeloma (MM), Hodgkin lymphoma and various subtypes of non-Hodgkin lymphoma. Cryopreservation of hematopoietic stem cells is standard practice that allows time for delivery of conditioning regimen prior to cell infusion. The aim of this Worldwide Network for Blood & Marrow Transplantation (WBMT) work was to assess existing evidence on non-cryopreserved autologous transplants through a systematic review/meta-analysis, to…

Rank104.2
Systematic review or meta-analysis

The role of allogeneic hematopoietic stem cell transplantation in adults with mature T-cell lymphomas.

The Cochrane database of systematic reviews · 2026 · PMID 42905121

RATIONALE: Mature T-cell lymphomas (MTCL) are a rare, heterogeneous group of malignancies that arise from post-thymic T-lymphocytes, with a generally poor prognosis. For a long time, the standard therapy for most MTCL subtypes has been polychemotherapies. Hopes to prolong overall survival in MTCL have been associated with transplant procedures such as high-dose therapy with autologous stem cell transplantation (autoSCT) or allogeneic stem cell transplantation (alloSCT). OBJECTIVES: To assess the benefits and harms …

Rank103.2
Systematic review or meta-analysis

Systemic Glucocorticoid Use and Risk of Site-Specific Cancers: A Methodologic Systematic Review of Observational Studies.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026 · PMID 41931525

Systemic glucocorticoids, widely prescribed for inflammatory and autoimmune diseases, have long been suspected of increasing cancer risk through immunosuppressive and metabolic effects. Randomized trials are often unethical and difficult to conduct, leaving observational studies the best option to determine whether the use of systemic glucocorticoids affects cancer development. However, these studies face significant methodologic issues that may compromise the validity of their findings. We systematically reviewed …

Rank102.4
Systematic review or meta-analysis

Rituximab Versus Watchful Waiting for Asymptomatic Advanced-Stage Low-Tumor-Burden Follicular Lymphoma: A Systematic Review and Meta-Analysis.

Clinical lymphoma, myeloma & leukemia · 2026 · PMID 42844116

The optimal initial management of asymptomatic patients with advanced-stage low-tumor-burden follicular lymphoma (LTB-FL) remains uncertain. Although watchful waiting (WW) has historically been the standard approach, rituximab monotherapy has emerged as an alternative strategy. A systematic review and meta-analysis comparing rituximab monotherapy with WW was performed in this population. PubMed, Embase, and Cochrane Library were systematically searched for studies comparing rituximab monotherapy with WW in adult pa…

Rank101.7
Systematic review or meta-analysis

Comparative Economic Evaluations of CAR-T Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Systematic Review.

PharmacoEconomics · 2026 · PMID 41345759

BACKGROUND AND OBJECTIVE: Chimeric antigen receptor T-cell therapies have changed the treatment paradigm of relapsed or refractory large B-cell lymphoma but are among the most expensive treatments. Moreover, their comparative economic value remains uncertain in adults with relapsed or refractory large B-cell lymphoma. The objective of this study was to understand the comparative value of these therapies in this population and the main factors that influenced conclusions on which intervention was considered more cos…

Rank101.3
Systematic review or meta-analysis

A public-data audit of transcriptomic prognostic transportability in R-CHOP-treated diffuse large B-cell lymphoma.

PloS one · 2026 · PMID 42912792

Gene-expression biomarkers for diffuse large B-cell lymphoma (DLBCL) are often transported across retrospective cohorts that differ in treatment, assay platform, and clinical annotation. Using REMARK as the reporting framework, we audited prognostic associations with fixed scoring rules. Four Gene Expression Omnibus cohorts were harmonized for survival analysis. Treatment context was assessed after outcome-blind transcriptional state discovery. A directly mapped five-gene historical benchmark was evaluated with con…

Rank100.4
Systematic review or meta-analysis

Chimeric Antigen Receptor T-Cell Therapy in T Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.

European journal of haematology · 2026 · PMID 42885507

T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare subtype of B-cell non-Hodgkin lymphoma with an aggressive clinical course and poor prognosis in the case of relapsed or refractory (r/r) disease. Recently, anti-CD19 chimeric antigen-receptor (CAR) T-cell therapy has been approved for the treatment of large B-cell lymphoma (LBCL), but subgroup-specific outcomes in these patients have never been reported. Therefore, only limited retrospective data on the safety and efficacy of CAR T-cell therapy in r/r…

Rank100.2
Randomized controlled trialResult signal: benefit

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

Lancet (London, England) · 2026 · PMID 42217458

BACKGROUND: Approximately 40% of patients with high-risk diffuse large B-cell lymphoma (DLBCL) are not cured with first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone). We aimed to investigate the addition of tafasitamab (an Fc-enhanced anti-CD19 monoclonal antibody) and lenalidomide to R-CHOP (tafa-len-R-CHOP) in patients with high-risk aggressive B-cell lymphomas. METHODS: frontMIND is a phase 3, randomised, double-blind, placebo-controlled study conducted at 29…

Rank100.0
Systematic review or meta-analysis

Clinical, economic, and quality-of-life outcomes of brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma and B-cell acute lymphoblastic leukemia: A systematic literature review and meta-analysis.

Journal of managed care & specialty pharmacy · 2026 · PMID 42808549

BACKGROUND: Brexucabtagene autoleucel (brexu-cel), a CD19 chimeric antigen receptor T-cell therapy, has shown efficacy in clinical trials for relapsed/refractory (R/R) mantle cell lymphoma (MCL) and B-cell acute lymphoblastic leukemia (B-ALL). However, although effectiveness and safety evidence is well established, real-world evidence (RWE) on health care resource use (HCRU), costs, and health-related quality of life (HRQoL) remains limited. OBJECTIVE: To systematically review and synthesize RWE on clinical, HCRU, …

Rank100.0
Systematic review or meta-analysisResult signal: harm

Pulmonary amyloidosis, gastric MALT lymphoma, and multiple sclerosis in a patient with Sjögren's disease: a case report and review of the literature.

Rheumatology international · 2026 · PMID 42640321

Sjögren's disease (SjD) is a systemic autoimmune disorder associated with lymphocytic gland infiltration and an increased risk of B-cell lymphomas, particularly mucosa-associated lymphoid tissue (MALT) lymphoma. Neurological involvement may mimic multiple sclerosis (MS), while true coexistence, especially with amyloidosis, is exceptionally rare. We performed a systematic review and present a representative clinical case. A registered systematic literature review (PROSPERO CRD4201332325) was conducted according to P…

Rank100.0
Systematic review or meta-analysis

Efficacy and safety of CD19 CAR T-cell therapy in relapsed/refractory follicular lymphoma: A systematic review and meta-analysis.

Current research in translational medicine · 2026 · PMID 42401099

BACKGROUND AND AIMS: Follicular lymphoma (FL) is an indolent B-cell non-Hodgkin lymphoma characterized by frequent relapses despite initial responsiveness to chemoimmunotherapy. CD19-directed chimeric antigen receptor (CAR) T-cell therapy has shown promising efficacy in relapsed or refractory disease, though safety concerns such as cytokine release syndrome (CRS) and neurological events remain. This study aimed to evaluate the efficacy and safety of CD19 CAR T-cell therapy in relapsed or refractory FL. METHODS: A c…

Rank100.0
Systematic review or meta-analysis

Attributable Fraction of Epstein-Barr Virus in Subtypes of Lymphoma: A Systematic Review and Global Meta-Analysis.

International journal of cancer · 2026 · PMID 41947331

There is evidence for a causal role of Epstein-Barr virus (EBV), a known carcinogen, in an increasing number of lymphoma subtypes, but a systematic evaluation of EBV attributable fraction is lacking. We conducted a systematic review and meta-analysis of EBV prevalence in lymphoma subtypes from 1990 to 2024, stratified by HIV status and geographical region. For each subtype, we calculated pooled prevalence and corresponding 95% confidence intervals (CIs) of EBV, measured by EBV-encoded RNA in situ hybridisation. 307…

Rank100.0
Systematic review or meta-analysis

Prognostic impact of high-grade transformation in low-grade B-cell lymphomas: a systematic review and meta-analysis.

Leukemia research · 2026 · PMID 42743819

Low-grade B-cell lymphomas generally follow an indolent course. Nonetheless, they can occasionally transform into high-grade lymphoma, leading to reduced survival. Despite therapeutic advances that have improved absolute survival in high-grade transformation (HGT) lymphomas, additional survival data are needed for patients with HGT lymphoma. We aimed to perform a pooled analysis of hazard ratios (HRs) comparing HGT lymphoma with low-grade lymphoma and de novo diffuse large B-cell lymphoma (DLBCL) to obtain more rob…

Rank99.6
Randomized controlled trial

A clinical study on fall risk assessment and preventive nursing in older adults with non-Hodgkin's lymphoma undergoing chemotherapy-a randomized controlled trial.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42470465

BACKGROUND: Non-Hodgkin's lymphoma (NHL) is a diverse group of lymphoproliferative malignancies that predominantly affects older adults. Chemotherapy remains the primary modality of treatment for many NHL subtypes, yet it often brings about adverse effects such as myelosuppression, anemia, and neuropathy, all of which contribute to a heightened risk of falls in older patients. Falls in this population can lead to serious complications, including fractures and intracranial injuries, thereby impacting functional stat…

Rank99.3
Randomized controlled trial

Baseline Tumor Transcriptional Features and Event-Free Survival After Anti-CD19 CAR T-Cell Therapy with Axicabtagene Ciloleucel in Large B-Cell Lymphoma: An Exploratory Reanalysis of the Randomized ZUMA-7 Trial.

Medical sciences (Basel, Switzerland) · 2026 · PMID 42930590

Background/Objectives: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with axicabtagene ciloleucel (axi-cel) improves outcomes in relapsed/refractory large B-cell lymphoma (LBCL), but many patients relapse despite retained CD19 expression. We explored baseline tumor transcriptional features associated with event-free survival (EFS) after axi-cel. Methods: We reanalyzed baseline NanoString IO 360 profiles from the randomized ZUMA-7 trial (axi-cel, n = 134; standard of care [SOC], n = 122) using differentia…

Preclinical Research159 records
Rank100.0
Systematic review or meta-analysis

Tyrosine kinase inhibitors and molecularly driven therapeutic approaches for canine lymphoma: a systematic review and meta-analysis.

Frontiers in veterinary science · 2026 · PMID 42656497

BACKGROUND: Canine lymphoma (cL), the second most common canine cancer after mammary carcinoma, presents therapeutic challenges due to limitations of conventional regimens, necessitating novel therapeutic approaches. Tyrosine kinase inhibitors (TKIs), which have demonstrated efficacy in human non-Hodgkin lymphoma (NHL), are increasingly being investigated as targeted therapies for cL, which also serves as a valuable translational model for NHL research. OBJECTIVES: To systematically evaluate the efficacy of TKIs in…

Rank96.0
Systematic review or meta-analysis

Somatic IRF4 mutations and thymic tropism in primary mediastinal large B-cell lymphoma.

Blood · 2025 · PMID 40540746

Disease-defining signatures in lymphomas, driven by intricate molecular mechanisms, have advanced molecular taxonomies, refined classification, and may guide clinical management; however, the role of these signatures in driving disease hallmarks, including subtype-specific organotropism, remains largely unexplored. Primary mediastinal large B-cell lymphoma (PMBCL) is an exemplary lymphoma characterized by disease manifestations in the thymic niche, unique genetic alterations, and immune escape. Here, we identified …

Rank92.0
Randomized controlled trial

Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.

Blood · 2025 · PMID 40749164

T-cell engagers (TCEs) are transformative therapeutics in hematologic malignancies, including non-Hodgkin lymphoma. Initially approved for relapsed/refractory disease settings, TCEs are now explored in first-line and second-line settings, often combined with standard-of-care (SOC) treatments, including chemotherapy and antibody-drug conjugates. This study investigates glofitamab (CD20×CD3 TCE) combinations in preclinical humanized lymphoma models, addressing heterogeneity of tumor antigen expression, immune evasion…

Rank85.0
Randomized clinical studyResult signal: null

Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma.

Blood · 2025 · PMID 40896830

Histone deacetylase inhibitors (HDACis) are valued treatment options for patients with T-cell malignancies. Romidepsin is a selective class I HDACi initially approved for patients with relapsed or refractory cutaneous and peripheral T-cell lymphomas (PTCLs). Romidepsin was withdrawn from its PTCL indication following a negative randomized phase 4 study (romidepsin-CHOP [cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone]) that showed no benefit over CHOP…

Rank74.0
Phase II clinical trial

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy.

Frontiers of medicine · 2023 · PMID 37060525

Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has achieved 40%-50% long-term complete response in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients. However, the underlying mechanism of alterations in the tumor microenvironments resulting in CAR-T cell therapy failure needs further investigation. A multi-center phase I/II trial of anti-CD19 CD28z CAR-T (FKC876, ChiCTR1800019661) was conducted. Among 22 evaluable DLBCL patients, seven achieved complete remission, 10 experienced partial…

Rank68.0
Phase I clinical trial

Selinexor plus tislelizumab in patients with relapsed/refractory natural killer/T-cell lymphoma after failure of PD-1 blockade: the phase 1b TOUCH trial.

The oncologist · 2026 · PMID 42438166

BACKGROUND: Relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R NKTCL) remains a highly lethal disease, particularly after failure of PD-1 blockade-based therapy. Preclinical data suggest that inhibition of exportin-1 (XPO1) may enhance antitumor immunity and synergize with PD-1 blockade. PATIENTS AND METHODS: We conducted a multicenter, open-label phase 1b study (TOUCH, Arm C) evaluating selinexor plus tislelizumab in patients with R/R NKTCL previously treated with L-asparaginase-containing regim…

Rank65.7
Phase I clinical trial

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study.

Blood advances · 2022 · PMID 34972202

Preclinical data demonstrated that combining an anti-programmed cell death 1 (PD-1) inhibitor with a cyclin-dependent kinase 9 (CDK9) inhibitor provided enhanced antitumor activity with no significant toxicities, suggesting this combination may be a potential therapeutic option. The multicohort, phase 1 KEYNOTE-155 study evaluated the safety and antitumor activity of the PD-1 inhibitor pembrolizumab plus the CDK9 inhibitor dinaciclib in patients with relapsed or refractory (rr) chronic lymphocytic leukemia (CLL), d…

Rank65.0
Phase I clinical trial

Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22.

Blood cancer discovery · 2026 · PMID 42446920

UNLABELLED: Disease recurrence is the main cause of treatment failure after CD19-directed chimeric antigen receptor (CAR) T cells, often due to CD19 antigen loss, stability, and/or coverage. To overcome single-antigen escape, we evaluated a trispecific CAR targeting CD19, CD20, and CD22 with an OX40 costimulatory domain. Preclinical studies demonstrated potent, antigen-specific cytotoxicity in in vitro and in vivo lymphoma models. We then conducted a first-in-human phase I trial in patients with relapsed/refractory…

Rank45.0
Other PubMed-indexed publication

The RNA-binding activity of the Drosophila Brat protein is necessary for viability and mRNA regulation.

RNA biology · 2026 · PMID 42206510

Brain tumor (Brat) is a Drosophila TRIM-NHL protein required for embryogenesis and neural stem cell differentiation. Although structural and biochemical studies established that the Brat NHL domain specifically binds RNA, the in vivo requirement for this activity has not been directly tested. Here, we used structure-guided mutagenesis and genome engineering to determine whether RNA recognition is essential for Brat function during development. The direct interaction between Brat's NHL domain and RNA containing Brat…

Rank45.0
Other PubMed-indexed publicationResult signal: null

FoxP3+ Regulatory T-Cells in Canine Cutaneous Lymphoma and Their Role in Immune Modulation.

In vivo (Athens, Greece) · 2026 · PMID 42957219

BACKGROUND/AIM: Regulatory T cells (Tregs) are immunosuppressive lymphocytes that maintain immune homeostasis but may also facilitate tumor immune evasion. Their role in canine cutaneous lymphoma (CCL) remains insufficiently understood. We hypothesized that dogs with CCL would exhibit increased Treg levels in both peripheral blood and tumor tissue, thereby contributing to local and systemic immune modulation. Our objective was to evaluate Treg levels in blood and skin of dogs with CCL compared with healthy controls…

Rank45.0
Other PubMed-indexed publication

Comprehensive phenotypic and clonality analysis of intraepithelial lymphocytes of intestinal T-cell lymphoma and chronic enteropathy in dogs.

Veterinary pathology · 2026 · PMID 41913572

Canine intestinal T-cell lymphoma (ITCL) may arise from intraepithelial lymphocyte (IEL) subsets expanded in chronic enteropathy (CE). To investigate this potential cell of origin, we performed flow cytometry, immunohistochemistry, and RNA in situ hybridization on IELs using biopsy samples from 62 dogs, including 6 large-cell lymphomas (LCLs), 9 small-cell lymphomas (SCLs), 31 CEs with increased IELs (IEL+CE), and 16 CEs without increased IELs (IEL-CE). IELs in ITCLs were predominantly CD4-CD8α- (LCL, 5/6; SCL, 4/9…

Rank45.0
Other PubMed-indexed publication

Mouse models of B cell lymphomas on the basis of genetic features.

Frontiers in immunology · 2026 · PMID 42614320

Diffuse large B cell lymphoma (DLBCL) is a highly aggressive form of lymphoma that is genetically and phenotypically diverse. Most DLBCLs arise from the germinal center and transcriptionally represent either germinal center or post-germinal center activated B cells by gene expression profiling. Recently, a revised classification of DLBCLs has identified at least six molecularly defined groups based on their genomic landscape. In this review, we discuss the use of transgenic animal models to study DLBCLs based on th…

Rank45.0
Other PubMed-indexed publication

Double-staining immunocytochemistry on Romanowsky-stained smears for CD20 and CD3ε in canine samples.

Research in veterinary science · 2026 · PMID 42575081

Romanowsky-stained smears (RSSs) can be used to immunophenotype lymphoid neoplasms by immunocytochemistry (ICC). This technique typically involves incubating the antibodies separately. However, there is no description of a manual double-staining ICC (dsICC) to characterize lymphocytes in canine samples. This study aims to develop, optimize, and validate a dsICC assay for two lymphoid markers on canine RSSs. An initial antibody selection phase using four candidate markers for B-cells (CD20, CD21, PAX-5, CD79a) and t…

Rank45.0
Other PubMed-indexed publication

Exploring the prognostic implications of programmed death-ligand 1 expression in canine nodal lymphoma: Insights from surface membrane expression, transcript amount and plasmatic levels.

Research in veterinary science · 2026 · PMID 42365729

Programmed Death-Ligand 1 (PD-L1) is an immune-checkpoint molecule involved in tumor-induced immunotolerance. While few studies explored its role in canine B-cell lymphoma (BCL), comprehensive analysis across lymphoma immunophenotypes remains limited. This study investigated associations between time to progression (TTP) and lymphoma-specific survival (LSS) with PD-L1 expression, including surface membrane protein (mPD-L1), mRNA levels in nodal aspirates, and soluble protein (sPD-L1) plasmatic concentrations, in do…

Rank45.0
Other PubMed-indexed publication

Fluorescent Light Energy (FLE) as an Adjunctive Therapy in Canine Cutaneous Epitheliotropic Lymphoma (CTCL).

Veterinary dermatology · 2026 · PMID 42363651

BACKGROUND: Fluorescent light energy (FLE; Phovia, Vetoquinol) is a photobiomodulation therapy that promotes healing and reduces inflammation. Cutaneous epitheliotropic lymphoma (CTCL) is a neoplastic skin disease with limited treatment options. Although FLE is not considered genotoxic, its use in neoplastic conditions is off-label. HYPOTHESIS: To assess the safety and clinical effect of FLE as an adjunctive treatment for canine CTCL. ANIMALS: Eight client-owned dogs were diagnosed with CTCL via biopsy analysis and…

Rank45.0
Other PubMed-indexed publication

Antitumor potential of ivermectin against T-cell lymphoma-bearing hosts.

Medical oncology (Northwood, London, England) · 2025 · PMID 40257544

Ivermectin, a broad-spectrum antiparasitic agent from the ivermectin family, has shown promising anticancer potential. Originally developed for veterinary and human use against parasitic infections, ivermectin demonstrated significant antitumor effects in our study against tumor cells (Dalton's lymphoma cells). A dose-dependent decrease in tumor cell viability was observed following 24-h treatment with ivermectin, with an IC₅₀ value calculated at 10.55 µg/mL. In comparison, the standard anticancer drug cisplatin ex…

Rank45.0
Other PubMed-indexed publication

Chemical Exposures, DNA Methylation and Whole Blood DNA Damage in Pet Golden Retrievers.

Veterinary and comparative oncology · 2026 · PMID 42003040

Canine multicentric lymphoma (CL) is a common and typically fatal cancer among dogs. Although certain breeds have a higher incidence of CL, its environmental risk factors remain uncertain. Exposures to herbicides and volatile organic compounds (VOCs) associate with non-Hodgkin lymphoma in people. These exposures also correlate with measurable in vivo DNA strand breaks in dogs, even at estimated systemic concentrations that do not reach genotoxic thresholds. Herbicides and VOCs can also exert genotoxicity through di…

Rank45.0
Other PubMed-indexed publication

Pharmacological aspects of FDA-approved novel drug therapies against cancer in 2023: a comprehensive review.

Naunyn-Schmiedeberg's archives of pharmacology · 2025 · PMID 40067439

This manuscript is aimed at preparing a scientific report on anticancer drugs, covering pharmacological aspects, approved by the FDA in the year 2023. This article is anticipated to serve as a handy document of interest for oncologists, patients as well as academicians. The manuscript was prepared by studying the pre-clinical and clinical data available in the public domain specifically on the website of the USFDA, Clinical Trials, National Library of Medicine, and other sources. The FDA reports were comprehensivel…

Rank45.0
Other PubMed-indexed publication

Celastrus orbiculatus Extract Inhibits Immune Inflammatory Thrombotic State of B-Lymphoma.

Chinese journal of integrative medicine · 2024 · PMID 38782853

OBJECTIVE: To investigate the inhibitory effect of Celastrus orbiculatus extracts (COE) on the proliferation of lymphoma cells and the immune regulation ability on inflammation and thrombophilia in vivo. METHODS: The 38B9 lymphoma cells were treated with COE (160 µ g/mL) and CTX (25 µ mol/L). The apoptosis rate and cell cycle of each group were detected by flow cytometry. The secretion of inflammatory factors, including interleukin (IL)-6, IL-10, and tumor necrosis factor α (TNF-α), in cell supernatant was detected…

Rank45.0
Other PubMed-indexed publication

Bi-directional support of T lymphoma and a lymphoma-associated monocyte population involving Notch signaling in mice.

Oncoimmunology · 2026 · PMID 42557693

Tumor-induced manipulations of myelomonocytic differentiation have been widely reported. Here, we describe the elicitation of a tumor-supportive cell type in a T lymphoma model in mice. We observed that the development of T lymphoma coincided with the appearance of a lymphoma-associated monocytic cell type (LAM) of host origin accompanied by a diminished dendritic cell (DC) population. RNA-sequencing and cytometric analyses revealed that LAMs shared markers with both DCs and with resident macrophages, most closely …

Rank42.0
Other PubMed-indexed publication

CDK12 activates MYC to repress miR-28-5p/EZH2 and amplifies tonic BCR signaling to promote the development of diffuse large B-cell lymphoma.

Cancer gene therapy · 2022 · PMID 35082399

Cyclin-dependent kinase 12 (CDK12) is a transcription-associated kinase that participates in various cellular processes. However, its regulatory role in the progression of diffuse large B-cell lymphoma (DLBCL), which is the most prevalent subtype of non-Hodgkin lymphoma (NHL), is still elusive and controversial.The expression of CDK12 was detected by immunohistochemistry (IHC), RT-qPCR was performed to detect miR-28-5p expression of OCI-LY3 and SU-DHL-4 cells. MTT and soft agarose colony formation assays were used …

Rank42.0
Other PubMed-indexed publication

DNMT3AR882H accelerates angioimmunoblastic T-cell lymphoma in mice.

Oncogene · 2023 · PMID 37127775

DNA methylation-related genes, including TET2, IDH2, and DNMT3A are highly frequently mutated in angioimmunoblastic T-cell lymphoma (AITL), an aggressive malignancy of T follicular helper (Tfh) cells associated with aberrant immune features. It has been shown that TET2 loss cooperates with RHOAG17V to promote AITL in mice but the functional role of DNMT3A mutations in AITL remains unclear. Here, we report that DNMT3AR882H, the most common mutation of DNMT3A in AITL, accelerates the development of Tet2-/-; RHOAG17V …

Rank36.0
Preclinical or laboratory study

Association of Epstein-Barr virus genomic alterations with human pathologies.

Blood · 2025 · PMID 40569273

Epstein-Barr virus (EBV) infects >90% of humans and is associated with both hematological and epithelial malignancies. Here, we analyzed 990 EBV genomes (319 newly sequenced and 671 from public databases) from patients with various diseases to comprehensively characterize genomic variations, including single nucleotide variations (SNVs) and structural variations (SVs). Although most SNVs were a result of conservative evolution and reflected the geographical origins of the viral genomes, we identified several conver…

Rank35.2
Preclinical or laboratory study

Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin's Lymphoma.

Clinical pharmacokinetics · 2024 · PMID 39240498

BACKGROUND AND OBJECTIVE: Axicabtagene ciloleucel (axi-cel, Yescarta) is an autologous, anti-CD19, chimeric antigen receptor (CAR) T-cell therapy approved for patients with relapsed and refractory non-Hodgkin's lymphoma. Substantial inter-individual variability in cellular kinetics has been observed with CAR-T therapies and factors impacting CAR-T cellular kinetics remain poorly understood. This work reports a population cellular kinetic model of axi-cel in relapsed and patients with refractory non-Hodgkin's lympho…

Rank35.1
Preclinical or laboratory study

Exploring Potential Multi-Target Inhibition Mechanisms of Ganoderma lucidum Against EBV-Mediated DLBCL Using Integrative Bioinformatics, Machine Learning, and Network Pharmacology Approaches.

Journal of food science · 2026 · PMID 42894887

Epstein-Barr virus (EBV)-associated diffuse large B-cell lymphoma (DLBCL) represents a significant clinical challenge with limited targeted therapeutic options. Despite the known antiviral and anticancer properties of Ganoderma lucidum, its specific molecular mechanisms against EBV-mediated DLBCL remain unexplored. Therefore, this study aimed to investigate the potential multi-target inhibitory mechanisms of G. lucidum compounds against EBV-associated DLBCL by integrating absorption, distribution, metabolism, excre…

Promising Experimental Therapies119 records
Rank99.4
Randomized controlled trial

RENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed/refractory follicular lymphoma.

Blood advances · 2026 · PMID 42349017

Maintenance treatment in older patients with relapsed or refractory (R/R) follicular lymphoma (FL) remains an area of investigation. RENOIR was a multicenter, phase 3, open-label randomized trial conducted by the Fondazione Italiana Linfomi (FIL) in older patients with R/R FL after 1 or 2 previous therapies. Patients achieving partial response or complete response (CR) after 4 to 6 cycles of standard rituximab (R)-based chemotherapy were randomized 1:1 to maintenance with R alone (standard arm) or R plus lenalidomi…

Rank98.3
Randomized controlled trialCorrection flagged

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy.

Blood · 2025 · PMID 39441941

Antibiotic (ABX)-induced microbiome dysbiosis is widespread in oncology, adversely affecting outcomes and side effects of various cancer treatments, including immune checkpoint inhibitors and chimeric antigen receptor T-cell (CAR-T) therapies. In this study, we observed that prior exposure to broad-spectrum ABXs with extended anaerobic coverage such as piperacillin-tazobactam and meropenem was associated with worse anti-CD19 CAR-T therapy survival outcomes in patients with large B-cell lymphoma (N = 422) than other…

Rank98.2
Randomized controlled trial

Efficacy of bepotastine compared with hydroxyzine in preventing rituximab-induced infusion-related reactions in non-hodgkin lymphoma patients: a phase II, double-blind, multicenter, and randomized trial.

International journal of clinical oncology · 2026 · PMID 41989666

BACKGROUND: This study evaluated the efficacy of hydroxyzine and bepotastine, first- and second-generation H1 receptor antagonists (H1RA), as pretreatments to prevent infusion-related reactions (IRRs) during the initial rituximab infusion in patients with non-Hodgkin lymphoma. METHODS: In this double-blind, multicenter, randomized phase II study, 40 patients received hydroxyzine or bepotastine with acetaminophen 30 min before rituximab infusion. Primary endpoint was incidence of ≥ grade 2 IRRs based on the National…

Rank98.1
Randomized controlled trial

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.

The Lancet. Haematology · 2026 · PMID 42285113

BACKGROUND: Anthracycline-free regimens are needed for older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL). We aim to evaluate the efficacy and safety of fixed-duration epcoritamab monotherapy versus epcoritamab with lenalidomide in this patient population. METHODS: This open-label, multicentre, randomised, phase 2 trial was conducted at 44 hospitals across 11 countries in Europe and Asia. Patients had newly diagnosed, histologically confirmed CD20-positive large B-cell lymphoma, were ineligible…

Rank97.2
Randomized controlled trialResult signal: null

Impact of resolved hepatitis B virus infection on clinical outcomes in patients with diffuse large B-cell lymphoma: a supplementary analysis of JCOG0601.

International journal of hematology · 2026 · PMID 42801438

The impact of resolved hepatitis B virus (HBV) infection, defined as pretreatment hepatitis B surface antigen (HBsAg) negativity with antibody to hepatitis B core antigen (anti-HBc) positivity, on the clinical characteristics and outcomes of diffuse large B-cell lymphoma (DLBCL) remains unclear. JCOG0601 was a randomized phase II/III trial showing no improvement in progression-free survival (PFS) with dose-dense rituximab plus CHOP in previously untreated DLBCL. This supplementary analysis of JCOG0601 evaluated whe…

Rank95.8
Randomized controlled trial

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.

American journal of hematology · 2026 · PMID 42283231

Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R-Pola) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun-Pola), with > 2 years of follow-up. Patients with R/R LBCL and ≥ 1 prior line of therapy were randomized to receive Mosun-Pola or R-Pola. Mosunetuzumab was administered subcutaneously with …

Rank95.4
Phase III clinical trial

Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaboration.

Leukemia · 2024 · PMID 39152324

Progression or relapse in the central nervous system (CNS) remains a rare but mostly fatal event for patients with diffuse large B-cell lymphoma (DLBCL). In a retrospective analysis of 5189 patients treated within 19 prospective German and French phase 2/3 trials, we identified 159 patients experiencing a CNS event (relapse: 62%, progression: 38%). Intracerebral, meningeal, intraspinal, or combined involvement was reported in 44%, 31%, 3%, and 22% of patients, respectively. 62 of 155 evaluable patients (40%) showed…

Rank95.2
Randomized controlled trial

Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.

The New England journal of medicine · 2026 · PMID 42341302

BACKGROUND: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. METHODS: We evaluated long-term outcomes in 38 patients with relapsed or refractory B-cell non-Hodgkin lymphomas (24 patients with large B-cell lymphoma and 14 with follicular lymphoma) who had been treated with CTL019 (now called tisagenlecleucel) - autologous T cells expressing CD19-directed, 4-1BB-costimula…

Rank93.2
Randomized controlled trialCorrection flagged

Decade-long persistence of CD19 CAR T cells in B cell lymphomas.

Nature medicine · 2026 · PMID 42575986

Chimeric antigen receptor (CAR) T cell therapy induces durable remissions in lymphoid malignancies, yet the extent and biology of long-term CAR T cell persistence in B cell lymphoma remain unclear. Here we report the persistence and characteristics of 4-1BB-costimulated anti-CD19 CAR T cells (CART19) up to 10 years after infusion in 38 patients with non-Hodgkin lymphoma. Beyond year five, the CAR19 transgene was detectable in five of eight long-term responders (7.0-10.1 years), with three patients maintaining B cel…

Rank92.6
Randomized controlled trial

End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial.

European journal of nuclear medicine and molecular imaging · 2024 · PMID 38795120

PURPOSE: To evaluate the reliability of the Deauville score (DS) in therapy response assessment and to define the prognostic value of the metabolic response of end of induction (EOI) [18F]FDG PET (PET) in follicular lymphoma patients. METHODS: Adult patients with untreated grade 1-3a FL/ stage II-IV enrolled in the multicentre, prospective, phase III FOLL12 trial (NCT02063685) were randomized to receive standard immunochemotherapy followed by rituximab maintenance (standard arm) versus standard immunochemotherapy f…

Rank92.0
Randomized controlled trial

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.

Blood · 2024 · PMID 38820500

Although initial therapy of mantle cell lymphoma (MCL) is not standardized, bendamustine plus rituximab (BR) is commonly used in older patients. Rituximab (R) maintenance after induction is often used. Thus, the open-label, randomized phase 2 ECOG-ACRIN Cancer Research Group E1411 trial was designed to test 2 questions: (1) does addition of bortezomib to BR induction (BVR) and/or (2) addition of lenalidomide to rituximab (LR) maintenance improve progression-free survival (PFS) in patients with treatment-naïve MCL? …

Rank92.0
Randomized controlled trial

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42447409

The TRIANGLE trial established an ibrutinib-containing therapy without autologous stem-cell transplantation (ASCT) as the new standard for younger, treatment-naïve patients with mantle cell lymphoma (MCL). However, the benefit of rituximab maintenance (RM) within this novel standard is unclear. We investigated whether RM improves progression-free survival (PFS) and overall survival (OS) with acceptable toxicity when added to the experimental arms of TRIANGLE. This secondary analysis of TRIANGLE included patients ra…

Rank85.0
Randomized clinical study

The current landscape of frontline large B-cell lymphoma trials.

Blood · 2025 · PMID 39316716

At least 25% to 35% of patients with large B-cell lymphoma (LBCL) are not cured with frontline treatment, with generally poor subsequent outcomes. This motivates ongoing and intense interest in improving the frontline treatment of this disease. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) has remained the standard of care for 20 years despite dozens of trials aiming to improve upon this regimen, and only recently has a novel regimen (pola-R-CHP [polatuzumab vedotin, rituximab, cycl…

Rank84.7
Phase II clinical trial

Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.

Clinical pharmacokinetics · 2025 · PMID 39708278

BACKGROUND AND OBJECTIVES: Epcoritamab is a CD3xCD20 bispecific antibody approved for the treatment of adults with different types of relapsed or refractory (R/R) B cell non-Hodgkin lymphoma (B-NHL) after ≥ 2 lines of systemic therapy. Here we report the first results from a population pharmacokinetic model-based analysis using data from 2 phase 1/2 clinical trials (EPCORE® NHL-1, NCT03625037 and EPCORE NHL-3, NCT04542824) evaluating epcoritamab in patients with R/R B-NHL. METHODS: Plasma concentration-time data in…

Rank84.2
Phase II clinical trial

Efficacy and safety of ifupinostat in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase 2 study.

Signal transduction and targeted therapy · 2026 · PMID 42893991

Ifupinostat (BEBT-908) is a novel dual-targeted inhibitor of histone deacetylase (HDACs) and phosphatidylinositol 3-kinase alpha (PI3Kα). We evaluated the efficacy and safety of ifupinostat monotherapy in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after at least 2 prior lines of systemic therapy. Eligible participants received intravenous ifupinostat at 22.5 mg/m² on days 1, 3, 5, 8, 10, and 12 of a 21-day cycle. The primary endpoint was objective response rate (ORR) assessed b…

Rank83.8
Phase II clinical trial

End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial.

International journal of hematology · 2024 · PMID 38519820

Response determined by 18[F]-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET)-CT after induction therapy can predict progression-free survival (PFS) in follicular lymphoma (FL). However, little prospective research has examined the significance of PET after second-line therapy. We conducted a prospective multicenter phase II trial (W-JHS NHL01) of bendamustine plus rituximab (BR) without rituximab maintenance for FL in first relapse. This study aimed to evaluate the usefulness of end-of-treatme…

Rank83.6
Phase II clinical trial

R-MINE-containing regimen in relapsed and refractory diffuse large B-cell lymphoma: a single-arm, multicenter phase II study.

BMC medicine · 2026 · PMID 42426809

BACKGROUND: Improving the prognosis of patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) remains an unmet need. This multicenter, phase II study (NCT05784987) aimed to assess the efficacy and safety of a mitoxantrone hydrochloride liposome (Lipo-MIT)-based rituximab with mitoxantrone/ifosfamide/mesna/etoposide (R-MINE)-containing regimen, in which conventional mitoxantrone was replaced with Lipo-MIT, with or without a targeted agent. METHODS: Patients older than 18 years with histologic…

Rank83.5
Phase II clinical trial

Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.

Blood advances · 2026 · PMID 42085626

This multicenter, single-arm, phase 1/2 study evaluated the safety and efficacy of CD19-directed allogeneic chimeric antigen receptor (CAR) immunotherapy CTX110 in adult patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Patients received 1 or 2 treatment courses: standard lymphodepletion, followed by 1 CTX110 infusion at dose levels (DLs) 1 to 4 (3 × 107 to 60 × 107 CAR T cells; dose escalation, N = 32), or 2 infusions at DL4 on days 1 and 35 (cohort expansion, N = 31). Primary end points i…

Rank83.2
Phase II clinical trial

Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma.

American journal of hematology · 2026 · PMID 42305039

First-line therapy for mantle cell lymphoma (MCL) represents a critical opportunity for clinical benefit via sustained complete response. We conducted a phase 2 multicenter trial in the academic and community cancer research united (ACCRU) network, testing a multitargeted 1st line regimen. CARiBOU (ACCRU-LY-1804) employs alternating VR-CAP and R-cytarabine with continuous acalabrutinib, in six 21-day cycles, for previously untreated MCL. The primary endpoint was complete metabolic response (CMR) rate. Secondary end…

Rank83.2
Phase II clinical trial

Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study.

MedScience · 2026 · PMID 42228038

This study evaluated the efficacy and safety of obinutuzumab plus bendamustine (GB) as first-line treatment for indolent B-cell lymphomas. In this prospective, multicenter, single-arm trial (NCT06415708), adults with newly diagnosed indolent B-cell lymphomas-including follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenström macroglobulinemia (WM), hairy cell leukemia variant (HCL-v), and unclassified B-cell lymphoproliferative disorder (BCLPD-U)-received six induction cycles of GB followed by 2 years of …

Rank83.2
Phase II clinical trial

Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

Blood · 2026 · PMID 42013019

Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), especially those progressing after Bruton tyrosine kinase (BTK) inhibitor and/or chimeric antigen receptor (CAR) T-cell therapy and those with high-risk features, have poor outcomes. The bispecific antibody, mosunetuzumab, combined with the antibody-drug conjugate (ADC), polatuzumab vedotin (Mosun-Pola), targets CD20 and CD79b via independent cell-killing mechanisms. In this multicenter phase 2 study, patients with MCL who had received ≥2 previous …

Rank83.1
Phase II clinical trial

Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study.

Blood · 2025 · PMID 39938019

ZUMA-12 is a multicenter phase 2 study evaluating axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy as part of first-line treatment for high-risk large B-cell lymphoma (LBCL). In the primary efficacy analysis (n = 37; median follow-up, 15.9 months), axi-cel demonstrated a high rate of complete responses (CR; 78%) and a safety profile consistent with prior experience. Here, we assessed updated outcomes from ZUMA-12 in 40 treated patients after ≥3 years of follow-up…

Rank83.1
Phase II clinical trial

Daratumumab in combination with GDP chemotherapy in CD38-positive relapsed/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana Linfomi.

Annals of hematology · 2026 · PMID 42209885

Peripheral T-cell lymphomas (PTCLs) are rare, aggressive malignancies with poor outcomes, particularly in the relapsed or refractory (R/R) setting. Given the frequent CD38 expression in PTCLs, this multicenter, open-label, single-arm phase II study (FIL_Dara-GDP; EudraCT 2018-002644-91) evaluated daratumumab, an anti-CD38 monoclonal antibody, combined with gemcitabine, dexamethasone, and cisplatin (D-GDP) in CD38-positive systemic PTCLs. The trial aimed to achieve a complete response (CR) rate of ≥ 40% after four c…

Rank82.9
Phase II clinical trial

RCLARITY: A Prospective Phase II Study of Rituximab Combined With Lenalidomide and Chidamide (RLC) for the Treatment of Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma.

American journal of hematology · 2026 · PMID 42124356

Relapsed/refractory (r/r) angioimmunoblastic T-cell lymphoma (AITL) is associated with a dismal prognosis, with historical overall survival (OS) < 6 months, underscoring the urgent need for novel therapies. We conducted the RCLARITY trial to evaluate the efficacy and safety of a chemotherapy-free regimen in this patient population. This single-arm, multicenter, prospective Phase II trial enrolled adult patients with r/r AITL. Patients received rituximab (375 mg/m2 intravenously on Day 1), lenalidomide (15 mg orally…

Rank82.8
Phase II clinical trial

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation.

Blood · 2025 · PMID 39437708

TP53-mutant mantle cell lymphoma (MCL) is associated with poor survival outcomes with standard chemoimmunotherapy. We conducted a multicenter, phase 2 study of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in untreated patients with MCL with a TP53 mutation. Patients initially received 160 mg zanubrutinib twice daily and obinutuzumab. Obinutuzumab at a dose of 1000 mg was given on cycle 1 day 1, 8, and 15, and on day 1 of cycles 2 to 8. After 2 cycles, venetoclax was added with weekly dose ramp-up to 400 mg da…

Prospective Cohort Studies91 records
Rank109.8
Systematic review or meta-analysis

Prognostic value of geriatric nutritional risk index in patients with diffuse large B-cell lymphoma: a meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024 · PMID 37438653

BACKGROUND: Geriatric nutritional risk index (GNRI) on the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) remains unclear. The purpose of this meta-analysis was to discuss the value of the GNRI in evaluating long-term outcomes in DLBCL. METHODS: We systematically and roundly retrieved PubMed, Cochrane Library, Embase, Scopus and Web of Science electronic databases from inception of the databases to March 20, 2023. At the same time, we calculated the pool hazard ratios (HRs) with their 95% confiden…

Rank108.2
Systematic review or meta-analysis

Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review/Meta-Analysis.

Transplantation and cellular therapy · 2026 · PMID 41525947

In oncology, overall survival (OS) is the benchmark endpoint for assessing therapy effectiveness, but requires large patient cohorts and extended follow-up to attain meaningful data. The identification of reliable surrogate markers for OS may enable earlier treatment decisions and streamline clinical trial design, potentially reducing costs and accelerating access to new therapies. The objective of this study was to evaluate whether complete response (CR) could serve as an early surrogate for OS in patients with re…

Rank102.6
Randomized controlled trial

Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 41260259

BACKGROUND: Preliminary reports suggest interim positron emission tomography (PET) could drive treatment duration in limited-stage diffuse large B-cell lymphoma (DLBCL). This phase III randomized study in first-line therapy for DLBCL patients with adjusted-age international prognostic index (aaIPI) risk = 0, evaluates an experimental PET-response adapted approach using PET response after two cycles of R-CHOP to de-escalate treatment duration. PATIENTS AND METHODS: LNH2009-1B study is a two-arm, open-label, multicen…

Rank101.7
Systematic review or meta-analysis

Vegetarian and vegan diets and cancer incidence: a systematic review and meta-analysis of prospective studies.

European journal of epidemiology · 2026 · PMID 41879966

Several studies have suggested that vegetarian and vegan vs. non-vegetarian diets are associated with lower cancer risk overall, however, results for specific cancer sites have been less consistent. We conducted a systematic review and meta-analysis of prospective studies on vegetarian and vegan diets and cancer incidence to clarify the associations across cancer sites. PubMed and Embase databases were searched for relevant studies up to 5 July 2025. Summary relative risks (RRs) and 95% confidence intervals (95% CI…

Rank101.0
Randomized controlled trial

The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.

Hematological oncology · 2026 · PMID 42062177

The randomized, multicenter, prospective Phase 3 trial (NCT02777736) evaluated central nervous system (CNS) prophylaxis using either intravenous (i.v.) or intrathecal (i.t.) methotrexate (MTX) in diffuse large B-cell lymphoma (DLBCL). Treatment consisted of six cycles of R-CHOP + 2xR or DA-EPOCH-R + 2xR. Patients with intermediate or high-risk CNS International Prognostic Index (CNS-IPI) were randomized to receive CNS prophylaxis with either 2 doses of MTX 3 g/m2 i.v. (arm A) or 6 doses of MTX 12 mg i.t. (arm B). P…

Rank99.6
Randomized controlled trial

A clinical study on fall risk assessment and preventive nursing in older adults with non-Hodgkin's lymphoma undergoing chemotherapy-a randomized controlled trial.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42470465

BACKGROUND: Non-Hodgkin's lymphoma (NHL) is a diverse group of lymphoproliferative malignancies that predominantly affects older adults. Chemotherapy remains the primary modality of treatment for many NHL subtypes, yet it often brings about adverse effects such as myelosuppression, anemia, and neuropathy, all of which contribute to a heightened risk of falls in older patients. Falls in this population can lead to serious complications, including fractures and intracranial injuries, thereby impacting functional stat…

Rank97.0
Systematic review or meta-analysis

Sexual problems in patients with hematological diseases: a systematic literature review.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022 · PMID 35061099

PURPOSE: Sexual problems are frequently reported by recipients of hematopoietic stem cell transplantation (HCT). However, little is known about the impact of hematological malignancies and their treatments, without HCT being a part of the treatment regimen. The goal of this systematic review was to examine the prevalence of various sexual problems among patients treated for hematological malignancies without HCT. METHODS: The work focused on online databases available from their inception until 11 November 2020. Th…

Rank95.9
Randomized controlled trial

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma.

Blood · 2024 · PMID 38669626

Obinutuzumab (O) and rituximab (R) are 2 CD antibodies that have never been compared in a prospective randomized trial of mantle cell lymphoma (MCL). Herein, we report the long-term outcome of the LyMa-101 trial, in which newly diagnosed patients with MCL were treated with chemotherapy plus O before transplantation, followed by O maintenance (O group). We then compared these patients with those treated with the same treatment design with R instead of O (R group). A propensity score matching (PSM) was used to compar…

Rank95.4
Phase III clinical trial

Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaboration.

Leukemia · 2024 · PMID 39152324

Progression or relapse in the central nervous system (CNS) remains a rare but mostly fatal event for patients with diffuse large B-cell lymphoma (DLBCL). In a retrospective analysis of 5189 patients treated within 19 prospective German and French phase 2/3 trials, we identified 159 patients experiencing a CNS event (relapse: 62%, progression: 38%). Intracerebral, meningeal, intraspinal, or combined involvement was reported in 44%, 31%, 3%, and 22% of patients, respectively. 62 of 155 evaluable patients (40%) showed…

Rank95.3
Randomized clinical studyResult signal: mixed

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 41329901

PURPOSE: Although most patients with follicular lymphoma (FL) can expect an indolent course, progressive lymphoma remains the primary cause of death during the first decade after diagnosis. Progression of disease within 24 months (POD24) of starting first-line (1L) immunochemotherapy defines a high-risk population with poor survival, but better risk stratification at diagnosis is needed. METHODS: The FLIPI24 model was developed and internally validated to predict 24-month event rates using individual data from 4,48…

Rank94.0
Systematic review or meta-analysisCorrection flagged

Vegetarian diets and cancer risk: pooled analysis of 1.8 million women and men in nine prospective studies on three continents.

British journal of cancer · 2026 · PMID 41748939

BACKGROUND: Vegetarian diets might influence cancer risk. METHODS: We studied 1,645,555 meat eaters, 57,016 poultry eaters, 42,910 pescatarians, 63,147 vegetarians and 8849 vegans in 9 cohorts (UK, US, Taiwan, India). After a median 16 years follow-up, incident cancers were: 4504 mouth and pharynx, 1308 oesophagus (squamous cell), 2105 oesophagus (adenocarcinoma), 3578 stomach, 30,528 colorectum, 2970 liver, 8030 pancreas, 3077 lung (never smokers), 61,368 breast, 11,220 endometrium, 8076 ovary, 45,946 prostate, 71…

Rank83.8
Phase II clinical trial

End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial.

International journal of hematology · 2024 · PMID 38519820

Response determined by 18[F]-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET)-CT after induction therapy can predict progression-free survival (PFS) in follicular lymphoma (FL). However, little prospective research has examined the significance of PET after second-line therapy. We conducted a prospective multicenter phase II trial (W-JHS NHL01) of bendamustine plus rituximab (BR) without rituximab maintenance for FL in first relapse. This study aimed to evaluate the usefulness of end-of-treatme…

Rank83.2
Phase II clinical trial

Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study.

MedScience · 2026 · PMID 42228038

This study evaluated the efficacy and safety of obinutuzumab plus bendamustine (GB) as first-line treatment for indolent B-cell lymphomas. In this prospective, multicenter, single-arm trial (NCT06415708), adults with newly diagnosed indolent B-cell lymphomas-including follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenström macroglobulinemia (WM), hairy cell leukemia variant (HCL-v), and unclassified B-cell lymphoproliferative disorder (BCLPD-U)-received six induction cycles of GB followed by 2 years of …

Rank82.9
Phase II clinical trial

RCLARITY: A Prospective Phase II Study of Rituximab Combined With Lenalidomide and Chidamide (RLC) for the Treatment of Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma.

American journal of hematology · 2026 · PMID 42124356

Relapsed/refractory (r/r) angioimmunoblastic T-cell lymphoma (AITL) is associated with a dismal prognosis, with historical overall survival (OS) < 6 months, underscoring the urgent need for novel therapies. We conducted the RCLARITY trial to evaluate the efficacy and safety of a chemotherapy-free regimen in this patient population. This single-arm, multicenter, prospective Phase II trial enrolled adult patients with r/r AITL. Patients received rituximab (375 mg/m2 intravenously on Day 1), lenalidomide (15 mg orally…

Rank80.6
Phase II clinical trial

Dose-reduced (24 Gy) involved-site radiotherapy combined with rituximab in early-stage non-gastric mucosa-associated lymphoid tissue lymphoma: a prospective phase II trial.

Leukemia · 2026 · PMID 42463943

While involved-site radiotherapy (ISRT) is the standard first-line treatment in localized non-gastric mucosa-associated lymphoid tissue (MALT) lymphoma, the cumulative risk of distant relapse poses a persistent clinical challenge. We conducted a prospective phase II trial evaluating rituximab with 24 Gy ISRT, aiming to reduce distant relapse and enhance long-term survival. By October 2025, 60 patients with early-stage non-gastric MALT lymphoma were enrolled. Among the per-protocol efficacy-evaluable cohort (n = 55)…

Rank80.5
Phase II clinical trial

Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study.

Blood cancer journal · 2026 · PMID 42386710

Diffuse large B-cell lymphoma (DLBCL) remains clinically heterogeneous, and outcomes with R-CHOP are suboptimal in patients carrying high-risk genomic alterations such as MYD88, CD79B, NOTCH1, TP53 mutations or MYC rearrangements. Many of these lesions are associated with aberrant BCR signaling, and prior studies in relapsed disease have suggested a degree of sensitivity to BTK inhibitors. These observations provided the rationale for evaluating zanubrutinib in the frontline setting for genomically defined high-ris…

Rank80.3
Multicenter clinical studyResult signal: mixed

Malignancies in inborn errors of immunity: a retrospective-prospective study on a large Italian cohort of pediatric and adult patients.

Frontiers in immunology · 2026 · PMID 42851687

BACKGROUND: Inborn Errors of Immunity (IEI) are associated with an increased risk of malignancy due to impaired immune surveillance, genetic instability and chronic inflammation, However, comprehensive epidemiological data from large national cohorts remain limited. METHODS: We conducted a multicenter, retrospective-prospective observational study involving 4,540 pediatric and adult patients with IEI, followed across 30 Italian referral centers, with the aim of evaluating those who developed cancer. Clinical, immun…

Rank80.0
Phase II clinical trial

Allogeneic hematopoietic cell transplantation in mature T- or NK-lymphomas: a phase II clinical trial.

Nature communications · 2026 · PMID 42026073

Allogeneic hematopoietic cell transplantation (HCT) is a potential cure for patients with peripheral T-/NK-cell lymphomas (PTCL), but its application is understudied. This prospective trial evaluates a unique reduced-intensity (RIC) transplantation platform in 31 patients with PTCL (NCT03922724). One-year progression-free survival, the primary endpoint, is 53% (95% CI 29-72%) on the RIC arm and 60% (95% CI 25-83%) on the modified-RIC arm. The 3-year overall survival is 61% (95% CI 42-76%), with relapse estimated at…

Rank80.0
Phase II clinical trial

Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.

Bone marrow transplantation · 2024 · PMID 38167647

Curative potential of allogeneic transplantation (AlloSCT) in high-risk non-Hodgkin lymphoma (NHL) could be enhanced by the integration of Ofatumumab (OFA), a 2nd generation anti-CD20 moAb, due to an antitumor effect and a role over graft-versus-host disease (GVHD). In this phase II trial (NCT01613300), we investigated safety and effectiveness of OFA-based reduced intensity conditioning (RIC). High-risk B-cell NHL patients with chemorrefractory disease or post-autologous SCT relapse were eligible. OFA was added to …

Rank78.8
Multicenter clinical study

Real-world evaluation of health-related quality of life in hematology patients treated with rituximab: results of a multicentric cross-sectional cohort study.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026 · PMID 41764665

BACKGROUND: Advancements in treating hematologic malignancies have improved survival, but health-related quality of life (HRQoL) remains a key concern due to the physical, emotional, and social impact of disease and treatment. AIMS: This study aimed to assess HRQoL in patients undergoing treatment for hematologic malignancies, identifying the most affected domains to guide supportive interventions. METHODS: HRQoL was evaluated using the 42-item Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) in a prospe…

Rank78.3
Multicenter clinical studyResult signal: null

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study.

European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42302353

BACKGROUND: Transformed indolent non-Hodgkin lymphoma (TiNHL) generally has poorer outcomes than de novo diffuse large B-cell lymphoma (dnDLBCL). Although anti-CD19 CAR T-cell therapy is standard for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), its prognostic role across histologies remains unclear. METHODS: We conducted a multicenter, retrospective/prospective observational study comparing R/R TiNHL and R/R dnDLBCL patients treated with commercial CAR T-cell therapy and enrolled in the Italian CART-SIE …

Rank78.1
Multicenter clinical study

Significant Impact of Treatment Abandonment on Survival of Children With "Common and Curable" GICC Index Cancers in Sub-Saharan Africa-A Multicenter Prospective CANCaRe Africa Study.

Pediatric blood & cancer · 2025 · PMID 40899378

BACKGROUND: The World Health Organization Global Initiative for Childhood Cancer (GICC) targets a global survival rate of 60% for childhood cancer, focusing initially on six common, curable cancers. This study describes survival rates of five of these cancers in sub-Saharan Africa and assesses the impact of treatment abandonment (TxA). METHODS: This multicenter, prospective, observational cohort study included newly diagnosed children (<16 years) with Burkitt lymphoma (BL), acute lymphoblastic leukemia (ALL), Wilms…

Rank78.1
Multicenter clinical study

Baseline Risk of Treatment Abandonment and Survival of Children With Common and Curable Cancers in the Zero Abandonment Cash Transfer Programme-A Multi-Centre Prospective CANCaRe Africa Study.

Pediatric blood & cancer · 2026 · PMID 42578510

BACKGROUND: The WHO Global Initiative for Childhood Cancer (GICC) targets a global survival rate of 60% for childhood cancer, focusing initially on six common and curable cancers. This study assessed the risk of treatment abandonment (TxA) and the impact on survival of five of these cancers in sub-Saharan Africa in preparation for a cash transfer intervention. METHODS: This multi-centre, prospective, observational cohort study included newly diagnosed children (<16 years) with Burkitt lymphoma (BL), acute lymphobla…

Rank78.0
Multicenter clinical study

High incidence of lymphoma in Sjögren's disease: predictors and mortality implications in a prospective cohort study.

Rheumatology international · 2025 · PMID 40767878

This study aimed to evaluate the standardized incidence ratios (SIRs) of non-Hodgkin lymphoma (NHL) in patients with Sjögren's disease (SjD) compared to the general population. Additionally, it sought to identify independent predictors of lymphoma and estimate both the relative risk (RR) and the etiologic fraction in exposed individuals (EFE) to assess the contribution of lymphoma to mortality in this population. This observational, multicenter, prospective study was conducted using data from a well-characterized S…

Rank76.8
Multicenter clinical study

Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study.

Blood advances · 2026 · PMID 41979332

Primary mediastinal large B-cell lymphoma (PMBL) achieves excellent outcomes with dose-dense immunochemotherapy, yet response assessment by positron emission tomography (PET) remains limited. In this prospective multicenter observational study, we evaluated the clinical relevance of circulating tumor DNA (ctDNA) minimal residual disease (MRD) in patients with newly diagnosed PMBL and assessed whether MRD enhances outcome discrimination beyond PET. Plasma and PET images were collected at baseline and after 2 and 4 c…

Quality Of Life78 records
Rank107.8
Systematic review or meta-analysis

Understanding the factors influencing quality of life among survivors of Non-Hodgkin lymphoma after completing primary treatment: a systematic review.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 41774244

PURPOSE: To evaluate and synthesize the existing evidence on factors influencing the quality of life (QoL) of non-Hodgkin lymphoma (NHL) survivors and the impact of these factors on their QoL. METHODS: A systematic review was conducted following PRISMA guidelines, with searches in CINAHL, MEDLINE, PubMed, ScienceDirect, Scopus, and Web of Science. Studies published between 2014 and 2025 were included if they were original English-language research involving adult (age ≥ 18 years) NHL survivors and focused on factor…

Rank105.9
Systematic review or meta-analysis

Reduced-Dose Total Skin Electron Beam Radiation Therapy in Mycosis Fungoides and Sézary Syndrome: Systematic Review and Meta-Analysis.

International journal of radiation oncology, biology, physics · 2026 · PMID 42128185

PURPOSE: Primary cutaneous T-cell lymphomas are a heterogeneous group of T-cell neoplastic entities associated with significant morbidity and high radiosensitivity. Although research on reduced-dose radiation treatment for mycosis fungoides and Sézary syndrome has significantly increased over the past 2 decades, randomized data are lacking. We aim to summarize the available evidence and analyze the safety and efficacy of reduced-dose total skin electron beam therapy (TSEBT). METHODS AND MATERIALS: A literature sear…

Rank104.2
Systematic review or meta-analysis

The role of allogeneic hematopoietic stem cell transplantation in adults with mature T-cell lymphomas.

The Cochrane database of systematic reviews · 2026 · PMID 42905121

RATIONALE: Mature T-cell lymphomas (MTCL) are a rare, heterogeneous group of malignancies that arise from post-thymic T-lymphocytes, with a generally poor prognosis. For a long time, the standard therapy for most MTCL subtypes has been polychemotherapies. Hopes to prolong overall survival in MTCL have been associated with transplant procedures such as high-dose therapy with autologous stem cell transplantation (autoSCT) or allogeneic stem cell transplantation (alloSCT). OBJECTIVES: To assess the benefits and harms …

Rank100.0
Systematic review or meta-analysis

Systematic literature review of clinical outcomes, health-related quality of life, and healthcare costs and resource use in relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel.

Leukemia & lymphoma · 2026 · PMID 42507490

The approval of axicabtagene ciloleucel (axi-cel) for use in second-line (2L) relapsed/refractory (R/R) large B-cell lymphoma (LBCL), emerging real-world evidence provides clinical and economic insights. We conducted a systematic review of studies reporting such outcomes among patients with treated with axi-cel in 2L and 2L + R/R LBCL. In routine care, axi-cel shows effectiveness comparable to clinical trials, with a lower rate of serious cytokine release syndrome in real-world 2L populations. Most real-world studi…

Rank100.0
Systematic review or meta-analysis

Clinical, economic, and quality-of-life outcomes of brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma and B-cell acute lymphoblastic leukemia: A systematic literature review and meta-analysis.

Journal of managed care & specialty pharmacy · 2026 · PMID 42808549

BACKGROUND: Brexucabtagene autoleucel (brexu-cel), a CD19 chimeric antigen receptor T-cell therapy, has shown efficacy in clinical trials for relapsed/refractory (R/R) mantle cell lymphoma (MCL) and B-cell acute lymphoblastic leukemia (B-ALL). However, although effectiveness and safety evidence is well established, real-world evidence (RWE) on health care resource use (HCRU), costs, and health-related quality of life (HRQoL) remains limited. OBJECTIVE: To systematically review and synthesize RWE on clinical, HCRU, …

Rank99.6
Randomized controlled trial

A clinical study on fall risk assessment and preventive nursing in older adults with non-Hodgkin's lymphoma undergoing chemotherapy-a randomized controlled trial.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42470465

BACKGROUND: Non-Hodgkin's lymphoma (NHL) is a diverse group of lymphoproliferative malignancies that predominantly affects older adults. Chemotherapy remains the primary modality of treatment for many NHL subtypes, yet it often brings about adverse effects such as myelosuppression, anemia, and neuropathy, all of which contribute to a heightened risk of falls in older patients. Falls in this population can lead to serious complications, including fractures and intracranial injuries, thereby impacting functional stat…

Rank97.9
Randomized controlled trial

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.

Blood · 2026 · PMID 40997297

Diffuse large B-cell lymphoma (DLBCL) poses a challenge in hematology given its varied symptoms, and the complex interplay between disease and treatment effects on health-related quality of life (HRQoL). The phase 3 POLARIX study demonstrated superior progression-free survival and a similar safety profile with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with previously unt…

Rank97.4
Randomized controlled trial

Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library.

Journal of patient-reported outcomes · 2026 · PMID 42329537

INTRODUCTION: Three patient-reported outcome (PRO) measures specific to lymphoma symptoms were previously defined using mixed-methods research, comprising questions from the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30) and Item Library (IL): measures of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Symptoms, Mantle Cell Lymphoma (MCL) Symptoms, and an Expanded Fatigue measure. The objective of this study was to assess ps…

Rank94.4
Randomized clinical study

Trials in progress: CARMAN - study protocol of a randomized controlled, international, multicenter, open-label phase II trial evaluating early treatment intensification in patients with high-risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance as compared to standard of care induction and maintenance.

BMC cancer · 2026 · PMID 42581349

BACKGROUND: Brexucabtagene-autoleucel (brexu-cel) is an anti-CD19 chimeric antigen receptor T-cell (CAR-T) product approved for relapsed/refractory Mantle Cell Lymphoma (MCL) after two prior treatment lines, including Bruton tyrosine kinase inhibitors (BTKi). Patients with high-risk (hr) disease-defined by high-intermediate or high-risk MIPI-c, p53 overexpression, or TP53 alterations-have a poor prognosis, underscoring the need for improved first-line strategies. The European Mantle Cell Lymphoma Network therefore …

Rank88.6
Randomized clinical study

A Parent-Delivered Foot Bath Intervention for Chemotherapy-Related Fatigue in Children with Cancer: A Family-Centered Randomized Controlled Trial.

Children (Basel, Switzerland) · 2026 · PMID 42509946

Background/Objectives: Chemotherapy-related fatigue (CRF) affects 50-80% of children receiving chemotherapy and significantly impairs quality of life. Despite the family-centered care framework guiding pediatric oncology practice, evidence on parent-delivered, home-based non-pharmacological interventions for CRF remains limited. This study aimed to evaluate the effect of a parent-delivered warm-water foot bath on CRF in children aged 7-12 years undergoing chemotherapy. Methods: A two-arm parallel randomized control…

Rank85.0
Randomized clinical study

Update on the pathophysiology and treatment of primary Sjögren syndrome.

Nature reviews. Rheumatology · 2024 · PMID 38982205

Sjögren syndrome or Sjögren disease is a chronic form of autoimmune epithelitis characterized by lymphocytic infiltration of the exocrine glands, particularly the salivary and lacrimal glands, leading to progressive glandular dysfunction and subsequent xerostomia and xerophthalmia. Other common manifestations include pain and fatigue, various systemic manifestations and non-Hodgkin's lymphoma. Sjögren syndrome is therefore a complex and disabling disease associated with a reduced quality of life and with considerab…

Rank85.0
Randomized clinical study

End points and outcomes in follicular lymphoma: what should we measure, how, and why?

Blood · 2025 · PMID 40019453

Overall survival (OS) and quality of life (QoL) are clinically relevant outcomes/end points during examination of therapies. However, with median OS approaching 20 years for patients with follicular lymphoma (FL), it is often not feasible to use OS as a primary end point in clinical studies. Although validated tools exist for assessing QoL in patients with lymphoma, QoL data are rarely the sole basis for drug approvals in FL. Therefore, other survival end points, surrogates, and intermediate clinical end points hav…

Rank80.6
Phase II clinical trial

Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma.

Blood advances · 2026 · PMID 41512176

The phase 2 ALYCANTE trial aimed to evaluate the investigator-assessed complete metabolic response at 3 months from the axicabtagene ciloleucel (axi-cel) infusion as a primary end point in patients with high-risk relapsed/refractory large B-cell lymphoma who are ineligible for autologous stem cell transplantation (ASCT). This study showed a significant improvement in complete metabolic response rate at 3 months based on historical controls. This study reports the health-related quality of life (HRQoL) results as a …

Rank78.8
Multicenter clinical study

Real-world evaluation of health-related quality of life in hematology patients treated with rituximab: results of a multicentric cross-sectional cohort study.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026 · PMID 41764665

BACKGROUND: Advancements in treating hematologic malignancies have improved survival, but health-related quality of life (HRQoL) remains a key concern due to the physical, emotional, and social impact of disease and treatment. AIMS: This study aimed to assess HRQoL in patients undergoing treatment for hematologic malignancies, identifying the most affected domains to guide supportive interventions. METHODS: HRQoL was evaluated using the 42-item Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) in a prospe…

Rank75.5
Multicenter clinical study

Age-related histopathological and immunophenotypic variations in early-stage mycosis fungoides: a multicentre retrospective study in Türkiye.

BMJ open · 2026 · PMID 41985965

OBJECTIVES: Early-stage mycosis fungoides (MF) is diagnostically challenging due to overlap with inflammatory dermatoses. Age-related immunological and cutaneous changes may modify histopathological presentation. We aimed to compare clinical, histopathological and immunophenotypic features of early-stage MF between geriatric and non-geriatric patients. DESIGN: Multicentre retrospective cross-sectional study. SETTING: Dermatology departments of tertiary centres in Türkiye. PARTICIPANTS: A total of 541 patients diagn…

Rank74.5
Multicenter clinical study

Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.

The Lancet. Haematology · 2026 · PMID 42285114

BACKGROUND: Chimeric antigen receptor (CAR) T cells have shown considerable promise in treating patients with haematological malignancies. We aimed to investigate short-term patient-reported symptomatic adverse events in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy and compare them with those reported by their treating physicians. We also examined factors predicting overall short-term burden of therapy. METHODS: This was a prospective, observational, multicentre study enrolling patients…

Rank74.4
Multicenter clinical study

Multi-omics profiling of chronic immune-mediated skin diseases: SKINERGY protocol and strategic evaluation.

Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · PMID 41645921

BACKGROUND: The Dutch flagship project Next Generation ImmunoDermatology (NGID) aims to profile five chronic immune-mediated inflammatory skin diseases: atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU) and cutaneous lupus erythematosus (CLE) in comparison with cutaneous T-cell lymphoma subtype mycosis fungoides (MF) and healthy volunteers. Within NGID, a clinical study entitled: 'SKIN disease profiling by an Exploratory, pRospective, biomarker study …

Rank73.0
Multicenter clinical study

Validation and Clinical Meaningfulness of the 18-item National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Symptom Index in Patients With Lymphoma.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2026 · PMID 42002076

OBJECTIVES: To further evaluate the psychometric properties of the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFLymSI-18), including estimates of meaningful within-patient change thresholds, to support its ability to reliably and validly measure clinical- and patient-relevant outcomes in diverse research settings. METHODS: Data from a longitudinal multicenter clinical trial in patients with indolent B cell lymphoma and a single-institution observational …

Rank62.8
Observational or cohort study

Longitudinal plasma neurofilament light chain and patient-reported outcomes as complementary markers of vincristine-associated peripheral neuropathy in adults with lymphoma: a cohort study.

Journal of neurology · 2026 · PMID 42732528

Chemotherapy-induced peripheral neuropathy (CIPN) is a common neurotoxicity of cancer treatment with limited diagnostic, monitoring, and treatment options. Neurofilament light chain (NfL) is an axonal cytoskeletal protein released during neuroaxonal injury and a promising biomarker of CIPN, but prospective evidence for NfL as a marker of CIPN from vincristine-containing lymphoma chemotherapy treatment remains limited. To fill this gap, we conducted a pragmatic single-center prospective observational cohort study of…

Rank60.0
Observational or cohort study

Psychological Distress, Symptom Burden and Quality of Life in Patients with Mycosis Fungoides and Sézary Syndrome.

Acta dermato-venereologica · 2026 · PMID 42454691

Mycosis fungoides (MF) and Sézary syndrome (SS) are rare cutaneous lymphomas with limited data on psychological burden. This observational, cross sectional questionnaire study assessed symptom burden, psychological distress and quality of life (QoL) in patients with MF and SS in Western Sweden and compared outcomes with psoriasis. Sixty patients were included, 80% with early-stage disease. Most reported minimal depression, anxiety and QoL impairment. Moderate-to-severe depression occurred in 36% of advanced disease…

Rank53.2
Other PubMed-indexed publication

Pre-Pectoral Breast Reconstruction after Mastectomy: Current Evidence, Knowledge Gaps, and Rationale for the I-PREPARE EUBREAST-11R Trial.

Breast care (Basel, Switzerland) · 2026 · PMID 42383235

INTRODUCTION: Pre-pectoral implant-based breast reconstruction (IBR) has emerged as a promising alternative to conventional subpectoral approaches following nipple- or skin-sparing mastectomy. However, long-term oncological safety, complication profiles, and outcomes in specific subgroups, such as patients receiving radiation therapy (RT), remain under investigation. Contemporary evidence is mainly derived from retrospective studies with limited follow-up, reporting heterogeneous results. The I-PREPARE trial (EUBRE…

Rank51.1
Other PubMed-indexed publication

Further validation of the patient roles and responsibilities scale.

Health psychology and behavioral medicine · 2026 · PMID 42549295

BACKGROUND: The Patient Roles and Responsibilities Scale (PRRS) measures the impact of cancer and treatment on 'real world' functioning such as caregiving and financial responsibilities. It was developed and validated in advanced cancer but with the intention to be sufficiently generic and appropriate for use in all cancers and stages. Here we further investigate the psychometric performance of the PPRS when completed by people three years after cancer diagnosis, treated with curative intent. METHODS: This is a sec…

Rank50.9
Other PubMed-indexed publication

The course of self-perceived cognitive functioning among patients with lymphoma and the co-occurrence with fatigue and psychological distress.

Journal of cancer survivorship : research and practice · 2025 · PMID 37755680

PURPOSE: To investigate the proportion of patients with lymphoma with persistent clinically relevant cognitive impairment, and its relation to treatment, fatigue, and psychological distress. METHODS: Patients with diffuse-large-B-cell-lymphoma (DLBCL), follicular-lymphoma (FL), and chronic-lymphocytic-leukemia (CLL)/small-lymphocytic-lymphoma (SLL), diagnosed between 2004-2010 or 2015-2019, were followed up to 8 years post-diagnosis. Sociodemographic and clinical data were obtained from the Netherlands Cancer Regis…

Rank50.7
Other PubMed-indexed publication

Low musculoskeletal health literacy is associated with inferior outcomes in total shoulder arthroplasty.

JSES international · 2026 · PMID 42063489

BACKGROUND: The aim of this study was to investigate the impact of musculoskeletal (MSK) health literacy on clinical outcomes and patient satisfaction following total shoulder arthroplasty (TSA). We hypothesized that low MSK health literacy score would be associated with inferior clinical outcomes and lower patient satisfaction rates. METHODS: A retrospective cohort study was conducted at a tertiary care center. Patients between 6 months and 9 years post-operative following shoulder arthroplasty, both anatomic tota…

Rank50.5
Other PubMed-indexed publication

Longitudinal Patient-Reported Symptom Change Patterns and Prediction of Future Health-Related Quality of Life in Childhood Cancer Survivors: A Machine Learning Approach from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort.

Cancers · 2026 · PMID 42192908

BACKGROUND: Adult survivors of childhood cancer face a significant risk for treatment-related late effects that may impair health-related quality of life (HRQoL). Incorporating longitudinal changes in patient-reported symptoms beyond treatment-based risk factors may enhance the prediction of HRQoL. METHODS: Survivors (n = 576) dually enrolled in the St. Jude Lifetime Cohort Study and Childhood Cancer Survivor Study reported 37 symptoms across 10 domains at three time points over 20 years to ascertain longitudinal s…

Randomized Controlled Trials97 records
Rank109.1
Systematic review or meta-analysisResult signal: null

Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence.

Blood cancer journal · 2026 · PMID 42362499

Pola-R-CHP regimen is the new standard of care for untreated diffuse large B-cell lymphoma (DLBCL) patients, following the POLARIX trial. This study evaluates whether clinical trial (RCT) efficacy and safety are reproducible in real-world evidence (RWE) settings. This systematic review and meta-analysis compared outcomes between RCTs and RWE studies. Primary endpoints were complete response (CR) rate, progression-free survival (PFS), and overall survival (OS). Meta-regression explored heterogeneity using age, Inter…

Rank107.2
Systematic review or meta-analysis

reFLASH: a proof-of-concept meta-analytic framework to validate surrogate endpoints in the absence of randomized clinical trial data.

Journal of clinical epidemiology · 2026 · PMID 42641770

BACKGROUND AND OBJECTIVES: Within a meta-analytic framework, validating surrogate endpoints traditionally requires individual patient data (IPD) from multiple randomized controlled trials (RCTs). This is rarely feasible in rare and indolent diseases. We propose a proof-of-concept strategy that creates synthetic comparative evidence from multiple single-arm trials to enable trial-level surrogacy assessment. METHODS: Using IPD from 12 follicular lymphoma RCTs (FLASH; 3996 patients), we decoupled each trial's randomiz…

Rank107.2
Systematic review or meta-analysisResult signal: benefit

Maintenance treatment and survival in patients with newly diagnosed diffuse large B cell lymphoma in the immunochemotherapy era: a systematic review and network meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 42213311

OBJECTIVE: To assess the comparative efficacy of various maintenance strategies for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL). METHODS: We conducted a comprehensive search of PubMed, Embase, Web of Science, the Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Trials for randomized clinical trials evaluating maintenance strategies in previously untreated DLBCL patients. The primary outcomes were progression-free survival (PFS) and overall survival (OS…

Rank106.7
Systematic review or meta-analysisResult signal: mixed

CAR-T Cell Therapy Versus Salvage Chemotherapy in Relapsed/Refractory DLBCL: A Systematic Review and Meta-Analysis Integrating Radiologic, Laboratory, and Histopathologic Correlates.

La Clinica terapeutica · 2026 · PMID 42340791

BACKGROUND: Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) remains a major therapeutic challenge, particularly among patients with high-risk molecular features or primary refractory disease. Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising treatment strategy; however, its comparative effectiveness versus salvage chemotherapy requires comprehensive evaluation. METHODS: This systematic review and meta-analysis were conducted in accordance with PRISMA 2020 and MOOSE guideli…

Rank106.7
Systematic review or meta-analysis

Role of rituximab in treatment of patients with primary central nervous system lymphoma: An updated systematic review and meta-analysis.

Acta neurologica Belgica · 2026 · PMID 41212511

BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a rare and aggressive form of extranodal non-Hodgkin lymphoma, most often a diffuse large B-cell lymphoma. Rituximab, an anti-CD20 monoclonal antibody is widely used in PCNSL treatment but its efficacy remains uncertain. Therefore, we conducted a systematic review and meta-analysis to assess the efficacy of rituximab in newly diagnosed adult PCNSL patients. METHODS: Medline/PubMed and Scopus were searched for studies comparing rituximab/rituximab-contai…

Rank106.4
Systematic review or meta-analysis

Application of CAR-T cell therapy in B-cell lymphoma: a meta-analysis of randomized controlled trials.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025 · PMID 39514165

BACKGROUND: This study aims to compare the efficacy and safety of chimeric antigen receptor T-cell (CAR-T) immunotherapy with standard treatment for B-cell lymphoma, providing evidence-based support for the more efficient use of CAR-T cell immunotherapy. METHODS: We conducted a comprehensive literature search of high-quality randomized controlled trials (RCTs) on CAR-T therapy for B-cell lymphoma in the following databases: Wanfang, Web of Science, CNKI, VIP database, and PubMed, up to February 2024. The outcome me…

Rank106.3
Systematic review or meta-analysis

Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review.

Bone marrow transplantation · 2026 · PMID 42332219

Lymphodepletion (LD) is a critical prerequisite for successful chimeric antigen receptor T-cell (CAR-T) therapy. While fludarabine and cyclophosphamide (Flu/Cy) remain the standard LD regimen, bendamustine has emerged as a potential alternative due to its distinct immunomodulatory properties and more favorable toxicity profile. This systematic review evaluates the safety, efficacy, and feasibility of bendamustine-based LD in patients undergoing CAR-T therapy for hematologic malignancies. A comprehensive literature …

Rank106.0
Systematic review or meta-analysisResult signal: harm

Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants.

Journal of hematology & oncology · 2026 · PMID 41957612

Dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium–glucose cotransporter 2 (SGLT2) inhibitors are widely prescribed for their cardiometabolic benefits, yet their hematologic oncologic safety remains uncertain. Because hematologic malignancies are highly lethal and biologically heterogeneous, delineating drug-specific risks across histopathologic subtypes is clinically crucial. This histopathology-stratified network meta-analysis (NMA) evaluated and compared the …

Rank105.9
Systematic review or meta-analysis

Reduced-Dose Total Skin Electron Beam Radiation Therapy in Mycosis Fungoides and Sézary Syndrome: Systematic Review and Meta-Analysis.

International journal of radiation oncology, biology, physics · 2026 · PMID 42128185

PURPOSE: Primary cutaneous T-cell lymphomas are a heterogeneous group of T-cell neoplastic entities associated with significant morbidity and high radiosensitivity. Although research on reduced-dose radiation treatment for mycosis fungoides and Sézary syndrome has significantly increased over the past 2 decades, randomized data are lacking. We aim to summarize the available evidence and analyze the safety and efficacy of reduced-dose total skin electron beam therapy (TSEBT). METHODS AND MATERIALS: A literature sear…

Rank104.2
Systematic review or meta-analysis

The role of allogeneic hematopoietic stem cell transplantation in adults with mature T-cell lymphomas.

The Cochrane database of systematic reviews · 2026 · PMID 42905121

RATIONALE: Mature T-cell lymphomas (MTCL) are a rare, heterogeneous group of malignancies that arise from post-thymic T-lymphocytes, with a generally poor prognosis. For a long time, the standard therapy for most MTCL subtypes has been polychemotherapies. Hopes to prolong overall survival in MTCL have been associated with transplant procedures such as high-dose therapy with autologous stem cell transplantation (autoSCT) or allogeneic stem cell transplantation (alloSCT). OBJECTIVES: To assess the benefits and harms …

Rank103.2
Systematic review or meta-analysis

Systemic Glucocorticoid Use and Risk of Site-Specific Cancers: A Methodologic Systematic Review of Observational Studies.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026 · PMID 41931525

Systemic glucocorticoids, widely prescribed for inflammatory and autoimmune diseases, have long been suspected of increasing cancer risk through immunosuppressive and metabolic effects. Randomized trials are often unethical and difficult to conduct, leaving observational studies the best option to determine whether the use of systemic glucocorticoids affects cancer development. However, these studies face significant methodologic issues that may compromise the validity of their findings. We systematically reviewed …

Rank101.0
Randomized controlled trial

The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.

Hematological oncology · 2026 · PMID 42062177

The randomized, multicenter, prospective Phase 3 trial (NCT02777736) evaluated central nervous system (CNS) prophylaxis using either intravenous (i.v.) or intrathecal (i.t.) methotrexate (MTX) in diffuse large B-cell lymphoma (DLBCL). Treatment consisted of six cycles of R-CHOP + 2xR or DA-EPOCH-R + 2xR. Patients with intermediate or high-risk CNS International Prognostic Index (CNS-IPI) were randomized to receive CNS prophylaxis with either 2 doses of MTX 3 g/m2 i.v. (arm A) or 6 doses of MTX 12 mg i.t. (arm B). P…

Rank100.3
Randomized controlled trial

Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium.

Blood · 2026 · PMID 41347825

We assessed the overall survival (OS) impact of time to relapse (TTR) in multinational cohorts with independent observational and randomized validation. Patients with nMTCL with frontline complete response were assigned to TTR12 (≤12 months) or without TTR12 based on time to progression or next therapy. OS analyses included modified landmark (m-LM), standard landmark (s-LM), and time-dependent Cox (td-Cox), adjusting for age, histology, and prognostic index for T-cell lymphoma (PIT) score. Across 452 patients, 165 …

Rank100.2
Randomized controlled trialResult signal: benefit

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

Lancet (London, England) · 2026 · PMID 42217458

BACKGROUND: Approximately 40% of patients with high-risk diffuse large B-cell lymphoma (DLBCL) are not cured with first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone). We aimed to investigate the addition of tafasitamab (an Fc-enhanced anti-CD19 monoclonal antibody) and lenalidomide to R-CHOP (tafa-len-R-CHOP) in patients with high-risk aggressive B-cell lymphomas. METHODS: frontMIND is a phase 3, randomised, double-blind, placebo-controlled study conducted at 29…

Rank100.0
Systematic review or meta-analysis

Efficacy and safety of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a systematic review and meta-analysis.

Systematic reviews · 2026 · PMID 42244006

BACKGROUND: Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) remains a therapeutic challenge, particularly for patients ineligible for stem-cell transplantation or CAR T-cell therapy. Loncastuximab tesirine, a CD19-directed antibody-drug conjugate, has demonstrated promising single-agent activity in recent studies and is approved in this setting. In this meta-analysis, we aim to assess the efficacy and safety of loncastuximab tesirine monotherapy in patients with R/R DLBCL. METHODS: A systematic review…

Rank100.0
Systematic review or meta-analysis

Antibody-drug conjugate development in lymphoma: a systematic clinical trial landscape analysis.

Frontiers in immunology · 2026 · PMID 42620849

INTRODUCTION: Antibody-drug conjugates (ADCs) have established roles in selected lymphoma settings, but the maturity, subtype distribution, and platform diversity of the clinical pipeline remain unclear. We mapped interventional trials to evaluate development trends, evidence maturity, molecular architecture, combination strategies, inactive development, and safety reporting. METHODS: We searched Trialtrove for Phase I-IV interventional trials evaluating at least one ADC in lymphoma, with actual or anticipated star…

Rank100.0
Systematic review or meta-analysis

Efficacy of bispecific T-cell engagers after CAR T-cell therapy failure in aggressive large B-cell lymphoma.

Current research in translational medicine · 2026 · PMID 42184607

No recognized standard of care exists at the present time for treatment for large B-cell non-Hodgkin lymphoma that relapses or progresses after chimeric antigen receptor T-cell (CAR T-cell) therapy. Bispecific T-cell engagers (BiTEs) have emerged as an effective treatment for patients with relapsed or refractory (R/R) LBCL. The purpose of this systematic review and meta-analysis is to appraise the totality of evidence on the role of BiTEs as treatment for LBCL after CAR T-cell therapy failure. Results showed that p…

Rank99.9
Randomized controlled trialResult signal: benefit

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Lancet (London, England) · 2026 · PMID 42134356

BACKGROUND: Adding ibrutinib to standard, first-line immunochemotherapy improves failure-free survival in adult patients aged 18-65 years with mantle cell lymphoma, according to the first results from the TRIANGLE trial. With prolonged follow-up, we investigated whether the addition of autologous stem-cell transplantation (ASCT) to an ibrutinib-containing regimen improves failure-free survival, and evaluated effects on overall survival. METHODS: We conducted a three-arm, randomised, open-label, phase 3 superiority …

Rank99.6
Randomized controlled trial

A clinical study on fall risk assessment and preventive nursing in older adults with non-Hodgkin's lymphoma undergoing chemotherapy-a randomized controlled trial.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42470465

BACKGROUND: Non-Hodgkin's lymphoma (NHL) is a diverse group of lymphoproliferative malignancies that predominantly affects older adults. Chemotherapy remains the primary modality of treatment for many NHL subtypes, yet it often brings about adverse effects such as myelosuppression, anemia, and neuropathy, all of which contribute to a heightened risk of falls in older patients. Falls in this population can lead to serious complications, including fractures and intracranial injuries, thereby impacting functional stat…

Rank99.4
Randomized controlled trial

Metabolic heterogeneity-based radiomic model predicts treatment outcomes of primary mediastinal B-cell lymphoma patients in the IELSG37 study.

British journal of haematology · 2026 · PMID 42304704

Early identification of patients at risk of failing first-line therapy remains a key challenge in primary mediastinal B-cell lymphoma (PMBCL). This study assessed whether positron emission tomography (PET) radiomics could predict treatment outcomes in PMBCL. Baseline PET/computed tomography (CT) scans from 501 patients enrolled in the International Extranodal Lymphoma Study Group 37 (IELSG37) trial and treated with rituximab- and doxorubicin-based immunochemotherapy were analysed. Functional PET parameters reflecti…

Rank99.4
Randomized controlled trial

RENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed/refractory follicular lymphoma.

Blood advances · 2026 · PMID 42349017

Maintenance treatment in older patients with relapsed or refractory (R/R) follicular lymphoma (FL) remains an area of investigation. RENOIR was a multicenter, phase 3, open-label randomized trial conducted by the Fondazione Italiana Linfomi (FIL) in older patients with R/R FL after 1 or 2 previous therapies. Patients achieving partial response or complete response (CR) after 4 to 6 cycles of standard rituximab (R)-based chemotherapy were randomized 1:1 to maintenance with R alone (standard arm) or R plus lenalidomi…

Rank99.3
Randomized controlled trial

Baseline Tumor Transcriptional Features and Event-Free Survival After Anti-CD19 CAR T-Cell Therapy with Axicabtagene Ciloleucel in Large B-Cell Lymphoma: An Exploratory Reanalysis of the Randomized ZUMA-7 Trial.

Medical sciences (Basel, Switzerland) · 2026 · PMID 42930590

Background/Objectives: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with axicabtagene ciloleucel (axi-cel) improves outcomes in relapsed/refractory large B-cell lymphoma (LBCL), but many patients relapse despite retained CD19 expression. We explored baseline tumor transcriptional features associated with event-free survival (EFS) after axi-cel. Methods: We reanalyzed baseline NanoString IO 360 profiles from the randomized ZUMA-7 trial (axi-cel, n = 134; standard of care [SOC], n = 122) using differentia…

Rank98.3
Randomized controlled trialCorrection flagged

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy.

Blood · 2025 · PMID 39441941

Antibiotic (ABX)-induced microbiome dysbiosis is widespread in oncology, adversely affecting outcomes and side effects of various cancer treatments, including immune checkpoint inhibitors and chimeric antigen receptor T-cell (CAR-T) therapies. In this study, we observed that prior exposure to broad-spectrum ABXs with extended anaerobic coverage such as piperacillin-tazobactam and meropenem was associated with worse anti-CD19 CAR-T therapy survival outcomes in patients with large B-cell lymphoma (N = 422) than other…

Rank98.2
Randomized controlled trial

Mecapegfilgrastim for Prophylaxis of Immunochemotherapy-Induced Neutropenia in Patients With Diffuse Large B-Cell Lymphoma: A Multicenter Pilot Trial.

Cancer medicine · 2026 · PMID 42030265

BACKGROUND: This study evaluated the efficacy and safety of mecapegfilgrastim for preventing immunochemotherapy-induced neutropenia in treatment-naive patients with diffuse large B-cell lymphoma (DLBCL). METHODS: In this open-label, multicenter exploratory trial, patients were randomized in a 2:1 ratio to receive mecapegfilgrastim or no prophylaxis. All participants received 4 cycles of R-CHOP or R-CHOP-like regimens. The primary endpoint was the incidence of grade ≥ 3 neutropenia during cycle 1. RESULTS: Between O…

Rank98.2
Randomized controlled trial

Efficacy of bepotastine compared with hydroxyzine in preventing rituximab-induced infusion-related reactions in non-hodgkin lymphoma patients: a phase II, double-blind, multicenter, and randomized trial.

International journal of clinical oncology · 2026 · PMID 41989666

BACKGROUND: This study evaluated the efficacy of hydroxyzine and bepotastine, first- and second-generation H1 receptor antagonists (H1RA), as pretreatments to prevent infusion-related reactions (IRRs) during the initial rituximab infusion in patients with non-Hodgkin lymphoma. METHODS: In this double-blind, multicenter, randomized phase II study, 40 patients received hydroxyzine or bepotastine with acetaminophen 30 min before rituximab infusion. Primary endpoint was incidence of ≥ grade 2 IRRs based on the National…

Safety And Adverse Effects395 records
Rank110.0
Systematic review or meta-analysis

Is tattooing associated with an increased risk of cancer? A systematic review and meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 42250187

BACKGROUND: Tattoo inks may contain carcinogenic compounds, and pigment migration to lymphatic tissues raises concerns regarding potential cancer risk. Epidemiological evidence remains inconclusive. OBJECTIVES: To assess the association between tattoo exposure and the incidence of skin cancer and hematological malignancies. METHODS: PubMed, Embase, and the Cochrane Library were searched from inception to January 2026 for cohort and case-control studies comparing cancer incidence in tattooed versus non-tattooed adul…

Rank107.9
Systematic review or meta-analysis

Second Primary Malignancies in Patients With B-Cell Lymphomas Treated With Bruton's Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis.

European journal of haematology · 2026 · PMID 42289275

OBJECTIVE: To evaluate the overall second primary malignancy (SPM) burden in patients with B-cell lymphomas treated with Bruton's tyrosine kinase (BTK) inhibitors and compare SPM risk versus non-BTK inhibitor or placebo controls. METHODS: We searched major databases from inception to September 30, 2025. The primary outcome was SPM incidence. Consistent treatment backgrounds were defined as comparable baseline clinical and treatment characteristics, with BTK inhibitor exposure as the main between-arm difference. RES…

Rank107.9
Systematic review or meta-analysisResult signal: null

Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma.

Molecular therapy : the journal of the American Society of Gene Therapy · 2025 · PMID 40170355

Bispecific antibodies (BsAb) are associated with distinct immune-related toxicities that impact morbidity and mortality. This systematic review and meta-analysis examined non-relapse mortality (NRM) with BsAb therapy in B-cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). A PubMed and Embase search up to October 2024 identified 29 studies (21 NHL, 8 MM) involving 2,535 patients. The overall NRM point estimate was 4.7% (95% confidence interval [CI] 3.4%-6.4%), with a median follow-up of 12.0 months. We noted…

Rank107.5
Systematic review or meta-analysis

Febrile neutropenia in adults with diffuse large B-cell lymphoma receiving first-line R-CHOP-based therapy: a systematic review and meta-analysis of observational and trial evidence.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42839187

INTRODUCTION: Febrile neutropenia (FN) is an important complication of first-line immunochemotherapy for diffuse large B-cell lymphoma (DLBCL). Thresholds for primary granulocyte colony-stimulating factor (G-CSF) prophylaxis are risk-based, but the FN burden in routine practice is uncertain, and whether trial-derived estimates describe it is unknown. METHODS: Systematic review and meta-analysis of proportions. MEDLINE, CENTRAL, ClinicalTrials.gov, Europe PMC, Epistemonikos, Lens.org, Google Scholar, and citation tr…

Rank107.2
Systematic review or meta-analysisResult signal: benefit

Maintenance treatment and survival in patients with newly diagnosed diffuse large B cell lymphoma in the immunochemotherapy era: a systematic review and network meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 42213311

OBJECTIVE: To assess the comparative efficacy of various maintenance strategies for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL). METHODS: We conducted a comprehensive search of PubMed, Embase, Web of Science, the Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Trials for randomized clinical trials evaluating maintenance strategies in previously untreated DLBCL patients. The primary outcomes were progression-free survival (PFS) and overall survival (OS…

Rank107.0
Clinical guideline or consensus statement

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).

Annals of oncology : official journal of the European Society for Medical Oncology · 2022 · PMID 34923107

BACKGROUND: Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lymphoma. Products for other diseases such as multiple myeloma and follicular lymphoma are likely to be approved by the European Medicines Agency in the near future. DESIGN: The European Society for Blood and Marrow Transplantation (EBMT)-Joint Accreditation Committe…

Rank106.4
Systematic review or meta-analysis

Application of CAR-T cell therapy in B-cell lymphoma: a meta-analysis of randomized controlled trials.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025 · PMID 39514165

BACKGROUND: This study aims to compare the efficacy and safety of chimeric antigen receptor T-cell (CAR-T) immunotherapy with standard treatment for B-cell lymphoma, providing evidence-based support for the more efficient use of CAR-T cell immunotherapy. METHODS: We conducted a comprehensive literature search of high-quality randomized controlled trials (RCTs) on CAR-T therapy for B-cell lymphoma in the following databases: Wanfang, Web of Science, CNKI, VIP database, and PubMed, up to February 2024. The outcome me…

Rank106.3
Systematic review or meta-analysis

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis.

Blood · 2024 · PMID 38696731

This meta-analysis evaluates the efficacy and safety of chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). We searched MEDLINE, Embase, and Cochrane databases until July 2023 for trials assessing CAR T-cell therapies and CD20×CD3 bispecific antibodies as third or subsequent lines in R/R DLBCL. Random-effects models estimated the complete response (CR) rate and secondary outcomes, with meta-regressions adjusting for relevant cov…

Rank106.3
Systematic review or meta-analysis

Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review.

Bone marrow transplantation · 2026 · PMID 42332219

Lymphodepletion (LD) is a critical prerequisite for successful chimeric antigen receptor T-cell (CAR-T) therapy. While fludarabine and cyclophosphamide (Flu/Cy) remain the standard LD regimen, bendamustine has emerged as a potential alternative due to its distinct immunomodulatory properties and more favorable toxicity profile. This systematic review evaluates the safety, efficacy, and feasibility of bendamustine-based LD in patients undergoing CAR-T therapy for hematologic malignancies. A comprehensive literature …

Rank106.0
Systematic review or meta-analysis

Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: a systematic review and meta-analysis.

Frontiers in immunology · 2024 · PMID 39308870

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy (CAR-T therapy) has demonstrated significant efficacy in the ZUMA-2 study. After regulatory approvals, several clinical trials and real-world studies on CAR-T therapy for relapsed or refractory mantle cell lymphoma (R/R MCL) were conducted. However, data on clinical safety and efficacy are inconsistent. In this study, we aimed to conduct a systematic analysis of the effectiveness and safety of CAR-T therapy across a wider and more representative cohort of p…

Rank105.9
Systematic review or meta-analysis

Reduced-Dose Total Skin Electron Beam Radiation Therapy in Mycosis Fungoides and Sézary Syndrome: Systematic Review and Meta-Analysis.

International journal of radiation oncology, biology, physics · 2026 · PMID 42128185

PURPOSE: Primary cutaneous T-cell lymphomas are a heterogeneous group of T-cell neoplastic entities associated with significant morbidity and high radiosensitivity. Although research on reduced-dose radiation treatment for mycosis fungoides and Sézary syndrome has significantly increased over the past 2 decades, randomized data are lacking. We aim to summarize the available evidence and analyze the safety and efficacy of reduced-dose total skin electron beam therapy (TSEBT). METHODS AND MATERIALS: A literature sear…

Rank104.5
Systematic review or meta-analysisCorrection flagged

Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation.

Bone marrow transplantation · 2025 · PMID 39375527

Autologous peripheral blood stem cell (PBSC) transplantation is a standard treatment of multiple myeloma (MM), Hodgkin lymphoma and various subtypes of non-Hodgkin lymphoma. Cryopreservation of hematopoietic stem cells is standard practice that allows time for delivery of conditioning regimen prior to cell infusion. The aim of this Worldwide Network for Blood & Marrow Transplantation (WBMT) work was to assess existing evidence on non-cryopreserved autologous transplants through a systematic review/meta-analysis, to…

Rank104.2
Systematic review or meta-analysis

The role of allogeneic hematopoietic stem cell transplantation in adults with mature T-cell lymphomas.

The Cochrane database of systematic reviews · 2026 · PMID 42905121

RATIONALE: Mature T-cell lymphomas (MTCL) are a rare, heterogeneous group of malignancies that arise from post-thymic T-lymphocytes, with a generally poor prognosis. For a long time, the standard therapy for most MTCL subtypes has been polychemotherapies. Hopes to prolong overall survival in MTCL have been associated with transplant procedures such as high-dose therapy with autologous stem cell transplantation (autoSCT) or allogeneic stem cell transplantation (alloSCT). OBJECTIVES: To assess the benefits and harms …

Rank103.8
Systematic review or meta-analysis

Clinical outcomes of Epstein-Barr virus infection/reactivation following CAR-T cell therapy: A systematic review.

Transplant immunology · 2026 · PMID 42442615

BACKGROUND: Epstein-Barr virus (EBV) infection or reactivation is an emerging but underrecognized complication following chimeric antigen receptor T-cell (CAR-T) therapy and is likely associated with treatment-induced immune dysregulation. Data regarding its clinical impact remain limited. OBJECTIVE: To evaluate the reported occurrence, clinical manifestations, and outcomes of EBV infection or reactivation in adults undergoing CAR-T therapy. METHODS: A systematic review was conducted in accordance with the PRISMA 2…

Rank103.2
Systematic review or meta-analysis

Systemic Glucocorticoid Use and Risk of Site-Specific Cancers: A Methodologic Systematic Review of Observational Studies.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026 · PMID 41931525

Systemic glucocorticoids, widely prescribed for inflammatory and autoimmune diseases, have long been suspected of increasing cancer risk through immunosuppressive and metabolic effects. Randomized trials are often unethical and difficult to conduct, leaving observational studies the best option to determine whether the use of systemic glucocorticoids affects cancer development. However, these studies face significant methodologic issues that may compromise the validity of their findings. We systematically reviewed …

Rank102.3
Systematic review or meta-analysisResult signal: benefit

Efficacy and safety of rituximab in the treatment of primary central nervous system lymphoma: A meta-analysis and systematic review of 1,388 patients.

Oncology letters · 2026 · PMID 42741313

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive form of non-Hodgkin's lymphoma with a generally poor prognosis, and the median age at diagnosis is 65 years. The clinical value of rituximab in the treatment of PCNSL remains controversial. The present study aimed to evaluate the therapeutic benefits and safety of rituximab in patients with newly diagnosed PCNSL. The EMBASE, PubMed, Web of Science and Cochrane Library were systematically searched from database inception to May 5, 2025, without…

Rank100.4
Systematic review or meta-analysis

Chimeric Antigen Receptor T-Cell Therapy in T Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.

European journal of haematology · 2026 · PMID 42885507

T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare subtype of B-cell non-Hodgkin lymphoma with an aggressive clinical course and poor prognosis in the case of relapsed or refractory (r/r) disease. Recently, anti-CD19 chimeric antigen-receptor (CAR) T-cell therapy has been approved for the treatment of large B-cell lymphoma (LBCL), but subgroup-specific outcomes in these patients have never been reported. Therefore, only limited retrospective data on the safety and efficacy of CAR T-cell therapy in r/r…

Rank100.2
Randomized controlled trialResult signal: benefit

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

Lancet (London, England) · 2026 · PMID 42217458

BACKGROUND: Approximately 40% of patients with high-risk diffuse large B-cell lymphoma (DLBCL) are not cured with first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone). We aimed to investigate the addition of tafasitamab (an Fc-enhanced anti-CD19 monoclonal antibody) and lenalidomide to R-CHOP (tafa-len-R-CHOP) in patients with high-risk aggressive B-cell lymphomas. METHODS: frontMIND is a phase 3, randomised, double-blind, placebo-controlled study conducted at 29…

Rank100.0
Systematic review or meta-analysis

Comparison of anti-PD-1/PD-L1-based regimens in relapsed/refractory diffuse large B-cell lymphoma: a meta-analysis.

PeerJ · 2025 · PMID 41282995

AIM: To evaluate the therapeutic value and find out potential combination agents of programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) monoclonal antibody (mAb) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). METHODS: We conducted a meta-analysis to assess the efficacy and safety of PD-1/PD-L1 mAb in r/r DLBCL, potential qualified studies were searched in PubMed, Embase, Web of Science, and ClinicalTrials.gov. This meta-analysis had been registered on the PROSPERO platform (CRD42023340031…

Rank100.0
Systematic review or meta-analysis

A Systematic Review and Meta-Analysis of Glyphosate-Based Herbicide Exposure and Risk of Non-Hodgkin Lymphoma.

International journal of environmental research and public health · 2026 · PMID 42652314

Glyphosate-based herbicides are widely used agricultural chemicals. Concerns regarding carcinogenicity, particularly non-Hodgkin lymphoma (NHL), persist. We conducted a systematic review and meta-analysis to better evaluate glyphosate exposure and NHL risk. MEDLINE and EMBASE were searched for eligible cohort, case-control, and pooled studies. Risk of bias was assessed using recommended criteria. Random- and fixed-effects meta-analyses were performed, with sensitivity analyses addressing overlapping cohorts, hazard…

Rank100.0
Systematic review or meta-analysis

Efficacy and safety of CD19 CAR T-cell therapy in relapsed/refractory follicular lymphoma: A systematic review and meta-analysis.

Current research in translational medicine · 2026 · PMID 42401099

BACKGROUND AND AIMS: Follicular lymphoma (FL) is an indolent B-cell non-Hodgkin lymphoma characterized by frequent relapses despite initial responsiveness to chemoimmunotherapy. CD19-directed chimeric antigen receptor (CAR) T-cell therapy has shown promising efficacy in relapsed or refractory disease, though safety concerns such as cytokine release syndrome (CRS) and neurological events remain. This study aimed to evaluate the efficacy and safety of CD19 CAR T-cell therapy in relapsed or refractory FL. METHODS: A c…

Rank100.0
Systematic review or meta-analysis

Systematic literature review of clinical outcomes, health-related quality of life, and healthcare costs and resource use in relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel.

Leukemia & lymphoma · 2026 · PMID 42507490

The approval of axicabtagene ciloleucel (axi-cel) for use in second-line (2L) relapsed/refractory (R/R) large B-cell lymphoma (LBCL), emerging real-world evidence provides clinical and economic insights. We conducted a systematic review of studies reporting such outcomes among patients with treated with axi-cel in 2L and 2L + R/R LBCL. In routine care, axi-cel shows effectiveness comparable to clinical trials, with a lower rate of serious cytokine release syndrome in real-world 2L populations. Most real-world studi…

Rank100.0
Systematic review or meta-analysis

Clinical, economic, and quality-of-life outcomes of brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma and B-cell acute lymphoblastic leukemia: A systematic literature review and meta-analysis.

Journal of managed care & specialty pharmacy · 2026 · PMID 42808549

BACKGROUND: Brexucabtagene autoleucel (brexu-cel), a CD19 chimeric antigen receptor T-cell therapy, has shown efficacy in clinical trials for relapsed/refractory (R/R) mantle cell lymphoma (MCL) and B-cell acute lymphoblastic leukemia (B-ALL). However, although effectiveness and safety evidence is well established, real-world evidence (RWE) on health care resource use (HCRU), costs, and health-related quality of life (HRQoL) remains limited. OBJECTIVE: To systematically review and synthesize RWE on clinical, HCRU, …

Rank100.0
Systematic review or meta-analysis

Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma - A systematic review of literature.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS · 2026 · PMID 41380366

INTRODUCTION: Breast Implant Associated - Anaplastic Large Cell Lymphoma (BIA-ALCL) cases are steadily increasing worldwide. When considering only the patients with textured implant as the active population, prevalence appears higher than previously reported, and uncertainty regarding incidence rate (IR) trends. We aimed to provide comprehensive estimates by identifying epidemiologic studies reporting prevalence, risk, and IR. METHODS: A systematic review was conducted up to November 2024 across PubMed, Google Scho…

Rank99.6
Randomized controlled trial

A clinical study on fall risk assessment and preventive nursing in older adults with non-Hodgkin's lymphoma undergoing chemotherapy-a randomized controlled trial.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42470465

BACKGROUND: Non-Hodgkin's lymphoma (NHL) is a diverse group of lymphoproliferative malignancies that predominantly affects older adults. Chemotherapy remains the primary modality of treatment for many NHL subtypes, yet it often brings about adverse effects such as myelosuppression, anemia, and neuropathy, all of which contribute to a heightened risk of falls in older patients. Falls in this population can lead to serious complications, including fractures and intracranial injuries, thereby impacting functional stat…

Treatments That Failed Clinical Trials89 records
Rank102.6
Randomized controlled trial

Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 41260259

BACKGROUND: Preliminary reports suggest interim positron emission tomography (PET) could drive treatment duration in limited-stage diffuse large B-cell lymphoma (DLBCL). This phase III randomized study in first-line therapy for DLBCL patients with adjusted-age international prognostic index (aaIPI) risk = 0, evaluates an experimental PET-response adapted approach using PET response after two cycles of R-CHOP to de-escalate treatment duration. PATIENTS AND METHODS: LNH2009-1B study is a two-arm, open-label, multicen…

Rank99.9
Randomized controlled trialResult signal: null

Health-related quality of life in patients with aggressive non-Hodgkin lymphoma: results from the PETAL trial.

Annals of hematology · 2025 · PMID 40397196

When different therapies provide similar cure rates, health-related quality of life (HRQoL) may become crucial for the choice of treatment. In the Positron Emission Tomography-guided Therapy of Aggressive non-Hodgkin Lymphomas (PETAL) trial, we compared six cycles of R-CHOP with or without two extra doses of rituximab in prognostically favorable interim PET (iPET)-negative patients, while eight cycles of R-CHOP were compared with two R-CHOP cycles followed by six cycles of a more intensive protocol in prognosticall…

Rank99.2
Randomized controlled trialResult signal: null

Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.

BMC cancer · 2024 · PMID 38267866

HLX01 (HanliKang®) is a rituximab biosimilar that showed bioequivalence to reference rituximab in untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) in the phase 3 HLX01-NHL03 study. Here, we report the 5-year follow-up results from the open-label extension part. Patients were randomised to either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or HLX01 plus CHOP (H-CHOP) every 21 days for up to six cycles. The primary efficacy endpoint was overall survival (OS), and se…

Rank98.2
Randomized controlled trial

Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial.

Hepatology communications · 2025 · PMID 41335575

BACKGROUND AND AIMS: Immunosuppression can cause hepatitis B virus (HBV) reactivation, leading to severe outcomes in patients with "resolved" HBV infection. This multicenter, randomized, placebo-controlled trial assessed the efficacy of preemptive antiviral therapy in HBsAg-negative, anti-HBc-positive patients receiving rituximab-based chemotherapy for non-Hodgkin lymphoma (NHL). METHODS: Patients were randomized 1:1 to tenofovir alafenamide (TAF)/placebo across 3 phases: chemotherapy plus TAF/placebo (phase 1), TA…

Rank97.3
Randomized controlled trialResult signal: benefit

Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma.

Blood advances · 2025 · PMID 40829107

In the phase 3 ECHELON-2 trial, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (BV-CHP) significantly improved progression-free survival (PFS) and overall survival (OS) compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with CD30+ peripheral T-cell lymphoma, benefits that were maintained at 5 years. Interim positron emission tomography (PET) scan can be used to assess prognosis and risk-stratify patients. The prognostic value of interim PET was assessed i…

Rank97.2
Randomized controlled trialResult signal: null

Impact of resolved hepatitis B virus infection on clinical outcomes in patients with diffuse large B-cell lymphoma: a supplementary analysis of JCOG0601.

International journal of hematology · 2026 · PMID 42801438

The impact of resolved hepatitis B virus (HBV) infection, defined as pretreatment hepatitis B surface antigen (HBsAg) negativity with antibody to hepatitis B core antigen (anti-HBc) positivity, on the clinical characteristics and outcomes of diffuse large B-cell lymphoma (DLBCL) remains unclear. JCOG0601 was a randomized phase II/III trial showing no improvement in progression-free survival (PFS) with dose-dense rituximab plus CHOP in previously untreated DLBCL. This supplementary analysis of JCOG0601 evaluated whe…

Rank97.0
Randomized controlled trialResult signal: null

Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.

JAMA oncology · 2026 · PMID 41746629

IMPORTANCE: Follicular lymphoma (FL) has historically been regarded as incurable, with patients experiencing late relapses after initial chemoimmunotherapy treatment. OBJECTIVE: To provide 15-year follow-up data from the SWOG S0016 trial that evaluated the potential for long-term remission and cure following chemoimmunotherapy with cyclophosphamide, hydroxydaunorubicin/doxorubicin, oncovin, and prednisone/prednisolone (CHOP)-based regimens. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, intergroup study was c…

Rank96.8
Randomized controlled trialResult signal: null

R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203.

British journal of haematology · 2024 · PMID 37996986

Anti-CD20 antibody in combination with chemotherapy extends overall survival (OS) in untreated advanced-stage follicular lymphoma (FL), yet the optimal associated therapy is unclear. Data on the cumulative incidence of secondary malignancies postrelapse after conventional immunochemotherapy are scarce. A long-term analysis of rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) as first-line treatment was conducted in a randomised clinical trial. A six-cycle R-CHOP regimen was …

Rank96.3
Randomized controlled trial

Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial.

Current medical research and opinion · 2024 · PMID 39376156

OBJECTIVE: We report patient-reported outcomes (PROs) measuring health-related quality of life (HRQoL) from the ROSEWOOD trial (NCT03332017), which demonstrated superior efficacy and a manageable safety profile with zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) in patients with heavily pretreated relapsed/refractory follicular lymphoma (R/R FL). METHODS: PROs were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) and E…

Rank96.3
Randomized controlled trial

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.

Blood · 2025 · PMID 40499012

Patients with follicular lymphoma who experience disease progression within 24 months of diagnosis (POD24) have a lower survival. Positron emission tomography (PET) response and circulating tumor DNA (ctDNA) minimal residual disease (MRD) assessment at end of induction (EOI) may allow their early identification. A representative cohort of 141 patients from the RELEVANCE phase 3 trial with both available serum samples for ctDNA testing and PET images at randomization and at EOI (week 24) was investigated. Twelve per…

Rank96.2
Randomized controlled trial

Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi.

Blood advances · 2025 · PMID 40106688

We analyzed metabolic response using interim positron emission tomography scan (iPET) in a subset of patients with follicular lymphoma (FL) enrolled in the randomized FOLL12 trial. Patients with grade 1-3a FL with an iPET performed between cycles 4 and 5 of first-line immunochemotherapy (ICT) were included; PET scan had to be centrally reviewed for the definition of Deauville score (DS) and were considered positive for DS 4-5. Overall 123 patients out of 211 with iPET were available for central review. Of these, 43…

Rank95.9
Randomized controlled trial

Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial.

Cancer communications (London, England) · 2023 · PMID 37403255

BACKGROUND: The current standard of care for non-bulky diffuse large B-cell lymphoma (DLBCL) patients with an International Prognostic Index (IPI) of 0 is four cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) but whether the same efficacy can be achieved with reduced chemotherapy regimen of four cycles for non-bulky DLBCL patients with an IPI of 1 remains unclear. This study compared four cycles versus six cycles of chemotherapy in non-bulky low-risk DLBCL patients with ne…

Rank95.9
Randomized controlled trial

Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study.

Journal of Korean medical science · 2023 · PMID 37463687

BACKGROUND: Rituximab occasionally induces reactivation of hepatitis B virus (HBV) in patients with resolved HBV, at times with fatal consequences. The optimal duration of prophylactic antiviral therapy in this situation is unclear. We aimed to investigate the difference in HBV reactivation according to the duration of prophylactic tenofovir disoproxil fumarate (TDF) in patients with resolved HBV and receiving rituximab. METHODS: A multicenter, randomized, open-label, prospective study was conducted in hepatitis B …

Rank95.6
Randomized controlled trialResult signal: null

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.

EBioMedicine · 2024 · PMID 39631145

BACKGROUND: We report extended follow-up of TROG99.03, a randomised phase III trial in early-stage follicular lymphoma (ESFL) including new information on the role of adjuvant rituximab and translational studies. METHODS: Patients with ESFL were randomised to involved field radiotherapy (IFRT) or IFRT plus 6-cycles cyclophosphamide/vincristine/prednisolone (IFRT + CVP). From 2006 rituximab was added to IFRT + CVP (IFRT + R-CVP). Clinical and multi-omic parameters were evaluated. Findings were validated in two indep…

Rank95.4
Randomized controlled trial

Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trial.

Leukemia · 2024 · PMID 38538861

The role of consolidative radiotherapy (RT) for patients with aggressive B-cell lymphoma has not been fully elucidated. The R-MegaCHOEP trial investigated the use of high-dose chemotherapy and rituximab with subsequent autologous stem cell transplantations compared to conventional immunochemotherapy (R-CHOEP) for high-risk patients up to 60 years. The study protocol included RT for patients with bulky (maximum diameter ≥7.5 cm) or extranodal disease. Two-hundred sixty-one patients were analyzed, 120 of whom underwe…

Rank95.4
Randomized controlled trialResult signal: null

Endoscopic ultrasound (EUS) elastography-guided fine-needle aspiration cytology (FNAC) versus conventional EUS FNAC for solid pancreatic lesions: A pilot randomized trial.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025 · PMID 39230660

BACKGROUND: Endoscopic ultrasound guided fine-needle aspiration (EUS FNA) is the first-line modality to diagnose suspected solid pancreatic malignant lesions. Elastography-guided FNA has been shown to improve the diagnostic yield of EUS FNA but prospective studies are limited. The aim of the study was to compare diagnostic accuracy, sensitivity and specificity of conventional and elastography-guided EUS FNA in patients with suspected malignant pancreatic solid masses. METHODS: Patients with suspected malignant soli…

Rank95.2
Randomized controlled trial

The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2023 · PMID 37014666

PURPOSE: This study aims to investigate the relationship between the intensity of the initial treatment given to patients with de novo diffuse large B-cell lymphoma (DLBCL) and the impact of their baseline cell-free DNA (cfDNA) levels on their long-term survival. EXPERIMENTAL DESIGN: The GOELAMS 075 randomized clinical trial compared rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with high-dose R-chemotherapy plus autologous stem cell transplantation (R-HDT) for patients aged ≤60.…

Rank95.2
Randomized controlled trial

Randomized Phase II Study of Brentuximab-Vedotin With High-Dose Chemotherapy in CD30 Positive Lymphoma.

Hematological oncology · 2025 · PMID 41117344

Patients with Hodgkin lymphoma (HL) or peripheral T-cell lymphoma (PTCL) who relapse after high-dose chemotherapy (HDCT) have a dismal prognosis. Brentuximab-vedotin (BV) is a CD30-targeting antibody-drug-conjugate (ADC) used in first-line-, salvage-, and maintenance-therapy of HL, as well as first-line- and salvage-therapy of PTCL. In phase I of this trial, we could show that BV can safely be added to BeEAM-HDCT (bendamustine, etoposide, cytarabine and melphalan). Here, we report the randomized phase II part of th…

Rank95.0
Randomized controlled trial

Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · PMID 38096461

PURPOSE: We report an analysis of minimal residual/detectable disease (MRD) as a predictor of outcome in previously untreated patients with follicular lymphoma (FL) from the randomized, multicenter GALLIUM (ClinicalTrials.gov identifier: NCT01332968) trial. PATIENTS AND METHODS: Patients received induction with obinutuzumab (G) or rituximab (R) plus bendamustine, or cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or cyclophosphamide, vincristine, prednisone (CVP) chemotherapy, followed by maintenance …

Rank94.6
Randomized controlled trial

The role of PET/CT in peripheral T-cell lymphoma: Results from the PET/CT substudy of the UK NCRI phase 2 CHEMO-T trial.

British journal of haematology · 2025 · PMID 40419413

The UK National Cancer Research Institute (NCRI) phase 2 randomised CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T) trial compared the regimens of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) and gemcitabine, cisplatin and methylprednisolone (GEM-P) in treatment-naïve patients with peripheral T-cell lymphoma (PTCL). Evaluation of the role of positron emission tomography/computed tomography (PET/CT) was a key secondary end-point. All patients require…

Rank93.2
Randomized controlled trialCorrection flagged

Decade-long persistence of CD19 CAR T cells in B cell lymphomas.

Nature medicine · 2026 · PMID 42575986

Chimeric antigen receptor (CAR) T cell therapy induces durable remissions in lymphoid malignancies, yet the extent and biology of long-term CAR T cell persistence in B cell lymphoma remain unclear. Here we report the persistence and characteristics of 4-1BB-costimulated anti-CD19 CAR T cells (CART19) up to 10 years after infusion in 38 patients with non-Hodgkin lymphoma. Beyond year five, the CAR19 transgene was detectable in five of eight long-term responders (7.0-10.1 years), with three patients maintaining B cel…

Rank92.8
Phase III clinical trial

Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial.

Scientific reports · 2024 · PMID 39043871

In the frontline high-dose phase 3 FIL-MCL0208 trial (NCT02354313), 8% of enrolled mantle cell lymphoma (MCL) patients could not be randomised to receive lenalidomide (LEN) maintenance vs observation after autologous stem cell transplantation (ASCT) due to inadequate hematological recovery and 52% of those who started LEN, needed a dose reduction due to toxicity. We therefore focused on the role played by CD34 + hematopoietic stem cells (PBSC) harvesting and reinfusion on toxicity and outcome. Overall, 90% (n = 245…

Rank92.6
Randomized controlled trial

End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial.

European journal of nuclear medicine and molecular imaging · 2024 · PMID 38795120

PURPOSE: To evaluate the reliability of the Deauville score (DS) in therapy response assessment and to define the prognostic value of the metabolic response of end of induction (EOI) [18F]FDG PET (PET) in follicular lymphoma patients. METHODS: Adult patients with untreated grade 1-3a FL/ stage II-IV enrolled in the multicentre, prospective, phase III FOLL12 trial (NCT02063685) were randomized to receive standard immunochemotherapy followed by rituximab maintenance (standard arm) versus standard immunochemotherapy f…

Rank92.2
Randomized controlled trialResult signal: null

A Phase III open-label randomized study to compare the efficacy of lenalidomide-rituximab with bendamustine-rituximab in treatment-naïve follicular lymphoma.

Indian journal of cancer · 2023 · PMID 38185869

INTRODUCTION: Bendamustine-rituximab (BR) is the preferred regimen for the treatment of naïve follicular lymphoma (FL). Recently, lenalidomide-rituximab (LR), a chemotherapy-free protocol, has shown a good response rate in advanced FL. These regimens have never been compared in a randomized controlled trial for treatment-naïve FL in Indian patients. MATERIALS AND METHODS: This Phase III open-label randomized controlled trial was conducted to compare the efficacy and safety of BR and LR. Treatment-naïve patients old…

Rank92.0
Randomized controlled trial

ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study.

Leukemia · 2026 · PMID 41145670

The firstMIND trial (NCT04134936) evaluated the safety and efficacy of adding lenalidomide to R-CHOP+tafasitamab in the first-line treatment settings of patients with diffuse large B-cell lymphoma. To address response dynamics and the impact of measurable residual disease (MRD), we analyzed prospectively collected plasma samples from 56 study patients using the EuroClonality immunoglobulin gene (IG)-NGS assay. At baseline, disease-related clonotypes were identified in 50/56 (89%) patients by IG-NGS in cell-free (cf…

i
Research information notice

Alexandria organizes PubMed-indexed literature. PubMed inclusion does not establish accuracy, endorsement, clinical applicability, or treatment suitability. Automated extraction can contain errors or omissions. This page is not medical advice.